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ABSTRACT

A growing body of evidence suggests that a diet rich in flavonoids, naturally occurring
plant-based compounds, is associated with improved health outcomes. However,
current knowledge relating to the measurement of dietary flavonoid intake is limited
and studies assessing the association of flavonoid-rich food supplementation with
cognitive and physical health outcomes are scarce. This doctoral thesis outlines six
studies that were developed to address two main research questions. Firstly, what
methods should be employed to measure flavonoid intake? Secondly, how does the
consumption of dietary flavonoid impact cognitive and physical outcomes?

In order to associate the impact of dietary flavonoids on health outcomes, accurate
dietary assessment is fundamental. A systematic literature review evaluates the
various methods employed by current literature to measure flavonoid intake. The
review emphasises the reliance of studies utilising unsound dietary assessment
methods to measure flavonoid intake and demonstrates that few studies utilise
objectives biomarkers as a measure of flavonoid intake.

Dietary flavonoid intake estimates in Australia are limited, and specifically the
estimations of flavonoid intake in older Australians are inadequate. A Food Frequency
Questionnaire for the measurement of dietary flavonoid intake in this cohort was
developed, based on secondary data analysis of detailed dietary information in older
adults. The tool is validated against food records and assessed for reliability in a group
of older Australians, showing to be a relatively useful instrument to measure flavonoid
intake.

In response to the lack of biomarker data utilised in current flavonoid research, a
sensitive and specific GC-MS method was developed to determine flavonoids and
phenolic acids in biological samples. The developed method has potential to measure
115 flavonoid-related biomarkers in various biological samples, and is applied in later
studies of this thesis.
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A second systematic literature review identifies a paucity of research regarding foodbased anthocyanin (a subclass of flavonoids) consumption and cognitive outcomes.
Various methodological limitations in published studies are highlighted, including a
lack of information regarding dosage and dose-timings, age related variations in
responses and small sample study sizes. The findings are utilised inform the
development of acute and longer-term intervention studies to assess the impact of a
flavonoid and anthocyanin-rich cherry juice supplementation on cognitive and
physical outcomes.

A pilot cross-over study assesses the acute effects on cognition, blood pressure and
plasma biomarkers associated with consumption of a 300ml cherry juice, provided
either as a single quantity or as 3x100ml doses administered over 2h. In young adults,
older adults, and older adults with dementia similarly, results indicated that the acute
impact of anthocyanin-rich cherry juice consumption on cognition was not supported,
but a dose-timing administration effect may influence blood pressure outcomes.

A longer-term intervention assesses whether daily consumption of anthocyanin-rich
cherry juice changed cognition and blood pressure in older adults with dementia over
12-weeks. The results indicate that anthocyanin-rich cherry juice consumption
improve cognitive performance and significantly reduced blood pressure. This study
provides the first evidence that a feasible serving of flavonoid-rich food may have
beneficial consequences in older adults with Alzheimer’s type dementia

Overall, this doctoral thesis provides a number of contributions to the literature.
Primarily it demonstrates that the dietary flavonoid intake measurement strategies are
lacking and the novel tools developed by this thesis improve upon current methods
with potential application in future research. Additionally, the findings of the
flavonoid intervention trials support the indication that flavonoid, and especially
anthocyanin-rich food consumption, may be beneficial for cognitive and physical
outcomes.

PUBLICATIONS CONSTITUTING THIS THESIS
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CHAPTER 1: INTRODUCTION

This chapter examines the scientific literature relevant to this thesis, introducing
concepts related to the measurement of flavonoid intake and a broad overview of the
assessment of flavonoid consumption on health outcomes. The introduction provides
a background to the thesis and exposes the gaps in current literature, and relates these
to the empirical chapters of this thesis. The main research questions are introduced
and the methodologies applied to address these are presented.
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1.
1.1

Flavonoids

Plant based foods form an integral component of the human diet and their consumption
is consistently linked to the maintenance of health and the prevention of a vast array
of diseases (1, 2). In the past, the compounds believed to be responsible for the
protective effects of a plant-based diet included carotenoids and other antioxidant
vitamins (1). More recently, a growing body of literature illustrates that other
phytochemicals, which are non-nutritive compounds, significantly contribute to the
antioxidant activity of fruits and vegetables and are consequently attributed to the
observed health benefits (3).

These polyphenolic compounds, or polyphenols, encompass a huge range of
compounds present in varying quantities in all plants and can be divided into the
subclasses flavonoids, lignans, stilbenes and phenolic acids (4) (Figure 1-1).
Flavonoids are further divided into six major classes: anthocyanins, flavanols,
flavanones, flavones, flavonols and isoflavones (4) (Figure 1-1).

Flavonoids

Flavonols

e.g. quercetin

Flavanones

e.g. hesperetin

Flavones

e.g. apigenin

Anthocyanins

e.g. cyanidin

Stilbenes
Polyphenols

e.g. epicatechin
Flavan-3-ols

Lignans
Phenolic Acids

Isoflavones

e.g. proanthocyanin
(polymeric flavanols)
e.g. daidzein

Figure 1-1 Classification of polyphenolic compounds and examples of flavonoids
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Flavonoids have been studied intensely with several hundred flavonoids identified in
foods. Flavonoids are found in particularly high concentrations in fruits and
vegetables, wine, tea, cocoa, and soy (5). The consumption of flavonoids is estimated
to be much higher than other dietary antioxidants; for example, around 10 fold higher
than vitamin C, and 100 times higher than both vitamin E and carotenoids (6).
Flavonoids are secondary plant metabolites, indicating they are not directly involved
with the growth of plants, but their role is related to the protection of plants from
microbe and insect damage (2). As a component of the human diet, flavonoids
contribute to the sensory characteristics of foods such as flavour, astringency and
colour (7).

1.2

Methods for measuring flavonoid intake

To link flavonoid consumption with positive health outcomes, the first and most
fundamental step is to accurately estimate dietary flavonoid intake. Despite the first
estimations of flavonoid intake being reported on a population level more than a
decade ago, the numerous methods currently employed have evident flaws (8). As
dietary flavonoid intake is difficult to quantify, numerous methods have been
developed for application in various settings. Methods include various techniques
within the fields of dietary assessment and biomarker analysis, as will be described
below and in further detail in Chapter 2.

1.2.1

Methods of measuring flavonoid intake using dietary assessment

The most common method of estimating flavonoid intake in a population relies on
dietary assessment and informatics (the development of computerised food
composition databases (FCDB)). Generally, usual dietary analysis is performed using
either a 24 hour diet recall, diet history or food record, which is then cross-referenced
with a flavonoid specific FCDB. There are very few flavonoid specific FCDBs that
exist, with the two most commonly used being the USDA Database for the Flavonoid
Content of Selected Foods (9) and Phenol Explorer Database on Polyphenol Content
in Foods (10). Aside from the limitations associated with each dietary assessment
method, there are several well documented problems associated with utilising food
composition databases to assign flavonoid content to foods to estimate dietary intake.
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These limitations include inadequate food lists, and the inability of FCDBs to account
for the specific growth and processing conditions that influence foods and the high
inter-individual variation in the bioavailability of flavonoids. These limitations are
suggested to have contributed to the large variations in estimations of flavonoid intake
(11).

The limitations associated with current methods hinder the interpretation of
observational research outcomes that associates dietary flavonoid intake and specific
health outcomes. In light of Australia’s expanding and ageing population and the need
for lifestyle recommendations to improve healthy ageing, these limitations must be
rectified to create advances in this research area. Most notably, there is currently little
information available on the dietary intake of flavonoids in older Australians and no
recommendations have been developed to advise the best way to measure flavonoid
intake in this cohort using dietary assessment methods (this will be discussed in more
detail in chapter 3 of this thesis).

1.2.2

Methods of measuring flavonoid intake using laboratory analysis

Dietary flavonoid intake can also be determined by quantifying biomarkers of
flavonoid intake, which include flavonoids and phenolic acids found in biological
samples (12). There are currently many methods of measuring flavonoid biomarkers
in human biological samples. However, like dietary methodology, there is no
standardised protocol of how to perform this analysis and researchers tend to develop
and validate their own methods. Biomarkers of flavonoid intake are generally
validated against dietary records (which capture either recent or habitual flavonoid
intake) or after a dietary intervention study (13). A major limitation associated with
accurately estimating flavonoid intake using biomarkers is that there are many
hundreds of dietary flavonoids, which are rapidly and extensively metabolised into a
wide range of metabolites (e.g. phenolic acids). There is currently no consensus
regarding which of the intact flavonoid(s) or their in vivo phenolic acid metabolites
are indicative of total dietary intake. Indeed, gaps in understanding of the exact uptake
and metabolism of dietary flavonoids make it unclear as to which biological fluids

29

(plasma, urine or faecal water) to target for analysis of biomarkers. This concept will
be addressed in more detail in chapter 4 of this thesis.

Another major limitation of these methods relates to the fact that they are physically
invasive in terms of collecting biological specimens, which may especially be
problematic to collect older adults and vulnerable groups. Moreover, most of the
biomarker analyses are expensive and quite often it is not possible to perform them as
part of a large epidemiological study (14). Future research should focus on identifying
specific biomarkers of flavonoid intake and confirm the best methods in which to
quantify these biomarkers in biological specimens in order to inform population
research.

1.3

Dietary flavonoids and health outcomes

A high consumption of total flavonoids and flavonoid subclasses has been consistently
linked with a protection against chronic diseases associated with ageing (15, 16),
including cardiovascular (17) and neurodegenerative diseases (18). Biologically,
flavonoids and their metabolites exert powerful antioxidant activities, influence
vascular changes (17) and may guard areas of the brain against age-related decline
(19, 20). The majority of research into the biological aspect of flavonoids has been
pre-clinical. However, some strong epidemiological research exists, linking habitual
flavonoid intake to various improved health outcomes in older adults, specifically
cognition (21), coronary (22) and ischemic heart disease (23). Experimental trials in
humans are rarer, but preliminary studies highlight positive results.

1.3.1

Dietary flavonoids and cardiovascular outcomes

Cardiovascular diseases (CVD), including stroke and coronary heart disease, are a
major cause of mortality in developed countries and are closely associated with
modifiable lifestyle factors including diet (24). A diet high in flavonoids has been
linked with a reduction in CVD mortality (24, 25), with a recent review indicating four
out of eight studies reporting a significant inverse association between coronary heart
disease mortality with at least one flavonoid subclass (24). The association between
flavonoid intake and incident stroke is less clear with three out of seven studies
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reporting an association with flavonoid intake (24). The inconsistencies in
epidemiologic studies associating flavonoid intake with CVD outcomes may relate to
the use of different dietary assessment methods and flavonoid composition databases,
differences in the types of flavonoid subclasses studied and differences between the
populations (26).

The consumption of flavonoid-rich foods have been hypothesised to alter CVD risk
factors including vascular function (27, 28) and blood pressure (29, 30), although the
results are inconsistent. The mechanisms of action of flavonoids and cardiovascular
outcomes are varied (25), with reviews indicating a multiplicity of effects (26). The
antioxidant capacity of flavonoids has been postulated to reduce arterial stiffness
through preventing the oxidation of LDL cholesterol (30). Another mechanism relates
to a reduction in circulating free-radicals, reducing thrombogenesis and platelet
aggregation in the body. The ability of flavonoids to modulate endothelial function,
and thus influence blood pressure has also been investigated and relates to the
modulation of nitric oxide bioavailability to the endothelium, resulting in
endothelium-dependant vasodilation (27, 31, 32). Additional evidence suggests that
flavonoid consumption may have the ability to prevent age-related vascular injury
(33). It is possible that a culmination of all these effects may provide a protection
against coronary heart disease and stroke.

Limitations in the literature surrounding flavonoid consumption and vascular
outcomes relate to the limited research in human controlled trials, the inconsistencies
with intervention (diet, pure flavonoids etc.), a lack of knowledge relating to timing
and dose-dependency of outcomes and inconsistencies in outcomes between different
population groups (34) (discussed in further detail in chapters 6 and 7 of this thesis).

1.3.2

Dietary flavonoids and cognition

The consumption of dietary flavonoids has been associated with improved cognitive
performance and a preservation of cognitive function with ageing (35-37), with the
flavonoid sub-groups flavanols, anthocyanins and flavanones having shown the most
beneficial effects in the area of neuroprotection (20).
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Initially, the biological actions of flavonoids on the brain were attributed solely to their
antioxidant actions, ability to scavenge free radicals and reduction of inflammation in
the body. It was then demonstrated that the antioxidant activity of flavonoids could
not fully account for their total bioactivity in the brain as their concentration in brain
tissue is very low, and their ability to cross the blood-brain barrier was questioned
(38). Therefore, the actions of flavonoids in the brain have been investigated further
and a variety of mechanisms have been postulated alongside their antioxidant activity.
These include an ability to protect vulnerable neurons, increase the number of, and the
strength of the connections between neurons (20), and an enhancement existing
neuronal function (via the modulation of signalling processes)(39). Additionally,
flavonoids have been shown to stimulate blood flow to the brain and induce
neurogenesis in the hippocampus, the area of the brain associated with memory (38).
The culmination of these mechanisms has been theorised as the potential pathways by
which flavonoids may influence memory, learning and cognition and prevent
neurodegeneration.

Limitations exist regarding the literature associating flavonoid intake with cognitive
outcomes. Firstly, controlled intervention trials in humans are rare, with small samples
sizes (40). Additionally, there is little consistency in the cognitive outcomes
investigated across the literature, a wide range of intervention vehicles, doses and
intervention durations investigated, which makes comparison and interpretation of
study findings difficult (40) (discussed in further detail in chapters 6 and 7 of this
thesis).

1.3.3

Dietary flavonoids and dementia

Neurodegenerative diseases is a term that describes a group of diseases that are
irreversible and have debilitating symptoms including permanent memory
impairment, continuous cognitive decline, and progressive behavioural disturbances
(41). While cognitive impairment increases exponentially with age, it is not an
inevitable consequence of ageing (42). Mild cognitive impairment and dementia
related diseases are diagnosed when the level of impairment is greater than what is
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associated with normal ageing (43). Dementia is the most common mental and
behavioural disorder in Australia, accounting for 89% of cases in 2006 (44). In light
of Australia’s ageing population, it is predicted that by 2050 spending on dementia is
set to exceed any other health condition if no significant developments in the
prevention or treatment of this disease are made (45). It is therefore necessary to
identify strategies that prevent or delay the onset of cognitive impairment and the role
of nutrition in neuroprotection is a promising area of research.

Habitual consumption of flavonoid-rich foods and/or beverages has been associated
with 50% reduction in the risk of developing a neurodegenerative disease (18) and a
delay in the onset of Alzheimer’s disease (46). The proposed mechanisms by which
flavonoids might delay the initiation of dementia and slow the progression of dementia
have been summarised in a recent review (19). The review suggests that flavonoids
have potential to inhibit neuronal apoptosis (cell death) which is generated by
neurotoxic species by reducing oxidative stress and neuroinflammation in the brain,
the latter of which is a characteristic of dementia progression (19). Dietary flavonoids
have also shown the potential to disrupt amyloid β aggregation and may inhibit the
production of amyloid β through the disruption of amyloid precursor protein
processing (19). However, much of this research relies on pre-clinical evidence, which
cannot easily be translated into the human experience. To date, there has been little
experimental research that investigates the impact of flavonoid rich foods on cognitive
and physical functioning, specifically in older adults with a neurodegenerative disease.
This may be a result of the difficulties in recruiting and retaining participants with
dementia to clinical trials, which tend to have restrictive inclusion criteria, be intrusive
and require large investments of time for participants (47).
The studies that have been conducted in healthy participants provide promising results
in terms of cognitive benefits of flavonoids, for both acute and longer-term trials (48,
49). It is therefore surprising that studies in have not been extended to include older
adults with a neurodegenerative disease. To the best of our knowledge, there are no
human studies investigating the impact of dietary flavonoids on cognitive outcomes in
older adults with a dementia, despite some small trials in older adults with mild33

cognitive impairment (50-52). A recent review (53) suggested that conclusions
regarding the impact of dietary flavonoids on dementia cannot be made due to a lack
of high quality research. It was recommended that future clinical trials be conducted,
focussing on elucidating an effective dose to result in neuroprotective effects and the
confirming bioavailability of flavonoids in population living with dementia (53)
(addressed in further detail in chapters 6 and 7 of this thesis).

1.4

Summary of evidence and gaps in the literature

This overview of the literature has highlighted that there have been substantial recent
advances in the measurement of dietary flavonoids and that preliminary studies
support the impact of flavonoids on cognitive and physical outcomes. However, some
major limitations of the current body of evidence are evident and there are a number
of important questions still to be resolved surrounding dietary flavonoids.

Firstly, the measurement of dietary flavonoids, both with dietary assessment tools and
with biomarkers of intake is not well established. Synthesis of the literature
surrounding the current use of dietary tools to measure flavonoid intake and biomarker
methods is needed to inform future research. Additionally, better methods to measure
flavonoid intake through dietary assessment tools and biomarkers of intake need to be
developed in light of the findings.

Secondly, the impact of flavonoid consumption on cognitive and physical outcomes
needs be further investigated, with an emphasis on research in older adults and older
adults with an existing neurodegenerative disease. While evidence exists for the
potential beneficial effect of the consumption of flavonoids on a range of health
outcomes, the body of evidence relating to flavonoid intake and improvements in
cardiovascular and neurological health, especially for older adults with a
neurodegenerative disease is sparse. There is a need to identify which cognitive
domains are impacted by flavonoid intake and the most appropriate tools to measure
the changes. The most notable gaps in the literature exist in relation to differences in
short and long-term responses to flavonoid intake and dose-response relationships.
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1.5

Aims and hypothesis

In light of the gaps in the literature surrounding flavonoids two main research
questions were proposed (Figure 1-2):

1. What methods should be employed to measure flavonoid intake?
2. How does the consumption of dietary flavonoids impact cognitive and physical
outcomes?

In order to effectively address these broad questions, six studies were developed
(Figure 1-2).

Study 1: A systematic literature review that evaluates the tools used to estimate dietary
flavonoid intake.
Study 2: Development and validation of a Food Frequency Questionnaire to determine
dietary flavonoid intake.
Study 3: Development of a method to determine the phenolic profile of human plasma
using Gas Chromatography/Mass Spectrometry technique.
Study 4: A systematic literature review that evaluates effect of anthocyanin-rich food
intake on cognitive outcomes.
Study 5: An acute crossover study to assess the impact of differing doses of
anthocyanin-rich cherry juice on cognitive and physical outcomes, and plasma
phenolic profile.
Study 6: A randomised controlled trial to assess the longer-term impact of
anthocyanin-rich cherry juice on cognition and physical outcomes in older adults, with
mild to moderate dementia.
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Assessment of the impact of
dietary flavonoids on cognitive
and physical outcomes

Measurement of dietary
flavonoid intake

A systematic literature review to
evaluate tools used to measure
flavonoid intake

Development and validation of a
flavonoid specific food frequency
questionnaire in older
Australians.

A systematic literature review to
evaluate literature associating
anthocyanin intake and cognition

Main Research
Questions
1. What methods should
be employed to measure
flavonoid intake
2. How does the
consumption of dietary
flavonoids impact
cognitive and physical
outcomes?

Development of a gas
chromatography/mass
spectrometry technique to
determine flavonoid related
biomarkers in biological
samples.

The acute impact of fruit
flavonoid supplementation on
cognitive and physical outcomes,
in young adults, older adults and
older adults with mild to
moderate dementia.

The longer-term impact of fruit
flavonoids on cognition and
physical outcomes in older
adults, with mild to moderate
dementia.

Figure 1-2 Overview of the thesis studies in relation to the central thesis questions
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1.6

Thesis structure and methodology

In order to address the central research questions, several study designs need to be
applied (Figure 1-2, Table 1-1). These approaches include various research
methodologies, incorporating systematic literature reviews, dietary assessment
methodologies, laboratory based methodologies and clinical trial study designs. The
combination of research designs reflects the complexity of the central research
questions. Each method is identified below, but significantly more detail pertaining to
the methods of each study will be described in each chapter.

Chapter 1 provides an introduction to the literature surrounding this thesis,
introduces each chapter and the methodology used throughout.
Chapter 2 is a systematic literature review that evaluates the tools used for
estimating dietary flavonoid intake in current literature, to describe their application
and relevance.
Chapter 3 and 4 describe the development of flavonoid intake assessment
methods, with chapter 3 outlining a secondary data analysis of the Blue Mountains
Eye Study to inform the development and validation of a food frequency questionnaire
for older Australians, and chapter 4 describing the development of a novel gas
chromatography/mass spectrometry technique to determine plasma phenolic profile in
humans for application in chapter 6.
Chapter 5 is a systematic literature review that synthesises the literature
relating to the impact of food-based anthocyanins on cognition, to inform the
development of the studies comprising chapters 6 and 7.
Chapter 6 and chapter 7 introduce and provide the results of the human
intervention trials conducted to assess the impact of fruit flavonoids on acute and
longer-term cognition, blood pressure and physical outcomes.
Chapter 8 summarises the findings and generates recommendation for future
research.

Each individual study comprising this thesis has been published or submitted for
publication, but will be presented in this thesis in a consistent and cohesive format
(with published papers included in the Appendices).
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Table 1-1 Overview of thesis studies and study design
Study number
Thesis component

(chapter

Study design utilised

number)
1 (2)

Systematic literature review
Secondary data analysis and

Measurement of dietary

2 (3)

flavonoid intake

validation study
3 (4)
4 (5)

Assessment of the impact of
flavonoids on cognition and

5 (6)

physical outcomes
6 (7)

1.7

dietary methodology

Laboratory methods
development (GC/MS)
Systematic literature review
Randomised acute crossover
study
Randomised controlled
clinical trial

Significance of research

A review of the methodology used to measure flavonoid intake is important to evaluate
the methods currently applied in flavonoid-related research and to provide
recommendations for future research. With no gold standard method for measuring
flavonoid intake, it is unclear which method for measuring or estimating dietary
flavonoid intake is most useful in intervention and empirical studies. The systematic
review provides an overview of the available strategies for measuring or estimating
dietary flavonoid intake and may provide an important resource for researchers when
developing future studies.

The development of new methodologies, both to estimate the intake of dietary
flavonoids through dietary assessment and to confirm the uptake and metabolism of
dietary flavonoids in biological samples, contributes significantly to a research area
with few valid tool options.
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The evaluation of current research that investigates the cognitive benefits
associated with specific flavonoid rich foods is important to highlight the gaps in the
literature and to provide recommendations for future research.

Investigations into the impact of anthocyanin-rich foods on acute and longerterm cognitive function and physical outcomes in specific population groups
contributes original knowledge related to a body of literature surrounding the impact
of flavonoids on cognition.

As a whole, this doctoral thesis provides a well-rounded approach to address the
most significant gaps in current literature surrounding the measurement of flavonoid
intake and the impact of flavonoids on cognitive and physical outcomes, with an
emphasis on older adults with a neurodegenerative disease. It contributes to the fields
of basic science, nutrition, psychology and public health, with each study contributing
a novel and innovative investigation, which together, advances our scientific
knowledge about dietary flavonoids.
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CHAPTER 2: EVALUATION OF TOOLS USED FOR ESTIMATING
DIETARY FLAVONOID INTAKE: A SYSTEMATIC REVIEW

In order to associate the impact of dietary flavonoids on health outcomes, accurate
measures of dietary intake are fundamental. The gaps in knowledge surrounding how
dietary flavonoid intake is measured, presented in the Introduction (Chapter 1) of this
thesis, indicated the need for improved methods for measuring dietary flavonoid
consumption. A systematic literature review was conducted to provide an evaluation
of the various methods employed by current literature to measure flavonoid intake,
and their associated limitations. The review presents findings showing the reliance of
studies utilising flawed dietary assessment methods to measure dietary flavonoid
intake. Additionally, the review concludes that despite several methods that measure
biomarkers of flavonoid intake being developed and validated, few studies apply
biomarkers as a measure of dietary flavonoid intake.
Katherine Kent1*, Karen E Charlton1, Yasmine C Probst1, Vivienne X Guan1
1

Faculty of Science, Medicine and Health, University of Wollongong

KK, KC and YP designed the study. KK and VG contributed to the literature search
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To assist clarity of formatting, Tables 2-2, 2-3 and 2-4 are provided at the end of this
chapter
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2
2.1

Introduction

While the association between flavonoid intake and health outcomes is promising,
more robust clinical data is needed. However, in order to associate flavonoid
consumption with positive health outcomes, the first and most fundamental step is to
accurately estimate dietary flavonoid intake. Despite the first estimations of flavonoid
intake on a population level being reported more than a decade ago, the methods
currently employed have evident flaws (1). Dietary flavonoid intake is difficult to
quantify, and consequently numerous methods have been developed for application in
various settings. With the absence of a gold standard approach, the methods utilised
include various techniques within the fields of both dietary assessment and biomarker
analyses.

There are currently numerous methods used to measure dietary flavonoid intake. With
no gold standard method for measuring flavonoid intake, it is unclear which method
for measuring or estimating dietary flavonoid intake is most useful in intervention and
empirical studies. The limitations associated with current methods hinder the
interpretation of observational and experimental research related to dietary flavonoid
intake and specific health outcomes. An evaluation and comparison of the tools to
measure flavonoid intake in observational and experimental research is imperative to
interpret current findings across the literature and to provide recommendations for
methods to apply in future research. Flavonoids are unlike other known nutrients in
foods, and therefore their complexity and variability needs to be carefully considered.
Traditional methods of dietary assessment require a recall or documentation of food
intake from a given time period in either a prospective or retrospective manner (2). To
determine the nutrient composition of individual or group intakes, this dietary intake
data is required to be converted to an estimated consumption of the nutrient of interest.
This can be done two ways, either applying a flavonoid specific food composition
database (FCDB) to the dietary intake data; or through the assessment of biomarkers
of intake that can be detected in biological samples.
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To improve methodological quality of future research, a clear understanding of
appropriate methods for measuring flavonoid intake is required. The proposed
systematic review aims to provide an overview of available strategies for measuring
or estimating dietary flavonoid intake and to provide an important resource for
researchers when developing future studies.

The overall purpose of this review is to summarise and synthesise the evidence about
the methods used in all published literature to measure or estimate dietary flavonoid
intake in adults. The following question guided the literature search:
“What method did researchers apply to determine intake of dietary flavonoids,
using a dietary assessment or biomarker method?”

2.2

Methods

This review is registered with the International Prospective Register of Systematic
Reviews (PROSPERO) under the registration number #CRD42014015607.

2.2.1

Types of studies

This review included randomised, non-randomised food-based trials, crossover foodbased trials, and analytical epidemiological study designs including prospective and
retrospective cohort, case-control and cross-sectional studies. Studies were restricted
to those published from January 2004 to November 2014 to ensure the literature was
current and relevant. Only studies published in English language were considered for
inclusion due to a lack of translation resources.

2.2.2

Types of participants

Adults aged 18 years or over.

2.2.3

Types of data

Dietary assessment methods (and the application of a flavonoid related FCDB) that
were utilised to investigate flavonoid intake were examined. Additionally, biomarkers
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including intact flavonoids or flavonoid metabolites, quantified in biological samples
(urine, plasma and/or faecal water) which are used to measure intake of flavonoids in
habitual diet or a flavonoid rich food were also reviewed

Flavonoid intake is defined as:
•

Total flavonoid intake

•

Intake of a single or multiple flavonoid subclass including
·

Flavonols

·

Flavanols (flavan-3-ols)

·

Flavones

·

Flavanones

·

Anthocyanins (anthocyanidins)

Estimation of isoflavone intake will be excluded from this analysis due to the specific
biological activities of isoflavones and the fact that isoflavone intake is often excluded
from studies that address total flavonoid intake. Additionally, the breadth of isoflavone
research is large enough to justify a distinct systematic review of the methods used to
estimate intake.

1.

Valid dietary assessment method employed, where applicable, which is cross-

referenced with food composition data for determining flavonoid content of dietary
intake/food/food groups. Including:
•

24-hour recall

•

food record/diary

•

food frequency questionnaire

•

diet history

2.

Biomarkers (intact flavonoids or associated metabolites) measured in

biological samples using one or a combination of the following methods, where
reported:
•

chromatography (high performance liquid; gas; column; thin layer; paper)

•

mass spectrometry;

•

nuclear-magnetic resonance spectroscopy;
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•

Folin–Ciocalteu assay

Validation and application assessment studies were also included. The exclusion
criteria were animal studies, food analytical experiment studies, studies related to
essential oils, mechanistic studies (bioavailability, pharmacokinetics or mechanistic
feeding studies) and reviews and meta-analyses. Studies were also excluded if ‘in
house’ or unpublished FCBDs not available to researchers were utilised. Lastly,
studies utilising non-specific biomarkers to measure flavonoid intake (i.e. antioxidant
activity or markers of inflammation) were excluded (Table 2-1).

2.2.4

Search Strategy

The search aimed to find both published and unpublished studies through electronic
databases, the World Wide Web and reference lists. Key terms were established:
•

Phenolic acid

•

Flavonoid*

•

Flavanol*

•

flavan-3-ol*

•

Anthocyanin*

•

Flavanone*

•

Flavonol*

•

Flavone*

•

Polyphenol*

Table 2-1 Overall inclusion and exclusion criteria for screening
Include if:
Language

Article published in English language

Yes

Design

Randomised or non-randomised food-based trials, or Yes
prospective or retrospective cohort or, case-control, crosssectional studies.
Case reports, reviews, editorials, letter to the editor, No
qualitative research
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Population Adults aged 18+ years

Yes

Animal studies or studies including <18 years
Content

No

Studies examining total or specific dietary flavonoid intake Yes
through valid dietary assessment or biomarkers

Access

Pharmacokinetics/bioavailability studies of intake

No

Full-text article accessible

Yes

A three-step search strategy was utilised in this review. The initial phase consisted of
searches of the following databases using the key terms searching in titles and abstracts
in the following databases:
•

Web of Science

•

Scopus

A second stage includes searching for key terms in the following sites on
www.googlescholar.com. A third stage of hand searching reference lists of articles
retrieved to identify further studies of interest was conducted.

2.2.5

Selection of studies

One review author (YP) conducted the literature search in the specified scientific
databases. Two review authors (KK and VG) independently assessed potential studies
identified by the search strategy for inclusion. Resolution of any disagreements was
mediated through discussion and as required, consultation with a third reviewer (YP)
for consensus.

Results of the search were collated in the reference manager, Endnote (EndNote X4
for Windows, Thomson Reuters). Duplicate publications were excluded. Articles
identified by database searches were assessed for relevance to the review based on the
title and abstract (Table 2-1). For those meeting the inclusion criteria, the full text
publication were retrieved and assessed for relevance to the review criteria.
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2.2.6

Data extraction, management and synthesis

Relevant data relating to flavonoid sub group, study design, tool used and where
relevant, the key methodological conclusions of the authors was extracted from the
studies into an Excel template, prepared for the purpose of this review. The studies
were grouped by total flavonoid intake and each flavonoid sub-group, described and
evaluated in accordance to their methodological similarities. The findings are
presented both in a narrative synthesis, as well as in tables and figures. When
information regarding any of the above was unclear, attempt was made to contact
authors of the original publication to provide further details.

2.3

Results

A PRISMA flow chart outlining the results of the search strategy and selection process
was developed (Figure 2-1). The search returned 833 articles, after duplicates were
removed, with 58 other potential studies identified through hand-sorting of reference
lists. After the abstracts were screened, 174 potential studies were identified. A further
77 were excluded according to the inclusion/exclusion criteria, leaving 97 final papers
in the review, with 76 estimating flavonoid intake using dietary assessment, and 20
relating to flavonoid biomarker analysis (including 15 validation studies and 5
application studies) (Figure 2-1).
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Records identified through

Additional records identified

database searching (duplicates

through other sources

removed)

(n = 58)

(n =833)

Total records identified
(n = 891)
Records screened

Records excluded

(abstract)

(n = 717)

(n = 891)

Full-text articles

Full text articles

assessed for eligibility

excluded (n =77)

(n = 174)
Studies included in qualitative

Studies included in

synthesis - Biomarkers

qualitative synthesis –

(n = 20)

Dietary assessment



(n = 76)

Validation studies (n = 15)
Application studies (n = 5)

Figure 2-1 PRISMA flowchart of the search strategy

2.3.1

Estimation of flavonoid intake from dietary assessment (Table 2-2)

Details regarding the studies that estimate dietary flavonoid intake using dietary
assessment are reported in Table 2-2. The study sample sizes ranged from 19 - 477,312
adults. The studies were conducted in the USA (n=28), Europe (multiple centre
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studies) (n=9), Finland (n=6), Spain (n=4), China (n=2), the Netherlands (n=2), UK
(n=2), Scotland (n=2), Australia (n=2), Mexico (n=2) and elsewhere. Study designs
included cohort studies (n=39), cross-sectional analysis (n=18), case-control studies
(n=16), randomised controlled trials (n=2) and an analytical study design (n=1).

Approximately a quarter of studies (n=19) were conducted with the primary aim of
estimating flavonoid intake, or intake of flavonoid subclasses in populations using a
dietary assessment tool. The majority of studies (n=57) estimated intakes to investigate
the association of flavonoid consumption with health outcomes, including various
cancers (n=29), cardiovascular diseases (n=14), diabetes (n=6), neuro-degenerative
conditions (n=3) and others (n=5). The majority of studies utilised a FFQ to estimate
dietary intake of flavonoids (n=57), while fewer estimated intake from 24 or 48h
recalls (single or multiple) (n=12), diet history methods (n=5) and food records (n=2).

The reference FCDBs utilised in the studies included data from one or a combination
of the USDA flavonoid database (2003, 2007, 2011) (n=49), the Phenol Explorer
database (n=11), other published data sources (n=21) and other databases (n=5) (Euro
FIR-eBASIS, ‘functional food database’).

Total flavonoid intake was reported by 58 studies (n=18 reported intake from a single
or multiple subclass only). However, the culmination of subclasses and sum of
individual flavonoids that contributed to this figure varied widely for each study, and
differences mainly reflected the different FCDBs applied in each study (Table 2-2).

Most studies provided detailed information pertaining to the individual flavonoids that
contributed to each subclass (the sum of which resulted in a measure of total flavonoid
intake). 24 studies provided insufficient detail on the individual flavonoids which
contributed to each subclass (denoted with NS – Table 2-2).

2.3.2

Estimation of flavonoid intake from biomarkers (Table 2-3)

Five studies were identified that utilised a biomarker as a measure of flavonoid intake
as outlined in Table 2-3. These studies were case-controls (n=4) and cross sectional
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(n=1) in nature, with populations ranging from 589 – 24,226 adults. Three studies
measured biomarkers in urine and the other studies assessed biomarkers in plasma
(n=2). Two studies assessed tea related biomarkers (EGC, EC, EGCG and ECG) using
HPLC, one study measured quercetin, kaempferol, two studies measured EC, EGC
and related metabolites using HPLC ESI-MS, and one study measured total
polyphenols in urine using the Folin-Cicocalteu assay.

2.3.3

Biomarker validation studies (Table 2-4)

Fifteen studies were identified that validated methods developed to measure
biomarkers of flavonoid intake or the intake of flavonoid-rich foods (Table 2-4). The
study sample sizes ranged from 19 – 786 adults, and were conducted in Norway (n=2),
Denmark (n=4), Australia (n=1), Africa (n=1), France (n=2), Spain (n=1), Finland
(n=1), China (n=1) and the UK (n=2). Twelve studies reported utilising Liquid
Chromatography, two studies reported utilising Gas Chromatography, and one study
utilised the Folin–Ciocalteu assay. Ten studies reported measuring intact flavonoids
in either urine or plasma. Other studies measured metabolites of flavonoid intake,
including phenolic acids (n=1) or a combination of both (n=3). Four studies
investigated the validity of the biomarkers in relation to total dietary flavonoid intake
(n=2), or the intake of specific flavonoid subclasses (n=2). Eleven studies validated
the biomarkers against the intake of flavonoid rich foods, such as fruit and vegetable
intake, tea consumption or the intake of specific foods (citrus and berries). The
reference methods were FFQs (n=7), food records (n=2), or controlled intervention
diets (n=3), food recall (n=1), and two studies did not adequately report on the
reference method utilised.

2.4

Discussion

This systematic literature review has presented and described the methods utilised by
researchers to measure or estimate dietary flavonoid intake, and/or intake of flavonoid
subclasses in studies, using a dietary assessment or biomarker method, published
between 2004 and 2014.
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The most common method of estimating flavonoid intake relied on dietary assessment
of habitual food intake. Generally, usual dietary analysis was performed using a FFQ,
a single or repeated 24-hour diet recall or a food record, which were cross-referenced
with a flavonoid FCBD. This review highlighted that there are very few flavonoid
specific FCBDs that exist globally and country-specific food composition data was
rarely available. Aside from the limitations associated with each dietary assessment
method (2), there are several well documented problems associated with utilising
FCBDs to assign flavonoid content to selected foods, resulting in large variations in
estimates of intake (3).

Firstly, estimation of dietary flavonoid intake is only as comprehensive as the
composition database utilised. If, for example, a composition database does not have
an extensive list of foods and the flavonoid content of a food in an individual’s diet
cannot be assigned or matched to its closest equivalent, then an individual’s intake
will certainly be under-estimated. This is particularly challenging when analysing food
intake data from a country that does not have a specific composition database for that
population, potentially resulting in significant sources of flavonoids for the population
not being captured. The primary databases utilised by studies identified in this review
(USDA, Phenol Explorer and Euro FIR-eBASIS) provide extensive and precise
information on the individual flavonoids in foods, with additional detail provided on
the variability of flavonoid contents in foods, as well as the values associated with
processing circumstances. It is interesting to note that the utilisation of different
databases may substantially influence the estimation of flavonoid intake in a study, as
highlighted by a recent comparison between estimates of dietary flavonoid intake
produced by the USDA and Phenol Explorer databases (4). However, this is not a well
researched concept and needs further verification.

Secondly, the flavonoid content of specific foods is highly variable and largely
influenced by a foods growth and processing conditions (5). Disregarding the
processes by which foods are manufactured and the impact on flavonoid levels leads
to an over-estimation of flavonoid intake. A flavonoid FCBD is largely unable to
account for this variability and can only provide an estimate for each food consumed
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(5). Studies did not generally apply retention factors, or comment if any methods were
applied to manage flavonoid degradation associated with cooking, for instance.

Lastly, estimating dietary flavonoid intake through dietary assessment is unable to
account for the high intra-individual variation associated with flavonoid metabolism
and absorption, which is influenced by factors other than intake, such as bioavailability
and genetic factors (6). Advances in informatics are crucial (5). Until the exact
bioavailability of all flavonoids are understood and the individual variations in
metabolism are accounted for, estimations of flavonoid intake and their correlation
with health outcomes should be interpreted with caution.

Despite the validation of several tools developed to specifically measure flavonoid
intake (7, 8), it appears that these tools have not been applied in further research. The
relative validity of these tools for the measurement of flavonoid intake can be partially
attributed to the fact that they effectively measure what they are hypothesised to
measure (i.e. estimated dietary flavonoid exposure). However, as true flavonoid intake
is difficult to establish, their objective validation, for example against a gold standard
assessment, remains questionable. This review highlighted that studies tended to
estimate flavonoid intake from a dietary assessment method that was not specifically
intended for the purpose of measuring flavonoid intake (e.g., a general FFQ designed
to capture energy intake). This can lead to misestimating exposure assessment, as
foods included in the surveys may not be comprehensive enough or specific enough
to capture the unique dietary exposure to flavonoids in that population. A major
limitation of FFQs in this sense is the practice of combining foods that are similar
nutritionally (e.g. apples and pears) into one question (thus, saving time coding and
entering data). However, as the flavonoid content of foods is very specific, this can
lead to misrepresentation of flavonoid intakes. It can not always be possible to collect
detailed dietary information due to the very large numbers of participants in large
epidemiological studies. However, the ability of these FFQs to capture flavonoid
intake and the intake of flavonoid subclasses must be questioned and considered when
interpreting the results of large studies.
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While dietary flavonoid intake can be determined by quantifying biomarkers which
include intact flavonoids and their metabolites found in plasma, urine and faecal water,
there is an obvious lack of validated biomarkers of dietary flavonoid intake. While
several of the validation studies outlined by this review (Table 2-4) found good
correlation between specific biomarkers and the intakes of tea, fruits and vegetables
(collectively), there is a lack of research to highlight the ability of a single, or multiple
biomarkers as a measure of total dietary flavonoid intake, or even intake of flavonoid
subclasses. This may be attributed to the difficulty in identifying useful biomarkers of
flavonoid intake. Many thousands of flavonoids have been identified and after
consumption they are quickly and extensively metabolised into various metabolites
(9). Consequently, there are thousands of potential biomarkers (this is
comprehensively explained in chapter 4 of this thesis) and there is no consensus
around which flavonoids or metabolites are indicative of total dietary intake or
reflective of intake for a certain food and/or food group. While many methods of
measuring flavonoid biomarkers in human biological samples exist, it appears there is
no standardised protocol of how to perform this analysis. This factor limits the
comparison of studies that have used different methods to measure certain biomarkers.

The usefulness of urinary metabolites to measure polyphenol (including flavonoid
intake) has been reviewed (10), and information pertaining to the bioavailability of
certain biomarkers after intake of foods. However, the review did not include synthesis
of studies that evaluated the ability of these biomarkers to measure dietary flavonoid
intakes in population settings. Another review recently summarised biomarkers of
fruit and vegetable intake applied in intervention studies (11). After reviewing 96
studies, the authors concluded that studies generally measured an antioxidant nutrient
(carotenoid or vitamin C) and highlighted that relatively fewer studies measured
flavonoid specific biomarkers such as quercetin (a flavonol). Some studies tried to
measure total flavonoid excretion in urine, but no studies measured flavonoid
biomarkers in plasma or faecal water.

Lastly, it is currently unknown which biological sample should be selected and some
research suggests each may be indicative of different consumption patterns. Previous
research has shown that urinary biomarkers of the flavonoid subclass of flavonoids
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may be more reflective of short-term intake (12, 13). Additionally, biomarkers in
fasting plasma or faecal water samples seem to be a suitable biomarker of short-term
intake and a possible biomarker of the medium-term intake (12). However, biomarkers
of long-term intake are not yet identified and may be unlikely due to the short halflives of dietary flavonoids. Lastly, most of the biomarker analyses are expensive and
often cannot be performed as part of large epidemiological studies (14). Future
research needs to focus on identifying specific biomarkers of flavonoid intake and
confirm the best methods in which to quantify these biomarkers in biological
specimens.

2.4.1

Conclusion

This review has highlighted the reliance of studies measuring dietary flavonoid intake
using dietary assessment methods (FFQs), with only a few studies associating
biomarkers of flavonoid intake with health outcomes (15, 16). This review has also
highlighted the considerable limitations surrounding the estimation of dietary
flavonoid intake, which are unlikely to be overcome in the near future. However, the
recent rapid advances in the understanding of flavonoid metabolism and
bioavailability is a promising sign for continuing future developments. Future research
needs to apply flavonoid specific dietary assessment methods that can adequately
measure total flavonoid intake and the intake of specific subclasses. Additionally,
future research needs to focus on identifying suitable biomarkers of flavonoid intake
for an objective measurement of flavonoid intake. Until such biomarkers are available,
reliance on dietary assessment methods will remain despite their many limitations.
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2.5

Tables 2-2 – 2-4

Table 2-2 Dietary assessment of flavonoid intake in published literature
Author

Study
design

Method

Flavonoid
total

Flavonoid Sub-classes
Flavonol

Flavan-3-ol

FCDB
used

Flavanone

Flavone

Anthocyanin

Other

Adebamo
wo et al.,
(24)

Cohort

FFQ, semiquantitative

-

quercetin,
kaempferol,
myricetin

-

-

-

-

-

Arem et
al., (26)

Cohort

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

NS

-

Bai et al.,
(27)

Crosssection
al

24h recall

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isorhamnetin

hesperetin,
naringenin,
eriodictyol

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

proanthocya
nidins

Bobe et
al., (28)

RCT

FFQ, semiquantitative

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG
catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG

hesperitin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

-

71

Published
data (25)
private
food
compositio
n data
2007
USDA
flavonoid
database,
2011
USDA
flavonoid
database

2007
USDA
flavonoid
database

Population &
Setting

Health
outcome

90,630
women,
USA

Cancer,
breast

537 104
adults, USA

Cancer,
pancreatic

17 900
adults, USA

-

1,859 adults,
USA

Cancer,
colorectal

Bobe et
al., (29)

Cohort

FFQ,
quantitative

Sum of
subclasses

kaempferol,
myricetin,
quercetin

catechin,
EC

-

luteolin,
apigenin

-

-

Published
data (25,
30-32)
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adults,
Finland

Cancer,
pancreatic

Bosetti et
al., (33)

Case
control

FFQ

Sum of
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kaempferol
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catechin

hesperitin
narigerin
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isoflavones

5,157 adults,
Italy

Cancer,
breast

Butchart et
al., (34)

Crosssection
al
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NS

catechins
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-

procyanidins

1091 adults,
UK

Cognition

Cassidy et
al., (36)
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93 600
women,
USA

Myocardia
l Infarction

Cassidy et
al., (37)

Cohort

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
EC

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

87,242
women,
USA

Hypertensi
on

Cassidy et
al., (38)

Cohort

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
EC

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

69 622
women,
USA

Stroke

Chun et
al., (39)

Crosssection
al

24h recall
(single)

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
EC, TF,
TR

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,

2003
USDA
flavonoid
database
a UK
flavonoid
database
(35)
2007
USDA
flavonoid
database,
EuroFIR
eBASIS
2007
USDA
flavonoid
database,
EuroFIR
eBASIS
2007
USDA
flavonoid
database,
EuroFIR
eBASIS
2003
USDA
flavonoid
database

8809 adults,
USA

-
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proanthocya
nidins,
theaflavins,
thearubigins

proanthocya
nidins,
theaflavins,
thearubigins

isoflavones

Chun et
al., (40)

Crosssection
al

24h recall
(single)

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
EC, TR,
TF

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

Cui et al.,
(41)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
EC, TR,
TF

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

Cutler et
al., (42)

Cohort

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

Dilis et al.,
(43)

Cohort

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

Djuric et
al., (44)
Dwyer et
al., (45)

Casecontrol
RCT

FFQ, semiquantitative
24h recall
(x3)

-

quercetin

-

-

-

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isorhamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin
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peonidin,
petunidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
NS

isoflavones

2003
USDA
flavonoid
database

8809 adults,
USA

-

-

2007
USDA
flavonoid
database

1395 adults,
USA

Cancer,
lung

isoflavones,
proanthocya
nidins

2003
USDA
flavonoid
database

34,708
women,
USA

cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
-

Proanthocya
nidins, TAC
indexes,

2007
USDA
flavonoid
database

28572
adults,
Greece

Cancer,
lung,
colorectal,
breast,
pancreatic
and upper
digestive
cancer
-

-

NS

cyanidin,
delphinidin,
malvidin,
pelargonidin,

isoflavones

2003
USDA
flavonoid
database

2664 adults,
USA
550 women,
USA

Cancer,
colorectal
-

Fink et al.,
(46)

Cohort

FFQ

Sum of
subclasses

NS

CG TF,
TDG,
TFG
NS

petunidin,
peonidin

Fisher et
al., (47)

Analyti
cal
study

FFQ

NS

-

-

-

-

-

proanthocya
nidin

GalvanPortillo et
al., (48)

Cohort

FFQ, semiquantitative

Sum of
subclasses

NS

NS

-

NS

-

-

Gates et
al., (49)

Cohort

FFQ, semiquantitative

Sum of
subclasses

myricetin,
kaempferol,
quercetin

-

-

Luteolin,
apigenin

-

Gates et
al., (50)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

myricetin,
kaempferol,
quercetin

-

-

Luteolin,
apigenin

-

-

Geybels et
al., (51)

Casecontrol

FFQ

-

-

-

-

Crosssection
al

FFQ, semiquantitative

myricetin,
kaempferol,
quercetin
NS

catechin,
EC

González
et al., (54)

Sum of
subclasses
Sum of
subclasses

NS

NS

NS

NS

Grosso et
al., (55)

Crosssection
al

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

NS

phenolic
acids,
lignans,
stilbenes
isoflavones,
phenolic
acids,
lignans,

NS

NS

NS

isoflavones,
lignans
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2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
Published
(25) and
unpublishe
d data
2007
USDA
flavonoid
database
Published
data (25,
31, 52, 53)
PhenolExplorer
database
PhenolExplorer
database

1210
women,
USA

Cancer,
breast
survival

19 older
adults, USA

Endothelia
l function

50 women,
Mexico

-

66,940
women,
USA

Cancer,
ovarian

2324
women,
USA

Cancer,
ovarian

58,279 men,
Netherlands

Cancer,
prostate

159 older
adults, Spain

Lipid
oxidative
damage

10477
adults,
Poland

-

stilbenes,
alkylphenols
, tyrosols
isoflavones,
proanthocya
nidins

Hardcastel
et al., (56)

Crosssection
al

FFQ

Sum of
subclasses

quercetin

Catechin,
EC

Hesperitin,
narigenin

NS

-

Hernandez
-Ramirez
et al., (57)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

NS

NS

-

NS

-

Hirvonen
et al., (58)

Cohort

-

NS

-

-

NS

-

Hirvonen
et al.,(59)

Cohort

-

NS

-

-

NS

-

-

Hughs et
al., (60)

Cohort

Selfreported,
modified diet
history
method
Selfreported,
modified diet
history
method
FFQ, semiquantitative

phenolic
acids,
lignans,
coumestans
-

-

myricetin,
kaempferol,
quercetin

-

-

-

Ivey et al.,
(61)

Cohort

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG
catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
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Published
data (35)
and 2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
Published
data (25,
31, 32)

3226
women,
Scotland

Bone
health

735 adults,
Mexico

Cancer,
gastric

25,041 men,
Finland

Intermitten
t
claudicatio
n

Published
data (25,
31, 32)

27,110 men,
Finland

Cancer

-

Published
data (25,
31, 52, 53)

4280 adults,
Netherlands

Stroke risk

proanthocya
nidins,
isoflavones

2007
USDA
flavonoid
database

1063 older
women,
Australia

Atheroscle
rotic
vascular
disease

Jacques et
al., (62)

Cohort

FFQ, semiquantitative

Sum of
subclasses

Quercetin,
kaempferol,
myricetin,
isohamnetin

Knaze et
al., (63)

Cohort

24 recall

-

-

Lagiou et
al., (64)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

Lagiou et
al., (65)

Casecontrol

FFQ, semiquantitative

Laurin et
al., (66)

Cohort

Letenneur
et al., (67)
Lin et al.,
(68)

TDG,
TFG
catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

Eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

proanthocya
nidin

2007
USDA
flavonoid
database

2915 adults,
USA

Diabetes

-

Cyanidin,
delphinidin,
nnalvidin,
pelargonidin,
petunidin,
peonidin
-

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG

-

proanthocya
nidin

36 037
adults,
Europe

-

NS

NS

NS

isoflavones

200 adults,
Greece

NS

NS

NS

NS

isoflavones

Peripheral
arterial
occlusive
disease
Coronary
heart
diseases

-

-

-

-

-

-

2009
PhenolExplorer
database,
2007
USDA
flavonoid
database
2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
Published
data (31)

NS

NS

Sum of
subclasses

NS

24h recall

NS

Cohort

FFQ

Cohort

FFQ, semiquantitative

Sum of
subclasses
-

quercetin,
kaempferol,
myricetin
quercetin,
kaempferol,
myricetin

-

-

luteolin,
apigenin

-

-

Published
data (25)

-

-

luteolin,
apigenin

-

-

Published
data (25,
69, 70)
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899 adults,
Greece

2,459 men,
HonoluluAsia
1064 older
adults,
France
66,360
women, a,
USA

Dementia

Cognitive
decline
Coronary
heart
disease

McCullou
gh et al.,
(71)

Cohort

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin.

Mink et
al., (72)

Cohort

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isorhamnetin

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

Mullie et
al., (73)

Crosssection
al

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isorhamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG
ECG,EGC
G
catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

Mursu et
al., (74)

Cohort

4-day FR

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isorhamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

Musru et
al., (76)

Cohort

4-day FR

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isorhamnetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

77

cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin

proanthocya
nidins,
isoflavones

2007
USDA
flavonoid
database

98469
adults, USA

Cardiovasc
ular
disease
mortality

proanthocya
nidins,
isoflavones

2003
USDA
flavonoid
database

34 489
women,
USA

Cardiovasc
ular
disease
mortality

cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin

proanthocya
nidins,
isoflavones

2003
USDA
flavonoid
database

45 women,
Belgium

-

-

1380 men,
Finland

Carotid
atheroscler
osis

cyanidin,
delphinidin,
malvidin,
pelargonidin,

-

2003
USDA
flavonoid
database
and
published
literature
(75)
2003
USDA
flavonoid
database
and

2590 men,
Finland

Cancer

petunidin,
peonidin
Nettleton
et al., (77)

Cohort

FFQ

Sum of
subclasses

NS

NS

NS

NS

NS

proanthocya
nidins,
isoflavones

Nothlings
et al., (78)

Cohort

FFQ,
quantitative

-

-

-

-

-

-

Nothlings
et al., (80)

Cohort

FFQ, semiquantitative

-

-

-

-

-

-

Ock et al.,
(81)

Crosssection
al

24h recall

Sum of
subclasses

quercetin,
kaempferol,
myricetin
quercetin,
kaempferol,
myricetin
quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
EC, TR,
TF

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

isoflavones

Otaki et
al., (82)

Crosssection
al

FFQ

Sum of
subclasses

EC, EGC,
catechin

Hesperitin,
narigenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
-

Ovaskaine
n et al.,
(83)

Crosssection
al

48h recall

-

EC,
catechin

Eriodictyol,
hesperetin,
and
naringenin.

-

cyanidin,
delphinidin

phenolic
acids

Perez
Jimenez et
al., (84)

Crosssection
al

24h recall
(x6)

-

NS

-

NS

NS

phenolic
acids,
lignans,
stilbenes,
minor

quercetin,
kaempferol,
myricetin,
fisetin
Isorhamnetin
,
kaempherol,
myricetin,
and
quercetin
NS

78

isoflavones

published
literature
(75)
2003
USDA
flavonoid
database
Published
literature
(79)
Published
literature
(79)
2003
USDA
flavonoid
database

35816
women,
USA

Diabetes
(Type II)

424 978
adults,
Europe
183,518
adults, USA

Cancer,
pancreatic

8809 adults,
USA

-

Functional
Food
Factor
database
Published
data (25,
32)

569 women,
Japan

-

2007 adults,
Finland

-

PhenolExplorer
database

4942 adults,
France

-

Cancer,
pancreatic

polyphenols
Rossi et
al., (85)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

NS

proanthocya
nidins,
isoflavones

Rossi et
al., (86)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

NS

proanthocya
nidins,
isoflavones

Rossi et
al., (87)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

NS

isoflavones

Rossi et
al., (88)

Casecontrol

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

NS

isoflavones

Somerset
et al., (14)

Crosssection
al

FFQ, semiquantitative

Sum of
subclasses

Sum of subclasses

Cohort

FFQ, semiquantitative

-

myricetin,
kaempferol,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG, TFG
-

eriodicty
ol,
hespereti
n,
naringeni
n
-

luteolin,
apigenin

Simons et
al., (89)

-

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin
-

Song et
al., (91)

Crosssection
al
Casecontrol

FFQ, semiquantitative

-

-

luteolin,
apigenin

-

-

FFQ, semiquantitative

Sum of
subclasses

myricetin,
kaempferol,
quercetin
NS

isorhamne
tin,
kaempfero
l,
myricetin,
quercetin
catechin,
EGC, EC,
EGCG,
ECG, GC,
CG
-

NS

NS

NS

NS

isoflavones

Tavani et
al., (92)
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2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
2003
USDA
flavonoid
database
2007
USDA
flavonoid
database

1362
women, Italy

Cancer,
endometria
l

978 adults,
Italy

Cancer,
pancreatic

3442
women, Italy

Cancer,
ovarian

6107 adults,
Italy

Cancer,
colorectal

60 adults,
Australia

-

Published
data (25,
31, 90)

120852
adults,
Netherlands

Cancer,
colorectal

Published
data (25,
31)
2003
USDA

38,018
women,
USA
1442 adults,
Italy

Diabetes
(Type II)
Myocardia
l infarction

Theodorat
ou et al.,
(93)
Wang et
al., (94)

Casecontrol

FFQ, semiquantitative

-

quercetin

Catechin,
EC

Hesperitin,
narigenin

NS

-

Cohort

FFQ, semiquantitative

-

Luteolin,
apigenin

-

Cohort

FFQ, semiquantitative

quercetin,
kaempferol,
myricetin
NS

-

Wang et
al., (95)

Sum of
subclasses
Sum of
subclasses

NS

NS

NS

NS

isoflavones,
proanthocya
nidins

Wedick et
al., (96)

Cohort

FFQ, semiquantitative

Sum of
subclasses

NS

NS

NS

NS

-

Welch et
al., (97)

Crosssection
al

FFQ, semiquantitative

Sum of
subclasses

quercetin,
kaempferol,
myricetin,
isohamnetin

catechins,
epicatachi
ns

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin.

Woo et al.,
(98)

Casecontrol

FFQ, semiquantitative

NS

NS

NS

NS

ZamoraRos et al.,
(100)

Cohort

FFQ or Diet
history
questionnaire

Sum of
subclasses
Sum of
subclasses

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin, and
petunidin
cyanidin,
delphinidin,
malvidin,
pelargonidin,
petunidin,
peonidin
NS

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin
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cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

isoflavones,
proanthocya
nidins
-

flavonoid
database
Published
data (35)

2912 adults,
Scotland

Cancer,
colorectal

Published
data (25,
31, 70)
2007
USDA
flavonoid
database
2007
USDA
flavonoid
database

38,408
women,
USA
43,268 men,
USA

Cancer

Prostate
cancer

200,894
adults, USA

Diabetes
(Type II)

proanthocya
nidins

2007
USDA
flavonoid
database

3160
women, UK

Bone
mineral
denisty

isoflavones

Published
data (99)

668 adults,
Korea

Cancer,
Gastric

lignans,
procyanidins
, isoflavones

2009
PhenolExplorer
database,
2007
USDA

477,312
adults,
Europe

Cancer,
gastric

ZamoraRos et al.,
(101)

Crosssection
al

Diet history
questionnaire

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG
catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

procyanidins
, isoflavones

ZamoraRos et
al.,(102)

Cohort

FFQ or Diet
history
questionnaire

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin,
quercetin

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

lignans,
procyanidins
, isoflavones

ZamoraRos et
al.,(103)

Cohort

FFQ or Diet
history
questionnaire

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

lignans,
procyanidins
, isoflavones

ZamoraRos et al.,
(104)

Cohort

FFQ or Diet
history
questionnaire

-

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

-

-

-

proanthocya
nidin
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flavonoid
database
2007
USDA
flavonoid
database,
UK Food
Standards
Agency
2009
PhenolExplorer
database,
2007
USDA
flavonoid
database
2009
PhenolExplorer
database,
2007
USDA
flavonoid
database
2009
PhenolExplorer
database,
2007
USDA
flavonoid
database

40,683,
Spain

-

334,850
women,
Europe

Cancer,
breast

340,234
adults,
Europe

Diabetes
(Type II)

340,234
adults,
Europe

Diabetes
(Type II)

ZamoraRos et al.,
(105)

Cohort

Diet history
questionnaire

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG TF,
TDG,
TFG

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin,
petunidin

lignans,
procyanidins
, isoflavones

2009
PhenolExplorer
database,
2007
USDA
flavonoid
database,

40,622
adults, Spain

Mortality

ZamoraRos et al.,
(106)

Cohort

24h recall

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin
and
quercetin

catechin,
EGC, EC,
EGCG,
ECG, GC,
CG

eriodictyol,
hesperetin
and
naringenin

apigenin
and
luteolin,

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin and
petunidin

isoflavones

35 628
adults,
Europe

-

ZamoraRos et al.,
(107)

Cohort

24h recall

-

-

eriodictyol,
hesperetin
and
naringenin

apigenin
and
luteolin,

-

-

36 037
adults,
Europe

-

ZamoraRos et al.,
(108)

Cohort

24h recall

-

isorhamnetin
,
kaempferol,
myricetin
and
quercetin
-

2009
PhenolExplorer
database,
2007
USDA
flavonoid
database
2007
USDA
flavonoid
database

-

-

-

-

2007
USDA
flavonoid
database

36 037
adults,
Europe

-

ZamoraRos et al.,
(109)

Casecontrol

Diet history
questionnaire

Sum of
subclasses

isorhamnetin
,
kaempferol,
myricetin,
quercetin

catechin,
EGC, EC,
EGCG,
ECG TF,

eriodictyol,
hesperetin,
naringenin

luteolin,
apigenin

cyanidin,
delphinidin,
malvidin,
pelargonidin,
peonidin and
petunidin
cyanidin,
delphinidin,
malvidin,

lignans,
procyanidins
, isoflavones

2009
PhenolExplorer
database,
2007

825 adults,
Spain

Cancer,
colorectal
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TDG,
TFG
Zhang et
al., (110)

Crosssection
al

FFQ, semiquantitative

-

Zhang et
al., (112)

Crosssection
al

FFQ, semiquantitative

Sum of
subclasses

quercetin,
myricetin,
kaempferol,
isorhamnetin
NS

-

-

luteolin,
apigenin

NS

NS

NS

pelargonidin,
peonidin,
petunidin
-

NS

-

proanthocya
nidins

USDA
flavonoid
database
Published
data (111)

2007
USDA
flavonoid
database
NS=details of individual flavonoids not specified, - = no data provided, FCDB = food composition database

5,046 adults,
China

-

3317 adults,
China

Bone
mineral
density

(-)-epigallocatechin (EGC), (-)-epicatechin (EC), (-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate (ECG), gallocatechin (GC), catechin3-gallate (CG)
theaflavin (TF), theaflavin 3,3-digallate (TDG), theaflavin 3-gallate (TFG), thearubigin (TR)
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Table 2-3 Studies identified that utilised a biomarker as a measure of flavonoid intake
Author
Iwasaki et
al., (22)

Study
design
Nested
casecontrol

Method
HPLC with
colorimetric
array detector

Biological
sample
Plasma

Biomarkers
EGC, EC, EGCG,
ECG

Health
outcome
Cancer,
breast

Population &
Setting
24,226 women,
Japan

353 incident breast
cancer cases, 701
individually
matched controls,
Japan
589 adults, Spain

Luo et al.,
(23)

Nested
casecontrol

HPLC/ESI-MS

Urine

Quercetin,
kaempferol, EC,
EGC, M4, M6, 40MeEGC

Cancer,
breast

MedinaRemón et al.,
(113)
Sasazuki et
al., (114)

Crosssectional

Folin-Ciocalteu
assay

Urine (spot)

Total polyphenol

Blood
pressure

Nested
HPLC
Plasma
EGC, EC, EGCG,
Cancer,
494 gastric cancer
caseECG
gastric
cases, 494
control
Controls, Japan
Yuan et al.,
NestedLC/ESI-MS, NMR
Urine
EGC, 40-MeEGC,
Cancer,
162 colorectal
(115)
caseEC, M4, M6
colorectal
cancer cases, 806
control
controls, China
high-performance liquid chromatography (HPLC), liquid chromatography (LC), electrospray ionization (ESI), mass spectrometry (MS), nuclear magnetic resonance (NMR)
(-)-epigallocatechin (EGC), (-)-epicatechin (EC), (-)-epigallocatechin 3-gallate (EGCG), (-)-epicatechin 3-gallate (ECG),
5-(30, 40, 50-trihydroxyphenyl)-c-valerolactone (M4), 5-(30,40,-dihydroxyphenyl)-cvalerolactone (M6), 40-MeEGC, the methylated form of EGC,
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Table 2-4 Validation of methods developed to measure biomarkers as markers of total flavonoid intake or intake of flavonoid rich foods
Author

Design

Refere
nce
metho
d
FFQ

Biomarker

Method

Biologic
al
Sample

Flavonoid subclasses or dietary
intake estimated

Population &
Setting

Sig. methodological conclusions

Brantsæte
r et al.,
(116)

Crosssectional

hesperitin, naringenin,
eriodictyol, phloretin,
quercetin, kaempferol,
isorhamnetin,
tamarixetin
apigenin
hesperetin, naringenin,
quercetin, kaempferol,
isorhamnetin,
tamarixetin, genistein,
daidzein,
apigenin, phloretin
eriodictyol, naringenin,
hesperetin; quercetin,
kaempferol,
isorhamnetin,
tamarixetin, phloretin

LC/MS

Urine

Fruit, vegetables,
tea intake

119 pregnant
women, West
Africa

FFQ estimate of fruit intake was
significantly correlated with phloretin (r
= 0.33), citrus fruit/juice with hesperetin
(r= 0.44), tea with kaempferol
(r = 0.41) (P < 0.01 for all)

Bredsdorf
f et al.,
(117)

Nested
casecontrol
study

FFQ

HPLCMS

Urine

Individual
flavonoids, sum
sub-classes, sum
total

393 cases (acute
coronary syndrome)
393 non-cases,
Denmark

Correlations between urinary kaempferol
excretion and intakes of tea 0.34 (P <
0.0001), wine 0.17 (P < 0.0001),
vegetables 0.08 (P = 0.020)

Brevik et
al., (118)

Randomi
sed
crossover
study

Contro
lled
interve
ntion
diet

HPLCMS

Urine

Fruit, vegetable
intake

40 adults, Norway

7-day
food
record
s

quercetin, kaempferol,
isorhamnetin,
apigenin, luteolin

HPLC

Plasma
(fasting)

quercetin,
kaempferol,
isorhamnetin,
apigenin, luteolin

92 adults, China

FFQ

apigenin, eriodictyol,
hesperidin, kaempferol,
naringenin, phloretin,
quercetin, tamarixetin,
isorhamnetin

HPLC

Urine
(2x24h
urine
samples)

Fruit, vegetables,
juice intake

85 adults, Norway

Increased intake of mixed fruits and
vegetables from 2 to 5 servings/day
significantly increased urinary excretion
of eriodictyol, naringenin, hesperetin,
quercetin, kaempferol, isorhamnetin, and
tamarixetin.
The mean 7 d intake of quercetin,
kaempferol, isorhamnetin, apigenin, and
luteolin was positively correlated to
corresponding plasma concentrations,
with correlation coefficients ranging
from 0·33 to 0·51 (all P<0·05).
Total urinary flavonoids showed good
correlation with fruit, juice, and
vegetable intake. The highest
correlations were observed between the

Cao et al.,
(119)

Crosssectional
study

Carlsen et
al., (120)

Crosssectional

85

Hodgson
et al.,
(121)

Crosssectional

Huxley et
al., (122)

Randomi
sedcontrolle
d trial

Koli et al.,
(123)

Randomi
sed,
placebocontrolle
d dietary
intervent
ion trial.

Krogholm
et al.,
(124)

Crosssectional

Self
report
ed tea
intake
(cups/
day)
FFQ

4-O-methylgallic acid
(4OMGA), isoferulic
acid

GC-MS

Urine
(24h)

Tea, coffee intake
(# cups/day), no
detail on data
collection method

455 adults,
Australia

quercetin, kaempferol,
isorhamnetin

Not
reported

Plasma

Fruit, vegetable
intake

690 adults, UK

Contro
lled
interve
ntion
diet

quercetin, p-coumaric
acid, 3hydroxyphenylacetic
acid, caffeic acid,
protocatechuic acid,
vanillic acid,
homovanillic acid, 3(3hydroxyphenyl)propion
ic acid

GC-MS,
HPLC

Plasma
(fasting),
Urine
(24h)

Berry intake

72 adults, Finl

24h
recall

quercetin, isorhamnetin,
tamarixetin,
kaempferol, hesperetin,
naringenin, eriodictyol,
daidzein, genistein,
phloretin

HPLCEI-MS

Urine
(24h)

Fruit intake

103 adults,
Denmark
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intakes of fruit (including juice) with
hesperidin and naringenin biomarkers.
4OMGA was related to usual (r 0·50,
P<0·001) and current (r 0·57, P<0·001)
tea intake, isoferulic acid was related to
usual (r 0·26, P=0·008) current (r 0·18,
P<0·001) coffee intake.
No change in total non fasting plasma
flavonol concentrations between baseline
and follow up in either the control or
intervention group. Flavonol
measurements may not predict total fruit,
vegetable intake.
Plasma quercetin, p-coumaric acid, 3hydroxyphenylacetic acid, caffeic acid,
protocatechuic acid, vanillic acid,
homovanillic acid, 3-(3hydroxyphenyl)propionic acid increased
significantly from the baseline in the
berry group compared to the control
group (p < 0.05). Urinary excretion of
quercetin, p-coumaric acid, 3hydroxyphenylacetic acid increased
significantly in the berry group compared
to the control group (p < 0.05). All the
biomarkers may reflect a diet containing
moderate amounts of blue/ red berries.
24 h urinary excretion of total flavonoids
and the estimated intake of fruits were
correlated (r0.31, P0.01). Intake of citrus
fruits, citrus juices was correlated with
total excretion of citrus specific
flavonoids (r0.28, P0.01), orange was

Krogholm
et al.,
(125)

Crosssectional

FFQ

quercetin, isorhamnetin,
tamarixetin,
kaempferol, hesperetin,
naringenin, eriodictyol,
phloretin apigenin

HPLCEI -MS

Urine
(spot,
morning
void)

Fruit, vegetables,
beverages

191 adults,
Denmark

Krogholm
et al.,
(126)

Randomi
sed,
controlle
d
crossove
r study

Interv
ention
diet

HPLCEI-MS

Urine
(spot,
morning
void) vs
Urine
(24h)

Fruit, vegetable
intake

12 men, Denmark

MedinaRemo´n et
al., (113)

Crosssectional

FFQ

flavonols quercetin,
kaempferol,
isorhamnetin,
tamarixetin, the
flavanones hesperetin
naringenin, the
dihydrochalcone,
phloretin
Total polyphenol

FolinCiocalte
u assay
vs FFQ

Urine
(spot)

Total polyphenol
intake

589 adults, Spain

Mennen et
al., (20)

Crosssectional

2-day
FR

HPLC–
EI–MS

Urine
(24h) vs
urine
(spot)

Polyphenol rich
food intake

53 adults, France

chlorogenic acid,
caffeic acid, mcoumaric acid, gallic
acid, 4-O-methylgallic
acid, quercetin,
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positively correlated with naringenin
(r0.24, P0.01) hesperetin (r0.24, P0.01).
Phloretin was correlated with apple
intake (r0.22, P0.01) and overall
estimated intake of fruit (r0.22, P0.01).
The intakes of fruit, juice, vegetables and
tea reported in the FFQ were reflected by
the flavonoid biomarker both in
overnight and 24h urine samples.
Validity coefficients for the flavonoid
biomarker in overnight urine ranged
from 0.39 to 0.49, while the
corresponding validity coefficients for
the biomarker in 24h urine ranged from
0.43 to 0.66.
The total excretion of flavonoids in 24-h
urine samples increased linearly with
increasing fruit vegetable intakes (rs =
0.86, P < 0.001). The total excretion of
flavonoids in morning urine also
increased, but the association was weaker
(r = 0.59, P < 0.0001)
The intake of 100 g of F&V (β=0.150;P
< 0.001) had a greater contribution to
TPE than 100 mL of coffee
β=0.141;P=0.001), the latter two foods
contributed more than the consumption
of 100 mL of wine (β=0.120;P=0.019).
Spot urine: apple intake
positively correlated to phloretin,
grapefruit intake to naringenin, orange to
hesperetin, citrus fruit consumption to
both naringenin and hesperitin (r

isorhamnetin,
kaempferol, hesperetin,
naringenin,
phloretin, enterolactone
enterodiol,

PujosGuillot
(127)

Ranka et
al., (128)

between 0·31 to 0·57) (P<0·05)
All fruits, juices positively correlated to
gallic acid, 4-O-methylgallic acid,
isorhamnetin, kaempferol, hesperetin,
naringenin, phloretin (r 0·24–0·44,
P<0·05). Coffee consumption positively
correlated to caffeic, chlorogenic acids (r
0·29 0·63, P<0·05 respectively). Black
tea, wine consumption were positively
correlated with gallic, 4-O-methylgallic
acids (r 0·37–0·54, P<0·001). The
present results suggest that several
polyphenols measured in a spot urine
sample can be used as biomarkers of
polyphenol-rich food intake.
Cohort
NS
Flavanone glycosides
LC-MS
Urine
Citrus intake
80 adults (40 low
Hesperetin 3′-O-glucuronide, naringenin
study
(spot)
40 high citrus
7-O-glucuronide were identified as
consumers), France
potential biomarkers of citrus intake,
however the assessment was not
sensitive enough to discriminate high
low citrus consumers
CrossFFQ
quercetin and
HPLC
Urine
quercetin and
49 adults, UK
The correlation between FFQ estimated
sectional
naringenin
(24h)
naringenin intake
intake of quercetin and naringenin and
levels excreted in the urine were r0.82
(P<0.0001) and r0.25 (P=0.05),
respectively.
high-performance liquid chromatography (HPLC), liquid chromatography (LC), electrospray ionization (ESI), mass spectrometry (MS)
food frequency questionnaire (FFQ), food record (FR), food composition database (FCDB)
NS- not specified
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CHAPTER 3: A SECONDARY DATA ANALYSIS CONDUCTED TO
INFORM THE DEVELOPMENT AND VALIDATION OF A FOOD
FREQUENCY QUESTIONNAIRE TO MEASURE FLAVONOID INTAKE
IN OLDER AUSTRALIANS

Accurate estimation of the impact of dietary flavonoids on health outcomes is
dependent on the tools used to measure dietary intake. However, as previously
described in Chapter 1 and 2, the current methods for measuring flavonoid intake are
flawed and there is an absence of dietary assessment tools for older Australians.
Therefore, this chapter describes two studies to address the measurement of dietary
flavonoids in older Australians. The first is a secondary data analysis of the Blue
Mountains Eye Study, conducted to describe the intake of flavonoids and flavonoid
subclasses, and the main dietary sources of these, in older Australian adults. Secondly,
this chapter outlines the utilisation of this data in the development and subsequent
validation of a food frequency questionnaire designed to easily estimate flavonoid
intake in older Australians.

This chapter has been written and presented as two separate publications:
Appendix C
Kent, K, Charlton KE, Russell J, Mitchell P, Flood V, 2015. Estimation of
flavonoid intake in older Australians: secondary data analysis of the Blue
Mountains Eye Study. Journal of Nutrition in Gerontology and Geriatrics.
http://dx.doi.org/10.1080/21551197.2015.1088917

Kent, K, Charlton, KE, 2015. Validation of a food-frequency questionnaire to
measure flavonoid intake in older adults. (In preparation)

This data was also presented in:
Caldwell* K., Charlton K., Flood V., and Russell, J., 2014. Development of a
Quantitative Food Frequency Questionnaire to Measure Flavonoid Intake in
Older Australians. 24 and 25 of November 2013, Adelaide, Australia. Making
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Research Matter Conference Proceedings: The 13th National Conference of
Emerging Researchers in Ageing (pp. 44-44).

The Food Frequency Questionnaire developed and assessed in this chapter can be
found in Appendix G.
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3
3.1

Introduction

Information on consumption patterns of flavonoids is sparse, and only a few Australian
estimations of flavonoid intake are available in the literature (1-3). Total flavonoid
consumption (2), and the main sources of flavonoids (3), has been estimated in an
Australian population using 24hr recall data from the 1995 National Nutrition Survey,
in combination with the U.S. Department of Agriculture (USDA) flavonoid
composition database (4). This analysis reported that the average adult intake of
flavonoids was 454 mg day, with 70% of the intake attributed to black tea alone (3).
The differing eating patterns of older Australians, compared with younger adults, were
reflected in identification of different contributors of foods to total flavonoid intake.
Notably, flavonoid contribution from tea and wine sources increased markedly with
age (2). However, there are major limitations to the use of a 24hr recall for capturing
the usual intake of flavonoids in a population. Some foods that are high in flavonoid
content, such as seasonal fruits, may not be reflected and the high day-to-day
variability in flavonoid intakes will introduce bias in estimation of habitual intakes. To
this end, the National Nutrition Survey analysis provides an initial insight into the main
sources of flavonoids and flavonoid subclasses in the Australian population, which
differed from varied international estimates (5-9). In older adults few estimates of total
flavonoid intake exist and a varied range of intake has been reported (8). The
Australian population-based estimation has a limited focus on older adults and thus
provides insufficient evidence of estimated flavonoid intake in older Australians.
Therefore, despite a large body of evidence that links flavonoid consumption with
improved health outcomes in older adults, there is little published information on
quantities, subtypes and food sources of flavonoids in this age group.

The aim of this research was to describe dietary flavonoid intake in a sample of older
Australians and identify the intake of flavonoids from various sub-classes (flavonols,
flavan-3-ols, anthocyanins, flavones, and flavanones), using weighed food record
(WFR) data obtained from a sub sample of older adults participating in the Blue
Mountains Eye Study (BMES).
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3.2

Methods

The BMES is a longitudinal, population-based cohort study of eye diseases and other
chronic health outcomes in residents aged 49 years and over in a defined area, west of
Sydney, Australia (16). The BMES is unique in that it collected detailed dietary
information specifically in older Australian adults. To the best of our knowledge, this
study provides the most comprehensive dietary information from older Australians to
date. The original cohort (n=3654) was enrolled at baseline (1992-1994) and were
followed up at 5 year intervals (1997-1999; 2002-2004; 2007-2009) (16). The dietary
intake data utilized in this study was collected in 1994, and comprised three separate
4-day WFRs, that is twelve days in total, collected four months apart in a randomly
selected sub-sample of the BMES cohort (n = 79), and thus reflected intake over a 12
month period, in different seasons (17-19). This dietary data was collected to assess
the validity and reproducibility of a self-administered food frequency questionnaire
developed to measure dietary patterns in the larger cohort (17). Of the 150 individuals
that agreed to participate in the validation study, a total of 79 participants adequately
completed three WFR over eight months(17). The sub-sample comprised 45 females
(57%) and 34 males (43%) with a mean age of 70.1 years (age range was 60y to 80+y)
(17) and a mean BMI of 21.27 (±3.3). WFR data was analysed using Microsoft Access
(2010). The proportion of men and women who participated in the WFR study and the
baseline BMES cohort were similar. By design, those who participated in the WFR
validation study were older than those in the BMES cohort study (70.1 years to 65.4
years, p<0.0001). An older sample was selected to conduct the validation study as
research interests were in age-related diseases uncommon in younger people and
researchers wanted to ensure a valid instrument for subjects likely to become incident
cases (17). The data was manually cross-referenced with the USDA Database for the
Flavonoid Content of Selected Foods (Release 3.1) (10) to assign each food reported
a total flavonoid value and a value for each flavonoid subclass: flavonols, flavan-3ols, anthocyanins, flavones, flavanones. The isoflavone content of foods is not reported
in the USDA flavonoid database (it is reported in a separate database). This point,
coupled with the fact that isoflavone consumption in Australia is very low (14)
(isoflavones are largely provided by soy foods), isoflavone intake was not assessed.
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Data was exported from Microsoft Access to SPSS statistical program (V17.0: 2006,
SPSS, Inc., Chicago, II, USA) for analysis. The mean and range of flavonoid intake
per 4-day food record was calculated and intake of flavonoids and flavonoid subclasses
per person, per day was estimated. Differences between males and females were
analyzed using a one-way ANOVA. Differences between the 4day WFRs taken across
three different time points were assessed using a one-way ANOVA. A p value ≤0.05
was considered to indicate statistical significance. The coefficient of variation was
calculated for total flavonoid intake to analyze the degree of inter-individual variation
between WFRs, and was reported as a percentage. The intra-individual variation was
calculated to assess the potential variability within each individual’s score at each
WFR. The proportion that each flavonoid subclass contributed to overall flavonoid
intake was determined by calculating the total reported amount (mg) of each subclass
divided by the total amount (mg) of flavonoids reported (described as percentage).
Rich and commonly consumed dietary flavonoid sources were identified and ranked
in relation to their contribution to overall flavonoid intake in the cohort, by calculating
the total reported amount (mg) of a flavonoid subclass present in each food (as per the
USDA database) divided by the total amount (mg) of flavonoids reported in each
subclass (described as percentage).

3.3

Results

Mean, standard deviation and range of intake for total flavonoids and for each
flavonoid subclass, per person each day was calculated (Table 3-1).
There were significant differences between males (9130.3±3197.8 kilojoules/day) and
females (7427.5±4699.1 kilojoules/day) for total energy intake (p=0.0005). However,
there were no significant differences between males and females for total flavonoids
(p=0.068) or for flavonoid subclasses; flavonol (p=0.621), flavone (p=0.364),
flavanone (p=0.431), flavan-3-ol (p=0.055) and anthocyanin (p=0.081). The total
percentage contribution of each flavonoid subclass to total flavonoid intake according
to BMES WFR data is shown in Figure 3-1.
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Table 3-1 Mean Intake of Total Flavonoids and Flavonoid Subclasses per Person, per
Day According to Weighed Food Records*
Flavonoid
Flavone
Flavonol
Flavanone
Flavan3ol
Anthocyanin
(total)
mg
n
mg /day
mg /day
mg /day
mg /day
mg /day
/day
Total
79
Male

683.2±506.7

28.7±20.4

1.9±2.9

21.2±25.4

629.4±494.1

7.0±9.2

(7.3–5060.9)

(0.4–204.4)

(0–26.8)

(0–147.8)

(0-4906.3)

(0-69.4)

1.7±2.4

22.6±26.9

561.3±419.3

8.1±1.0

(0-16.1)

(0-147.8)

(0-1921.3)

(0-49.1)

616.9±435.4
34

Female
45

(7.3-2038.2)

27.9±22.1
(0.375204.3)

732.6±550.1

29.2±19.1

2.1±3.1

20.1±24.3

(38.7-5060.9)

(2.6-181.6)

(0-26.2)

(0-131.9)

680.2±538.9
(7.564906.3)

6.1±8.4
(0-69.4)

*Data are expressed as mean±SD (range: min - max).

One way ANOVA assessed the difference in total flavonoid intake and intake of
flavonoid subclasses between the three separate 4-day WFRs and showed no
significant differences in total intake or intake of any subclass between each of the
collection periods. The inter-individual variation between WFRs showed a similarly
large variation for WFR1 (55%), WFR2 (53%) and WFR3 (57%). The coefficient of
variation, which assessed the intra-individual variation in flavonoid intake across the
three separate 4-day WFRS, showed a mean variation of 28.6% (range 0.9%-122.9%,
median 22.2%).

The total number of reported foods in the collated BMES WFR data was 895 foods
and flavonoid content was assigned to 171 of these foods. The sources of total
flavonoids that contributed the most to each food group as reported in the BMES WFR
data, were calculated (Table 3-2). The top five foods that contributed to the flavan-3ols, flavonols, flavones, flavanones and anthocyanin subclasses of flavonoids are
shown in Table 3-3.
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Flavonol, 5.15%
Flavone, 0.15%
Anthocyanin,
0.046

Flavanone,
1.90%

Flavan3ol,
88.10%
Figure 3-1 Percentage contribution of flavonoid subclasses to total flavonoid intake.
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Table 3-2 Top 10 Flavonoid Containing Foods Ranked in Order of Contribution to Total Consumption
Fruit
Vegetables
Beverages
Alcohol*
Other foods
Food (mean
Food (mean
Food (mean
Food (mean
Food (mean
%
%
%
%
%
serve, g)
serve, g)
serve, g)
serve, g)
serve, g)
Wine, Red
1 Orange (129.0) 1.37 Onion (63.5) 0.34 Black tea (237.6) 89.1
0.44
Parsley (13.94)
0.18
(128.0)
Tomato, raw
Green tea
Wine, White
Marmalade
2 Banana (100.7) 0.86
0.19
1.3
0.06
0.08
(59.5)
(307.4)
(140.9)
(19.4)
Apple , Raw
Green Bean
Orange Juice
Milo Powder
3
0.66
0.12
1.1
Beer (151.2)
0.04
0.03
(112.0)
(187.84)
(127.9)
(12.4)
Apple, Stewed
Grapefruit Juice
Chocolate, Dark
4
0.12 Potato (104.8) 0.09
0.09
Sherry (73.1)
0.02
0.019
(110.7)
(137.1)
(18.3)
Apple Juice
Champagne
5 Mandarin (93.5) 0.12 Spinach (66.5) 0.05
0.06
0.002 Almond (24.8) 0.011
(148.6)
(271.1)
Brussels Sprout
6
Peach (125.3)
0.12
0.04 Coffee (188.9)
0.06
Pecan (34.0)
0.08
(67.6)
Strawberry
Pumpkin
Lemon Juice
7
0.09
0.04
0.04
Date (36.4)
0.007
(99.4)
(66.21)
(24.6)
Grape, black
Milk, chocolate
Cocoa powder
8
0.08 Radish (47.7) 0.04
0.02
0.065
(160.9)
(256.5)
(4.31)
Grapefruit
Tomato Juice
Jam, Berry
9
0.06 Celery (53.5) 0.04
0.006
0.004
(79.3)
(235.6)
(24.75)
Grape Juice
10
Plum (121.1)
0.06 Lettuce (42.1) 0.03
0.001
Ginger (10.1)
0.004
(102.55)
% = percentage contribution to overall flavonoid intake according to 12 days of WFRs (n=79) from participants in the Blue
Mountains Eye Study; * Alcohol only had five contributing beverages.
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Table 3-3 The Five Main Dietary Sources of Each Flavonoid Subclass Based on
Weighed Food Records
Flavonoid
Subclass
Flavan-3-ols

Tea, Black
Tea, Green
Apple
Banana
Wine, red

% contribution
to subclass
94.55
3.52
0.40
0.39
0.155

Flavonols

Tea, Black
Onion
Apple
Tea, Green
Beans

68.59
7.73
3.39
2.78
2.76

Flavones

Parsley
Tomato
Celery
Pumpkin
Watercress

98.52
0.69
0.27
0.23
0.13

Flavanones

Oranges
Orange Juice
Mandarin
Tomato
Grapefruit Juice

44.47
36.78
4.07
3.06
2.80

Anthocyanins

Blueberry
Banana
Radish
Wine, red
Cabbage, red

29.56
22.81
9.14
8.19
7.71

Food
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3.4

Discussion

The BMES WFR data was derived from 12 days of weighed food records in 79 people,
equating to 948 person-days analysed.

The mean intake of total flavonoids

(683mg/day) was significantly higher than previous estimations (454mg/day) (2) for
the total Australian population. However, it is similar to the estimation of flavonoid
intake (693mg/day) for the 65+ year old age group within the study from the
Australian population estimates (2). The proportional intake of each flavonoid
subclass in our data (Figure 3-1) compares closely with the Australian nationally
representative 1995 National Nutrition Survey (NNS) data that was based on a 24hr
recall method (3). Flavan-3-ols contributed the majority of flavonoid intake (92%),
followed by flavonols (4%), flavanones (3%) and flavones (<1%). The difference in
total flavonoid intake estimated between the studies may reflect the difference in
dietary assessment methods and the size of the study population, however, the
agreement seen between the comparative age group may confirm a higher flavonoid
intake in this age range.

The major food sources of flavonoids identified by the current analysis were black tea
(89.1%), oranges and orange juice (1.37% and 1.3% respectively), green tea (1.3%)
and bananas (0.87%). The strength of this data relates to the 12 days of dietary data
being collected over 12 months, to reduce the impact of seasonality of food
consumption and consequently flavonoid intake. However, it is interesting to note that
no difference was seen in total flavonoid intake or intake of any flavonoid subclass
between the three separate 4-day WFR, when comparing the group intakes as a whole.
This is likely to be attributed to the habitual nature of tea consumption, which is fairly
stable throughout the year. However, the high intra-individual variation, where on
average there is a variation of nearly 29% in flavonoid intake between the 3 separate
4-day WFRs, is quite significant. Therefore, the impact of seasonality for the group as
a whole may be low, but the extent to which a particular individual may fluctuate is
quite substantial. This should be a consideration in future studies investigating dietary
flavonoid intake, whereby collecting dietary data in different seasons may not
significantly influence flavonoid intake estimates on the population level, but the
importance of individual variation should be considered.
99

The food sources identified are similar to the foods reported in the Australian NNS95
population based analysis (3). In another Australian study (1), similar food sources
were reported to contribute to flavonoid subclasses in a group of healthy, young
women. Major sources of flavonols were reported to be tea, apples and onions, while
major sources of flavones were parsley and celery, and significant sources of
flavanones were citrus fruits, including oranges and grapefruit. Additionally, tea was
shown to be the main contributor to total flavonoid intake (1), a finding confirmed by
our study.

International comparisons identify large variations in estimates of flavonoid intakes
of older adults, with one US study reporting adults aged ≥51 years to consume only
191mg/day, as estimated from two 24h diet recalls (15). A Finnish study of males aged
48, 54 or 60 reported a similarly low estimate of 139mg/day, based on a 4-day food
record (16). However, the trend showing higher intake of dietary flavonoids in older
adults compared with other age groups is similar across all the national and
international estimates. The low flavonoid intake estimates may be attributable to
different dietary assessment methods and may also be potentially linked to the
application of more limited flavonoid reference databases, leading to an underreporting of total flavonoid intake.

While there was no significant difference between genders for total flavonoid intake
or intake of any flavonoid subclasses, a difference in total energy intake was noted.
This indicates that the major contributors to flavonoid intake may be minor
contributors to total energy intake. This is highlighted by the influence of black and
green tea, which account for more than 90% of total flavonoid intake and are low in
kilojoules. Future research could adjust for energy intake to assess whether there are
differences in flavonoid intake between genders after accounting for differences in
energy intake.

Despite providing sound dietary data, there are several limitations identified with
utilizing the BMES WFR data to estimate flavonoid intake in older Australians.
Firstly, this data was collected in the mid-1990s and the diets of older adults may have
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evolved or changed over time to present. There is, however, a notable lack of
population-based studies in older Australian adults that has collected dietary
information with this level of precision since that time. A 10-year follow up of the
BMES cohort showed overall fruit and vegetable consumption had not significantly
changed from baseline (17). Changes that were found in dietary patterns over time
generally related to fat (MUFA, PUFA, and SFA) and total sugar (not CHO) intake.
These macronutrients are not present in large quantities in flavonoid-rich foods.
Despite little change in fruit and vegetable intake over time in cohort survivors,
applicability of the study findings may be limited by the changing food supply,
limiting the generalizability of this data to the current population for specific food
groups. However, further research is required to confirm these assumptions. While the
BMES study population was generally representative of the older Australian
population, they had slightly a higher socioeconomic status and a slightly higher level
of post-school qualifications than the general population (18). Additionally, people
who agree to complete 12 days of WFRs are also more likely to be highly motivated
about recording the details of their diet (18), and could also therefore tend to have
higher quality diets with an increased nutrient density, compared to the general
population. Lastly, this secondary data analysis relied on the WFR data which had
previously been transcribed into Diet 1.3 software (19). This software was not
designed to incorporate phytochemical information and consequently there are
limitations associated with our ability to manually assign flavonoid values to foods.
One major example of this is green tea, which is combined with other herbal teas in
the food composition databases. Despite perhaps having similar nutritional properties
in terms of nutrients, the phytochemical properties of different herbal teas are
extremely varied (20).

Another major limitation relates to utilisation of the USDA database to determine the
flavonoid content of selected foods as a reference database. The flavonoid content of
foods in the database may not reflect that of Australian produce, as flavonoid content
is heavily influenced by growth and processing conditions and the USDA recognizes
this variability (4). Another well-established limitation relates to the inability of a
reference database to account for storage and cooking methods (4). Future research
should attempt to account for this through the application of retention factors for some
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food preparation techniques, including boiling. However, retention factor applications
in this instance were not warranted, as full disclosure of food treatment and cooking
was not available due to limitations associated with secondary data analysis.
Additionally, bioavailability of flavonoids is not taken into account, despite showing
extreme individual variability (21). Once retention factors for all foods are perfected
and the metabolism of flavonoids is adequately understood, they should be primary
considerations in estimating bioavailability and therefore the bioactivity of flavonoids.
It is also important to highlight that the USDA database attributed a delphinidin value
for bananas of 7.39 mg/100 g, which may incorrectly reflect banana proanthocyanidin
degradation during content analysis (22). However, all values that were presented in
the USDA database were accepted as it was outside the scope of this analysis to
question a critically evaluated and widely used database; however, this limitation
means anthocyanin intake may be overestimated in this cohort.

A further limitation of this study relates to the measurement of flavonoids alone, as
many other classes of polyphenolic compounds hold similar biological properties.
Total flavonoid intake and the intake of total flavonoid subclasses only were measured
instead of specific flavonoids, in order for the results to have a more general
application in broad nutrition research. Additionally, it is likely that specific
flavonoids within a subclass have similar bioactivities.

3.4.1

Conclusion

Accurate estimation of flavonoid intake in populations is an important methodological
consideration for studies that investigate the health impact of these food-derived
bioactive compounds. Our analysis provides an assessment of usual intakes of
flavonoids that may be useful for planning intervention studies in which dose-response
outcomes are of interest.
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3
3.1

Introduction

Currently, the consumption patterns of flavonoids in older adults have not been adequately
assessed, and only a few Australian estimations are available in the literature (1, 2). The
dietary assessment instruments currently used to measure flavonoid intake have
limitations in their ability to accurately assess habitual intake, which hinders investigation
of the association of the health benefits of flavonoids in epidemiologic studies (3).
Inconsistent methodologies have been used to quantify flavonoid intake and few survey
tools have been validated for this purpose (4). The collection of dietary information using
food recall or food record (FR) methods has been employed most frequently when
determining intake of flavonoids, and is cross-referenced with flavonoid-specific food
composition databases. However, the burden of these methods can be large on both
participants and researchers.

Previously published food frequency questionnaires (FFQ) that have been developed to
measure flavonoids have focused on specific flavonoids or flavonoid subclasses, rather
than a comprehensive range to reflect total dietary intake. Hakim et al. (5) validated a FFQ
that assessed intake of tea and tea polyphenols against a standard FFQ and 4-day FRs. In
a more focused study, Hakim et al. (6) measured D-limonene contents in a range of citrus
juices as the basis for the assessment of the intake of this flavonoid. Although accurate, if
these types of instruments were expanded to provide information on the full range of
flavonoids, their time burden on the respondent and researcher would be excessive.
Research has also utilised post-hoc analysis of pre-existing FFQs that were not developed
or validated for the purpose of measuring flavonoid intake (7, 8). This method has
demonstrated large limitations in accurately assessing flavonoid consumption, because of
grouping foods that may have similar nutritional profiles (pears and apples) and appear
sensible to the respondent to consider together when reporting their intake, but which have
vastly different flavonoid contents.

Recent Australian research has validated a flavonoid specific FFQ in young adults, against
3 day FRs (9). Additionally, total flavonoid consumption (1), and the main sources of
flavonoids (4), have been estimated in an Australian population using 24hr recall data
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from the National Nutrition Survey, 1995. The different eating patterns of older
Australians was reflected in different dietary sources of flavonoids compared to younger
adults, whereby contributions from tea and wine flavonoids increased markedly with age
(1). Given the differences in total flavonoid intake, as well as the different major dietary
sources of flavonoids in the diets of young and older adults (1), it is important to develop
and validate a FFQ to measure the intake in older adults specifically. Despite a large body
of evidence that links flavonoid consumption with improved health outcomes in older
adults (10), there is little published information on habitual intake of food sources of
flavonoids in this age group. A flavonoid specific FFQ, that includes a list of both
flavonoid rich and the most commonly consumed food items that contribute to total intake,
would be a useful contribution to research that investigates flavonoid consumption in
older Australian cohorts, for the purpose of exposing diet-health associations, as well as
to inform the development of dietary guidelines. The advantages of a FFQ over dietary
recall and diary methods to assess long term intake patterns of nutrients, and to a lesser
extent, foods and food groups, is well established (11). A FFQ is a cheaper and markedly
less burdensome method for measuring dietary exposure to dietary attributes (12).

A focused retrospective analysis of dietary flavonoid intake older adults was necessary to
inform the development of a novel dietary assessment tool (2). We recently estimated the
mean intake of total flavonoids, and the major dietary sources thereof, in an older
Australian population using twelve days of weighed FRs (2), collected as a part of the
Blue Mountains Eye Study (13). These findings (14) were utilised to develop a FFQ for
use in older adults, the validation and reproducibility of which is the objective of this
study. Validity, in this context, is the degree to which the FFQ measures specific dietary
attributes, and the validation process involves appraisal of the FFQ against a reference
method to determine their agreement in measuring the same dietary attributes (15). The
reproducibility of an FFQ relates to the ability of the tool to accurately and equally
measure the same dietary attributes on more than one occasion (15).

The aim of this study was to assess the validity and reproducibility of a FFQ developed to
measure total flavonoid intake, and flavonoid subclasses, in older adults against a 4-day
FR.
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3.2

Methods

3.2.1

Development of the FFQ

A FFQ was developed to quantitatively assess individual intake of dietary flavonoids over
12 months and is structurally based on the National Health and Nutrition Examination
Survey (NHANES) FFQ (16). All points of recommendation as outlined by Cade et al.,
(11) were addressed in the development of the instrument.
As reported elsewhere (2), 12 days of weighed FR data from the Blue Mountains Eye
Study (BMES) were used as the main basis for the development of the FFQ. To ensure all
rich sources of flavonoids and top contributors to flavonoid intake were captured; foods
were selected for inclusion in the FFQ if they met the following criteria:
1. Any food with >30mg/100g total flavonoids and/or >30mg/average portion size.
2. Any flavonoid containing food in the top 25% of all foods.
3. A top 25% contributor in each flavonoid subclasses according to the average
portion size (g) of that food.
Several additional inclusions from the USDA database of flavonoid containing foods were
selected on the basis of the definition of a flavonoid rich food, >30mg/100g edible weight,
and if they were available in Australia and could form part of usual cuisine. Additionally,
any foods highlighted as top contributors of flavonoid intake by previous Australian
literature (1, 4) were also included. Of the total 96 foods included in the FFQ, 73 foods
were identified from the BMES WFR data. An additional 23 foods were included from
rich sources identified from the USDA flavonoid database (Table 3-1) and from other
current literature sources (Table 3-2).
The USDA database for the flavonoid content of selected foods was selected as the
reference database for this study, as it is one of the most complete sources of flavonoid
content data. The lack of an equivalent Australian database for the assessment of flavonoid
intake from dietary records necessitated the use of an international one. While other
databases, including PhenolExplorer and EURO-FIR-eBasis. As the USDA database was
adequately comprehensive (i.e. all included foods were able to be assigned flavonoid
content), no other flavonoid databases were consulted.

Table 3-1 Rich flavonoid sources (>30mg/100g) identified from the USDA database (3.1)
(12).
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Food source

Flavonoid
content/100g

Dried Parsley

215.46

Dill

55.15

Thyme

45.25

Capers (canned)

259.19

Mint

30.92

Coriander

52.9

Lime

43.0

Eggplant

85.69

Blackcurrant juice

45.27

Red onion (raw)

39.21

Rocket

66.19

Oregano

311.73

Table 3-2 Flavonoid sources identified from Australian literature sources (2, 5).
Food source

Flavonoid
content/100g

Cherries

30.21

Lemon

53.38

Silverbeet (chard)

1.75

Endive

10.1

Beans (broad)

0.9

Spring onion

30.6

Mango

2.0

Rhubarb

2.35

Olives (green)

0.56

Olives (black)

4.93

Kale

92.98

Grouping of food items was decided a priori to the analysis, with items being coded into
the food categories of beverages, alcohol, fruit, vegetables, herbs and other foods. With
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the aim of accurately quantifying flavonoid intake, serving sizes derived from the BMES
WFR data were used (2). Median portion size (g) and the inter-quartile range informed
the basis for four portion size options, specific to each food. A time period of 12 months
was selected to ensure that habitual intake and the influence of seasonal dietary change
was captured in the FFQ.

3.2.2

Subjects

A total of 42 community dwelling older adults aged 60 years and over from the Illawarra
region of NSW, Australia, were recruited to the study between June and September 2014.
Generally healthy older adults were recruited via advertising material distributed at local
community groups. The study excluded individuals with major food intolerances or a
condition that impacts usual diet (e.g. Cohn’s disease). Ethics approval was obtained from
the University of Wollongong Human Research Ethics Committee and all subjects
provided written informed consent. To determine an adequate sample size, a previous
study (17) which assessed the validity of an FFQ against multiple 24h recalls, minimum
of approximately 42 subjects were required to obtain a correlation coefficient of 0.377.

Participants attended two identical interviews, held one month apart, and based on their
preference for either a home visit or attendance at the university testing facility (Illawarra
Health and Medical Research Institute). A single interviewer (KK) conducted the
interview, at which weight (kg) and height (m) was measured and body mass index (BMI;
weight (kg) / height (m) 2) was calculated. Resting blood pressure (BP) and heart rate (HR)
was measured while seated, in triplicate and averaged using an Omron HEM7200 Deluxe
Automatic Monitor. Personal and demographic information was collected including age,
smoking and drinking habits, and education level.

3.2.3

FFQ Analysis

The self-administered FFQ, completed by the participant at home on the day before the
interview, was screened during the interview for errors and missing data. Any questions
about the foods contributing to the FFQ were clarified. The paper-based FFQ data was
entered into a template created for this purpose in Microsoft Excel (Microsoft version
14.1.2). The template was developed using nutritional information for each food or
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beverage, for each serving size option in the FFQ, from the Foodworks dietary analysis
package (Xyris software, version 5, 2007, Highgate Hill, QLD, Australia) and USDA
database for the flavonoid content of selected foods (18). Foods reported were converted
to daily intake frequencies as follows: 6+ per day= 7.5; 4-5 per day = 4.5; 2-3 per day =
2.5; 1 per day = 1; 5 - 6 per week; 0.8; 3-4 per week = 0.5; 1-2 per week = 0.2; 2 - 3 per
month = 0.09; 1 per month or less = 0.04; Never = 0.

3.2.4

Dietary Assessment

Participants were briefly trained by a nutritionist (KK) and instructed to complete a 4-day
FR on any four consecutive days between the two interview dates, including 3 week days
and 1 weekend day. Participants were instructed to record in detail all the foods and drinks
they consumed during that period and to estimate the portion sizes using cup measures,
weights or other household measurements. Dietary data from the 4-day FR was screened
during the final interview and analysed using the Foodworks dietary analysis package
(Xyris software, version 5, 2007, Highgate Hill, QLD, Australia). As dietary data relating
to flavonoid content of foods is not integrated into the Xyris software, the food items were
manually cross-referenced with the USDA database for the flavonoid content of selected
foods (18) to estimate flavonoid consumption.

3.2.5

Statistical analysis

Statistical analysis was performed using the Statistical Package for Social Sciences
(SPSS) V15.0.0 (SPSS Inc., Chicago IL, USA). Descriptive statistics were performed on
demographic data. For each participant, mean (±SD) flavonoid intake, intake of each
flavonoid subclass from FFQ1, FFQ2 and 4-day FR was calculated. From this the mean
(±SD) intake per person/per day for each method was determined. Major dietary sources
of flavonoids and each flavonoid subclass were determined. Mean daily flavonoid intakes
for the FFQ1, FFQ2 and 4-day FR were assessed for normality using histograms and the
Shapiro Wilk test for normality. Data was not normally distributed for FFQ1, FFQ2 and
4-day FR.
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3.2.6

Validity

A combination of tests was applied to assess several different facets of validity, which
may therefore provide a superior assessment of validity than a single measure (19). A
Wilcoxon signed rank sum test was used to compare flavonoid and flavonoid subclass
intakes obtained from the two methods (FFQ1 and 4-day FR). Spearman correlation
coefficients were calculated between the two dietary assessment methods (i.e. FFQ1 and
FR) for total flavonoid intake and each dietary flavonoid subclass to test the strength of a
relationship between two variables.
The FFQ1 and 4-day FR were assessed for level of agreement using Bland-Altman plots
(20), where the difference between the FFQ1 and 4-day FR (FFQ1 - 4-day FR) was plotted
against the mean of the FFQ1 and 4-day FR (FFQ1 + 4-day FR)/2. Limits of agreement
(the mean difference±1.96SD) for the difference between the two measures were
calculated to evaluate if they were acceptable. A regression line was fitted in the graph to
detect proportional differences and to indicate the direction and magnitude of the bias.
Lastly, the Cohen's kappa (κ) test determined the FFQ’s ability to rank individuals into
quartiles of intake (FFQ1 vs 4-day FR) for total flavonoid intake and flavonoid subclasses
(21, 22), whereby values ≤ 0 as indicating no agreement and 0.01–0.20 as none to slight,
0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as
almost perfect agreement.

3.2.7

Reproducibility

A combination of tests was applied to assess reliability (19). The mean percentage
difference between FFQ1 and FFQ2 for total flavonoid intake and intake of flavonoid
subclasses was calculated. Wilcoxon signed rank sum test was used to compare flavonoid
and flavonoid subclass intakes obtained from the FFQ1 and FFQ2. The association
between FFQ1 and FFQ2 was assessed using the Spearman correlation for total flavonoid
intake and each flavonoid subclass. Bland-Altman graphs were drawn for the difference
between FFQs (FFQ1 - FFQ2) plotted against the mean of the FFQs ((FFQ1 + FFQ2)/2).
Limits of agreement (the mean difference±1.96SD) for the difference between the two
measures were calculated to evaluate if they were acceptable and to indicate the direction
and magnitude of the bias. A regression line was fitted in the graph to detect proportional
differences. The Cohen's kappa (κ) was determined to assess the FFQ’s reliability to
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ranking individuals into quartiles of intake (FFQ1 vs FFQ2) (21, 22), whereby values ≤ 0
as indicating no agreement and 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41–0.60
as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost perfect agreement.

3.3

Results

The developed flavonoid FFQ (Appendix G) includes 93 questions, pertaining to 9 nonalcoholic beverages, 5 alcoholic beverages, 25 fruit, 33 vegetables, 8 herbs, 13 other foods
(dried fruit, nuts, fruit spreads), and an additional 3 summary questions about usual
alcohol intake, and fruit and vegetable consumption. The characteristics of the study
participants are presented in Table 3-3.

Table 3-3 Summary statistics of subject characteristics (n=42).
Male

14 (33.3%)

Female

28 (66.7%)

Age (y)

Mean±SD

75.3 ± 8.6

BMI (kg/m2)

Mean±SD

27.7 ± 4.3

English

40 (95.2%)

Other

2 (5.8%)

Non-smoker

28 (66.7%)

Current smoker

1 (2.4%)

Ex-smoker

13 (30.9%)

Any supplement

24 (57.2 %)

No supplement

14 (42.8%)

Tertiary

27 (64.3%)

Gender

Primary Language

Smoking status

Supplement Use

Education

(highest

completed)

Blood Pressure

level Secondary (complete)

15 (35.7%)

Secondary (incomplete)

0

Primary

0

Systolic Mean±SD

138.1 ± 18.4

Diastolic Mean±SD

83.74 ± 9.3

Heart rate: Mean±SD

67.2 ± 10.6

The mean intake, standard deviation and range of total flavonoid intake and intake of each
flavonoid subclass (mg/day) for each method were determined (Table 3-4). For both the
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FFQ (1 and 2) and the 4-day FR, a large variability in dietary flavonoid intake and intake
of flavonoid subclasses is described (Table 3-4). The percentage contribution that each
food made to total flavonoid intake and intake of each flavonoid subclass was calculated
for each person (FFQ1) and averaged to indicate the major (top 10) foods contributing to
intake in the total group (Table 3-5).

Table 3-4 Description of mean flavonoid intake (mg/day) according to the FFQ1, FFQ1
and 4-day FR (n=42)
(mg/day)
FFQ

Total Flavonoids

1

Mean

Std.
Deviation

Minimum Maximum

%
contribution

1050.4717 725.52905

80.02

3253.48

Anthocyanins

103.3685

104.66311

11.45

368.27

9.84

Flavan-3-ols

829.5545

690.60154

32.27

2953.08

78.96

Flavanones

42.4992

28.47302

2.39

105.35

4.04

Flavones

6.5072

8.03556

.27

37.74

0.61

Flavonols

68.5423

34.99465

19.68

147.20

6.52

1047.0211 724.85865

140.14

2488.98

FFQ

Total Flavonoids

2

Anthocyanins

103.4143

99.03593

14.75

367.82

9.88

Flavan-3-ols

829.7809

686.56737

60.92

2312.23

79.25

Flavanones

40.4190

29.37282

4.87

103.56

3.86

Flavones

7.3939

9.20604

.46

37.70

0.71

Flavonols

66.0130

32.80539

16.44

131.84

6.30

Total Flavonoids

847.5078

534.75680

22.08

2490.47

4-day

Anthocyanins

38.8653

58.98484

.00

224.65

4.59

FR

Flavan-3-ols

754.6830

502.21665

6.93

2366.47

89.05

Flavanones

18.5490

20.92953

.00

69.78

2.19

Flavones

3.7307

5.24328

.00

27.40

0.44

Flavonols

32.7868

18.88830

1.16

99.38

3.87

114

Table 3-5 Top 10 foods contributing to total flavonoid and flavonoid subclass intake ranked in order of contribution to total
consumption according to the developed FFQ.
Flavonoid Total

Anthocyanin

Flavan-3-ol

Flavanone

Flavone

Flavonol

Food

%

Food

%

Food

%

Food

%

Food

%

Food

%

1

Tea, black

56.97

Wine, red

31.13

Tea, black

75.22

Orange juice

40.86

Parsley

35.50

Tea, black

29.03

2

Wine, red

7.63

Grapes,
red

13.29

Tea, green

7.42

Mandarin

19.18

Wine, red

17.06

Onion,
brown

9.79

3

Tea, green

6.05

Cherry

10.28

Broccoli

4.80

Oranges

17.59

Pumpkin

11.08

Beans

8.93

4

Orange

3.33

Blueberry

7.94

Apple, red

2.48

Wine, red

6.75

Grapes,
red

7.35

Peas

5.04

5

Broccoli

2.57

Banana

7.04

Peach

1.46

Wine, white

3.64

Tea, green

4.22

Onion, red

4.44

6

Grapes,
red

2.08

Pear

5.96

Wine, red

1.42

Brussels
sprout

3.59

Celery

4.02

Wine, red

4.26

7

Mandarin

2.07

Strawberry

5.53

Banana

1.06

Grapefruit

2.46

Spinach

2.30

Tea, green

3.81

8

Cherry

1.95

Apple red

3.78

Nectarine

1.02

Lemon, flesh

2.26

Orange

2.28

Apple

3.37

9

Apple, red

1.86

Plum

2.72

Cherry

0.94

Tomato

1.63

Kiwi fruit

1.93

Kale

2.66

10

Banana

1.10

Peach

1.47

Grapes,
green

0.65

Lemon juice

0.67

Rock
melon

1.83

Spinach

2.60
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3.3.1

Validity

Wilcoxon signed rank sum test showed significant differences in total flavonoid
(p<0.001), anthocyanin (p<0.001), flavanone (p<0.001) and flavonol (p<0.001) intakes as
measured by the FFQ1 and 4-day FR, and no significant difference for flavone and flavan3-ol measurements (Table 3-6). The strength of the relationship as tested by Spearman’s
correlation coefficients between the FFQ1 and 4-day FR are shown in Table 3-6.

The Bland-Altman plot of the bias (average of the differences between methods) against
the mean value for the two methods is shown in Figure 3-1. Visually, this demonstrates
that the bias and limits of agreement are large for total flavonoid intake (+202.96), and
intake of anthocyanins (+64.5), flavan-3-ols (+74.85), flavanones (+ 23.9) and flavonols
(+35.75). The bias is small, with narrow limits of agreement for flavone intake (+2.77).
These results indicate that the FFQ1 and 4-day FR are systematically producing different
results. Interpretation of the systematic bias shows that the FFQ is overestimating
flavonoid intake (and intake of flavonoid subclasses) in comparison to the 4-day FR. The
linear regression analysis indicates a strong positive correlation for total flavonoid intake,
and intake of anthocyanins, flavan3ols and flavonols, whereby the greater an individual
estimates their flavonoid intake, the greater the systematic bias (or overestimation by the
FFQ). This relationship is lesser for flavone and flavanone intakes, as shown visually in
Figure 3-1.
The Cohen's kappa (κ) indicates that there was substantial agreement (21) between the
FFQ1 and 4-day FR for total flavonoid intake (κ =0.619, p<0.001), moderate agreement
for flavan-3-ol intake (κ=0.492, p<0.001) and flavonol intake (κ =0.619, p<0.001); fair
agreement for flavone intake (κ=0.238, p=0.008); slight agreement for anthocyanin intake
(κ=0.142, p=0.111); and poor agreement for flavanone intake (κ=0.048, p=0.587).
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Table 3-6 Comparison of the total flavonoid intake and intake of flavonoid subclasses
(mg/day) for FFQ-1 vs FR (validity) and FFQ-1 vs FFQ-2 (reliability)
Wilcoxon
signed
(mg/day)

rank sum

Spearman’s Correlation

Sig.

test

Coefficient

(p-value)

Sig. (pvalue)
Total flavonoids

<0.001

0.93

<0.001

Anthocyanins

<0.001

0.32

0.042

Flavan-3-ols

0.413

0.87

<0.001

Flavanones

<0.001

-0.17

0.27

Flavones

0.004

0.18

0.25

Flavonols

<0.001

0.75

<0.001

Total flavonoids

0.912

0.91

<0.001

Anthocyanins

0.955

0.92

<0.001

Flavan-3-ols

0.957

0.92

<0.001

Flavanones

0.350

0.73

<0.001

Flavones

0.119

0.85

<0.001

Flavonols

0.328

0.90

<0.001

FFQ-1 vs
4-day FR

FFQ-1 vs
FFQ -2
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(a)

(b)

118

(c)

(d)

119

(e)
(f)

Figure 3-1 Bland Altman plots (difference in intake (mg/day) (FFQ1 – 4-day FR) against the mean intake of flavonoids and subclasses
(mg/day) [FFQ1+4-day FR)/2]) showing the relative validity of the FFQ 1 vs the 4-day FR for total (a) flavonoids, (b) anthocyanin, (c)
flavan-3-ol, (d) flavanone, (e) flavone and (f) flavonol intake.

120

3.3.2

Reproducibility

The mean percentage difference between FFQ1 vs FFQ2 showed small variations for
total flavonoid intake (6.74%), and intake of anthocyanins (13.75%), flavan-3-ols
(14.07%), flavanones (10.73%), flavonols (-1.11%), with slightly higher variation for
flavones (22.34%).

Wilcoxon signed rank sum test showed no significant differences in the measurement
of total flavonoid or any flavonoid subclass intakes (mg/day) between the FFQ1 and
FFQ2 (Table 3-5). Total flavonoid intake showed excellent reliability (>0.9) and each
flavonoid subclass showed between acceptable (>0.7) and excellent reliability (Table
3-5). The Bland Altman plots visually showed small, non-significant bias (Figure 32) and wide limits of agreement. Linear trends in the bias are not evident between
FFQ1 and FFQ2 (Figure 3-2).
The Cohen's kappa (κ) indicated substantial agreement (21) between the FFQ1 and
FFQ2 for total flavonoid intake (κ =0.619, p<0.001), anthocyanin intake (κ=0.651,
p<0.001), flavan-3-ol intake (κ=0.746, p<0.001), flavone intake (κ=0.714, p<0.001)
and flavonol intake (κ =0.619, p<0.001), and moderate agreement (21) for flavanone
intake (κ=0.492, p<0.001).
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(a)

(b)

122

(c)

(d)
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(e)

(f)

Figure 3-2 Bland Altman plots (difference in intake (mg/day) (FFQ1 – FFQ2) against the mean intake of flavonoids and subclasses
(mg/day) [FFQ1+FFQ2)/2]) showing the relative validity of the FFQ 1 vs the FFQ2 for total (a) flavonoids, (b) anthocyanin, (c) flavan3-ol, (d) flavanone, (e) flavone and (f) flavonol intake.
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3.4

Discussion

A novel flavonoid-specific FFQ was developed for use in older Australians by applying a
systematic approach using data obtained from 12 days of weighed FRs and the most appropriate
flavonoid composition data (18). Total flavonoid intake as measured by the FFQ (1050mg/day)
was significantly higher than that reported in other Australian studies (1, 4, 23), including the
analysis of the cohort of older adults who were used to inform the development of this tool (14)
(683mg/day). The 4-day FR similarly measured flavonoid intake (847mg/day) and intake of
flavonoid subclasses as being higher than previous Australian estimations, however the
percentage contributions of each flavonoid subclass to total flavonoid intake are closely related
to previously reported estimates for the total Australian population (1). An overestimation of
flavonoid intake was similarly reported in a validation study of an FFQ developed to measure
flavonoid intake in younger Australian adults (9), and appears to be a typical finding when
validating a FFQ against FRs (24). Nevertheless, the major sources of total flavonoids as
estimated by the FFQ are black tea (57.0%), red wine (7.6%) and green tea (6.0%), which has
previously been described as significant flavonoid sources in this age group (1). Inclusion of
both the most commonly consumed flavonoid-containing foods; in addition to the richest
dietary sources according to the food composition database in the FFQ provided a sound basis
that enabled the most accurate estimation of habitual intake of all flavonoids. For example,
although consumed sporadically and in small amounts, parsley provided the major source of
flavone intake. Previous dietary questionnaires that have not incorporated both considerations
(10, 25, 26) and have shown limitations in the assessment of total flavonoid intake.

Despite the FFQ1 and 4-day FR being strongly correlated, except for flavanone and flavone
intake, there were significant differences in estimation of the total flavonoid intake and intake
of flavonoid subclasses (except for flavan-3-ols) between the two measures. This is a result of
the FFQ consistently measuring flavonoid intake to be higher than the 4-day FR analyses. This
finding was confirmed by the Bland-Altman analysis, which indicates a case of proportional
error (strong positive correlation) (Figure 3-1). As correlation quantifies the degree to which
two variables are related, but does not automatically imply that there is good agreement
between the two methods (20), this finding is not uncommon. The agreement between the FFQ
and the 4-day FR to assign an individual to quartiles of intake suggests that the FFQ is an
excellent method for total flavonoid intake, but exhibits differing levels of agreement for
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individual subclasses of flavonoid, particularly flavanone intake which are commonly found in
citrus related foods. The misclassification for the flavonoid subclasses may also relate to the
influence of seasonal foods being under-reported in the 4-day FR in comparison to the FFQ.
This is of particular relevance for anthocyanins and flavanones that showed the poorest
agreement between methods. Berries and cherries (summer fruits) and mandarins (winter fruit)
are highly seasonal fruits that are available for short periods of time in Australia, but are rich
in anthocyanins and flavanones, respectively. The period of reporting for the FFQ was
consumption of fruits and vegetables over the previous 12 months, whereas the 4 day-FR
measured intake over a short period between June and September which corresponds to winter
and early spring in Australia. Thus, the FFQ could be expected to over-estimate the flavonoid
intake related to seasonal fruit consumption. Alternatively the 4-day FR, which was considered
to be robust reference method in our study, could be considered inadequate at estimating overall
habitual flavonoid intake. These considerations are important when deciding on the purpose of
the instrument, whether to measure absolute intakes in order to assess acute changes as would
be needed in a short term intervention study or clinical trial, or whether the instrument is
required for ranking individuals according to usual intake, as is required in epidemiological
studies (12). Our study has demonstrated the latter, as is the desirable strength of a FFQ and
highlights its potential application for use in large cohort studies.

Our findings are consistent with a Flemish study in which an 86-item FFQ was validated
against a 4-day non-consecutive food diary in dietitians (27). That FFQ was similarly able to
assign subjects to correct quartiles of flavonoid intake and to identify high flavonoid containing
foods and regular sources of flavonoid intake, but was less suitable for estimating total intake
(mg/day). The FFQ also showed only weak or no correlation to the 4-day food diary in relation
to specific flavonoid subclasses, for example, anthocyanins (27). In that study, the poor
correlation was related to the sporadic consumption of high flavonoid-containing foods, such
as red wine, that were not captured in the 4-day food diary; a result which appears to be
replicated in our study.

Using various statistical tests, the novel FFQ developed by this study showed an excellent level
of reproducibility. The repeated FFQs were highly correlated, displayed a small percentage
disagreement (21), and showed no difference between measured total intakes of flavonoids or
their subclasses. These findings were confirmed in the Bland-Altman analyses that visually
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indicated a low level of bias and the Cohen's kappa (κ) results that indicated moderate (κ =
0.41– 0.60) to substantial agreement (κ = 0.61–0.80) (21) between the two time points. The
FFQs were administered one month apart; therefore it is unlikely that any seasonal variation in
diet would have impacted its reproducibility.

There are limitations to this study, which partially relate to the general limitations associated
with using a FFQ to measure dietary components. While FFQs are a cheap and relatively simple
to apply, they are associated with large measurement error due to inaccuracies in estimating
frequencies and food serving sizes (12). Longer FFQs have shown to overestimate fruit and
vegetable intake (12), which could have been a contributor to measurement error in this study.
Another potential source of bias in validation studies of this nature is that, because the FFQ
was unable to make provision for information on the cooking processes associated with each
food, a ‘raw food’ value was attributed for each food which may have over-inflated intake
values. However, in the case of the 4-day FR method cooking-related flavonoid losses were
able to be accounted for as cooking methods were advised. Future work should attempt to
address the amount of cooked vs fresh food consumption that is associated with of each food
item. The potential to add a retention factor to the raw food values and address the degradation
associated with cooking should be investigated in the further refinement of this instrument.
Future research should also consider the influence of the reference food composition database
used, and the impact that it may have on the estimated flavonoid intake. A recent study by
Witowska et al., (28) showed that utilizing the Phenol Explorer database and the USDA
database resulted in different polyphenol estimations in Polish adults. However, until there is
an Australian specific, comprehensive flavonoid reference database, then the relative validity
of applying one database versus another (i.e. USDA vs Phenol Explorer) is questionable.

To improve the validity of a FFQ, design issues including the length, closed vs open-ended
responses, seasonality, time-frame and portion sizes can be manipulated (12). Future research
may focus on adjusting the time-frame of the recall if short-term intake is required over habitual
consumption. Additionally, a shorter version of the FFQ could be trialled, excluding foods that
did not significantly contribute to flavonoid intake in our study (e.g. herbs). The usefulness of
this FFQ over other general FFQs, such as the Block, Willett, and National Cancer Institute
FFQ (16), should be a consideration for future research. However, due to the highly specific
flavonoid content of foods, grouping of food items that are similar nutritionally (e.g. citrus
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fruits) into a single question (12), which is the case for many pre-existing FFQs (16), is not
recommended. Lastly, as diet is highly influenced by season, future studies may consider
confirming these findings in all seasons across a year.

3.4.1 Conclusion
A novel FFQ developed to estimate flavonoid intake for use in older Australians has been
shown to demonstrate fair validity against a 4 day FR method and substantial reproducibility.
The FFQ could allow for an easier estimation of flavonoid intake and intake of flavonoid
subclasses in older adults, especially when ranking individuals according to total flavonoid
intake in epidemiological research. Future studies may attempt to validate this tool against
repeated FRs collected across several seasons, in order to assess the instrument’s ability to
more accurately capture seasonal food intake, and potentially improve the validity of the tool
for measuring flavonoid subclasses.

128

3.5
1.

References
Johannot L, Somerset SM. Age-related variations in flavonoid intake and sources in the

Australian population. Public Health Nutrition. 2006;9(8):1045-54.
2.

Kent K, Charlton KE, Russell J, Mitchell P, Flood V. Estimation of flavonoid intake in

older Australians: secondary data analysis of the Blue Mountains Eye Study. Journal of
Nutrition in Gerontology and Geriatrics. Journal of Nutrition in Gerontology and Geriatrics.
2015;In Press.
3.

Louise IM, David S, Angelika de B, Nathalie A. Consumption of Foods Rich in

Flavonoids Is Related to a Decreased Cardiovascular Risk in Apparently Healthy French
Women1. Journal of Nutrition. 2004;134(4):923.
4.

Somerset SM, Johannot L. Dietary flavonoid sources in Australian adults. Nutrition and

Cancer. 2008;60(4):442-9.
5.

Hakim IA, Hartz V, Harris RB, Balentine D, Weisgerber UM, Graver Eet al.

Reproducibility and relative validity of a questionnaire to assess intake of black tea polyphenols
in epidemiological studies. Cancer Epidemiology Biomarkers Prev. 2001;10(6):667-78.
6.

Hakim IA, Hartz V, Graver E, Whitacre R, Alberts D. Development of a questionnaire

and a database for assessing dietary D-limonene intake. Public Health Nutrition.
2002;5(6a):939-45.
7.

Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong C-P, Nettleton JAet al. Flavonoid

intake and cardiovascular disease mortality: a prospective study in postmenopausal women.
American Journal of Clinical Nutrition. 2007;85(3):895-909.
8.

Cassidy A, O'Reilly ÉJ, Kay C, Sampson L, Franz M, Forman JPet al. Habitual intake

of flavonoid subclasses and incident hypertension in adults. American Journal of Clinical
Nutrition. 2011;93(2):338-47.
9.

Somerset S, Papier K. A food frequency questionnaire validated for estimating dietary

flavonoid intake in an Australian population. Nutrition and Cancer. 2014;66(7):1200-10.
10.

Chun OK, Lee SG, Wang Y, Vance T, Song WO. Estimated flavonoid intake of the

elderly in the United States and around the world. Journal of Nutrition in Gerontology and
Geriatrics. 2012;31(3):190-205.
11.

Cade J, Thompson R, Burley V, Warm D. Development, validation and utilisation of

food-frequency questionnaires – a review. Public Health Nutrition. 2002;5(4):567-87.
12.

Thompson FE, Subar AF. Dietary Assessment Methodology-Chapter 1. Elsevier Inc;

2001. p. 3-30.
129

13.

Smith W, Mitchell P, Reay EM, Webb K, Harvey PWJ. Validity and reproducibility of

a self-administered food frequency questionnaire in older people. Australia New Zealand
Journal of Public Health. 1998 22(4):456-63.
14.

Kent KC, KE.; Russell, J.; Mitchell, P.; Flood, V.;. Estimation of flavonoid intake in

older Australians: secondary data analysis of the Blue Mountains Eye Study. Journal of
Nutrition in Gerontology and Geriatrics. 2015;In Press.
15.

Willett WC, Lenart, E. Reproducibility and validity of food-frequency questionnaires.

Chapter 6. . WC W, editor. New York: Oxford University Press; 1998.
16.

Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt Set al.

Comparative validation of the Block, Willett, and National Cancer Institute food frequency
questionnaires : the Eating at America's Table Study. American Journal of Epidemiology.
2001;154(12):1089-99.
17.

Tan L, Charlton, KE, Tan S-Y, Batterham M. . Validation of an iodine-specific Food

Frequency Questionnaire to estimate dietary iodine intake in older Australians. Nutrition and
Dietetics 2012.
18.

Bhagwat S, Haytowitz, DB, Holden, JM. USDA Database for the Flavonoid Content of

Selected Foods Maryland: Nutrient Data Laboratory, U.S. Department of Agriculture 2013.
19.

Lombard MJ, Steyn NP, Charlton KE, Senekal M. Application and interpretation of

multiple statistical tests to evaluate validity of dietary intake assessment methods. Nutrition
Journal. 2015;14(1):1-11.
20.

Bland JM, Altman, D.G. Statistical methods for assessing agreement between two

methods of clinical measurement. Lancet. 1986;i:307-10.
21.

McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica.

2012;22(3):276-82.
22.

Cohen J. A Coefficient of Agreement for Nominal Scales. Educational and

Psychological Measurement. 1960;20(1):37-46.
23.

Lyons-Wall P, Autenzio, P, Lee, E, Moss, R, Samman, S. Catechins are the major

source of flavonoids in a group of Australian women. Asia Pacific Journal of Clinical Nutrition.
2004;13:pS72.
24.

Flood VM, Smith WT, Webb KL, Mitchell P. Issues in assessing the validity of nutrient

data obtained from a food-frequency questionnaire: folate and vitamin B-12 examples. Public
Health Nutrition. 2004;7(6):751-6.

130

25.

Maras JE, Talegawkar SA, Qiao N, Lyle B, Ferrucci L, Tucker KL. Flavonoid intakes

in the Baltimore Longitudinal Study of Aging. Journal of food composition and analysis.
2011;24(8):1103-9.
26.

Beking K, Vieira A. An assessment of dietary flavonoid intake in the UK and Ireland.

International Journal of Food Sciences and Nutrition. 2011;62(1):17-9.
27.

Mullie P, Clarys P, Deriemaeker P, Hebbelinck M. Estimation of daily human intake

of food flavonoids. International Journal of Food Sciences and Nutrition. 2007;59(4):291-.
28.

Witkowska AM, Zujko ME, Terlikowska KM, Waśkiewicz A, Piotrowski W.

Comparison of various databases for estimation of dietary polyphenol intake in the population
of polish adults. Nutrients. 2015;7(11):9299-308.

131

CHAPTER 4: DEVELOPMENT OF A GAS CHROMATOGRPHY/MASS
SPECTROMETRY TECHNIQUE TO DETERMINE PHENOLIC ACID
BIOMARKERS OF FLAVONOID INTAKE AND METABOLISM

This chapter describes the potential for phenolic acid metabolites as biomarkers of flavonoid
intake. This chapter demonstrates the candidate’s knowledge about the analytical techniques
of Gas Chromatography (GC) and Mass Spectrometry (MS). It the describes the process
undertaken to develop and establish a GC-MS technique to measure phenolic acids in human
plasma at the University of Wollongong, in the Illawarra Health and Medical Research Institute
under the supervision of Dr. Andrew Jenner (Senior Research Fellow). This method is applied
in Chapter 6 of this thesis: ‘Developing methodology to assess the acute dose-dependent effects
of flavonoids in cherry juice on cognition and blood pressure: a pilot cross-over study.’

KK carried out experimental work and wrote the manuscript. Dr A Jenner devised and
supervised the experimental work. Dr A. Jenner is an experienced GC/MS scientist, who
trained KK in GC/MS methodology, carried out the GC/MS maintenance and designed the
GC/MS programs. Undergraduate students, Linnea Svenson and Vijay Kuppurajan also
contributed to the experimental work related to the method development.
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4
Background
4.1

Flavonoid Absorption and Metabolism

Flavonoids encompass a wide group of compounds that form a subclass of polyphenols and
comprise 15 carbons, with two aromatic rings bound together by three carbon atoms (denoted
as A, B and C) that form an oxygenated heterocycle (Figure 4-1). Common flavonoids and
their chemical structure are shown in Table 4-1.

Figure 4-1 Generic flavonoid structure (1)
Until relatively recently, very little was understood regarding flavonoid bioavailability,
absorption and metabolism. However, with evidence from human studies linking flavonoid
intake to improved health outcomes, there has been a rapid increase in our knowledge
surrounding their metabolism and bioactive effects (2). The bioavailability of specific
flavonoids that are abundant in the human diet has been well established and reviewed (3).
Manach et al., 2005 (3) reviewed 97 studies to conclude that polyphenols (including
flavonoids) markedly differ to one another in relation to their bioavailability and intestinal
metabolism. Additionally, intra-individual variation significantly impacts their uptake and
biological effects (4).
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Table 4-1 Chemical structure of common dietary flavonoids
Flavonoid group

Example

Flavones

Apigenin

Flavanones

Hesperetin

Flavan-3-ols

Catechin

Anthocyanins

Cyanidin

Isoflavones

Genistein

Flavonols

Quercetin

Chemical Structure

Flavonoids are subjected to extensive metabolism following ingestion. Flavonoid metabolism
may begin in the oral cavity, with hydrolysis of flavonoid glucosides occurring when they make
contact with saliva, which possesses strong hydrolic activity (5). In the upper GI tract, evidence
suggests that only a small proportion of dietary flavonoids are directly absorbed and become
available to tissues and cells (1-2%). Some flavonoids may be absorbed through the gut and
once absorbed, they are transported to the liver where they are conjugated, commonly by
methylation, sulphation and glucuronidation (6). Secretion via the biliary route will expose the
conjugated compounds to the gut flora and are therefore subjected to reabsorption in the colon
(6). A significantly greater proportion of dietary flavonoids are passed through the intestine to
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the colon, where an abundance of colonic microflora metabolise them into a variety of phenolic
acids and other metabolites (3).

The structures of phenolic acids are related to derivatives of either benzoic or cinnamic acids
(Figure 4-2), with some common phenolic acid metabolites and their structure is shown in
Table 4-2. Although the basic skeleton remains the same, the numbers and positions of the
hydroxyl groups on the aromatic ring produces is responsible for the many different phenolic
acids (1). Phenolic acids are consumed through their presence in all plant-based foods, in
addition to their endogenous production via the metabolism of flavonoids.

a)

b)

Figure 4-2 a) Benzoic Acid Chemical Structure b) Cinnamic Acid Chemical Structure
(adapted from (1))
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Table 4-2 Common phenolic acid metabolites according to Benzoic or Cinnamic Acid
derivatives
Benzoic

Acid Structure

Cinnamic Acid Structure

Derivatives

Derivatives

Vanillin

Ferulic Acid

Gallic Acid

p-Coumaric
Acid

Syringic Acid

Caffeic Acid

It has only been fairly recently that the biological actions of flavonoid metabolites, including
phenolic acids, has been investigated, meaning their relative contributions to the health benefits
of a flavonoid rich diet are largely unknown. However, the association of phenolic acids and
health outcomes has been made, and is largely underpinned by their antioxidant, antiinflammatory and anti-proliferative activities (1, 7). Given the vast difference in
bioavailabilities between flavonoids and phenolic acids, it has been hypothesised that phenolic
acids may therefore be responsible for the observed health effects of flavonoid consumption.
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4.2

Biomarker analysis

Biomarkers are important in the study of the effects of diet on health outcomes. It is usually
defined as any biochemical measure of events occurring in a biological system following
dietary exposure to a particular compound (8).

Dietary flavonoid intake can be determined by quantifying biomarkers which include intact
flavonoids and their derivatives (e.g. phenolic acids) found in plasma, urine and faecal water
(9). Many methods of measuring flavonoid biomarkers in human biological samples exist,
with no standardised protocol of how to perform this analysis. Consequently researchers must
develop and validate their own methods, limiting the ability to compare studies that have used
different methods to measure certain biomarkers. As there many thousands of flavonoids
identified, that are quickly and extensively metabolised into various metabolites, there are
thousands of potential biomarkers (10). To date, there is no consensus around which flavonoids
or metabolites are indicative of total dietary intake.

In addition, it is currently unknown which biological sample (plasma, urine or faecal water)
should be selected and some research suggests each maybe indicative of different consumption
patterns. Previous research shows urinary biomarkers may be more reflective of short-term
intake (11). The flavonoid content in fasting plasma or faecal water samples seems to be a
suitable biomarker of short-term intake and a possible biomarker of the medium-term intake
(11). However, biomarkers of long-term intake are not yet identified and may be unlikely due
to the short half-lives of dietary flavonoids in vivo. Most of the biomarker analyses are
expensive and quite often it is not possible to perform them as part of a large epidemiological
study (12).

4.2.1 Flavonoids as biomarkers
Measurement of intact flavonoids (generally in a glucuronidated form) provides a potential
biomarker to assess the intake and biological activities of flavonoid rich foods and can be
measured in urine and plasma. There is little indication of the expected concentrations of
flavonoids in biological samples, with examples from current literature highlighted in table 43. Unfortunately, there are few expected flavonoid concentrations in plasma published in the
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literature. With such a small and variable percentage of flavonoids consumed reaching the
circulatory system intact (Table 4-3), they may be difficult to measure.

Table 4-3 Concentrations of a selection of flavonoids in human plasma (fasting)
Plasma
Phenolic compounds

concentration (nM)
Mean±SD

Radtke et al., 2002 (11)

Cao et al., 2010 (13)

Quercetin

22.87±16.61

Kaempferol

10.65±7.89

Naringenin

8.15±15.43

Hesperetin

22.16±44.85

Quercetin

80.23±81.73

Kaempferol

57.86±60.88

Isorhamnetin

39.94±45.01

Apigenin

10.62±12.26

Luteolin

99.9±97.65

4.2.2 Phenolic acid metabolites as biomarkers
Phenolic acids can also be measured as metabolic biomarkers of flavonoid intake and can be
quantified in plasma (14), urine (14) and faecal water (15). Table 4-4 shows the concentrations
of some phenolic acids in human plasma, measured using a GC-MS technique.

Due to the complexity of plant-based foods, which contain many hundreds of compounds, the
best metabolite for each flavonoid or flavonoid containing food, and which is indicative of
dietary intake or reflects the bioactive effects, remains unknown (3, 10). Thus, a ‘metabolite
profiling’ approach, in which researcher’s measure multiple biomarkers related to flavonoid
intake, may be a superior method a single biomarker (flavonoid or phenolic acid) to improve
the specificity of dietary exposure to a compound or food (4, 14).
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Table 4-4 Concentrations of a selection of phenolic compounds in human plasma
Plasma concentration (nM)

Phenolic compounds

Mean±SEM (range)

4 ethyl phenol

1749 ± 233 (387, 8713)

phenyl acetic acid

49411 ± 2559(13160, 97114)

Catechol

1306 ± 631 (93, 30835)

3-phenylpropionic acid

682.20±117.19 (192.78, 5504.99)

t-cinnamic acid

173.20±22.31 (0.00, 640.21)

3-hydroxyphenylacetic acid

356.51±82.64 (0.00, 2401.27)

4-hydroxybenzoic acid

2511.89±101.00(1403.93, 4211.34)

4-methoxyphenylpropionic acid

545.40±77.54 (0.00, 1922.35)

4-hydroxy 3-methoxybenzoic acid (vanillic acid)

262.83±15.18 (98.72, 465.94)

2-hydroxycinnamic acid (o-coumaric acid)

590.99±127.40 (0.00, 3417.39)

3,4-dihydroxybenzoic acid

227.51±18.75 (73.10, 430.01)

3,4-dihydroxyphenylacetic acid

7.89±2.09 (0.00, 49.68)

3,4,5-trihydroxybenzoic acid (gallic acid)

5.05±1.73 (0.00, 58.35)

4-hydroxy 3-methoxycinnamic acid (ferulic acid)

40.12±6.85 (0.00, 193.38)

3,4-dihydroxycinnamic acid (caffeic acid)

1707.24±595.77 (71.87, 18887.12)

Values via Dr A Jenner. Personal Communication, 14 April 2011

The rapid and systematic measurement of phenolic acids and flavonoids in biological samples
is challenging, due to their inherent structural diversity and low concentrations in biological
samples. A recent review highlighted the numerous and various was in which researchers have
quantified phenolic acids and flavonoids in samples (both biological and plant-based) (1). They
concluded that the analytical methods selected by researcher depend on a variety of factors
including the availability of tools and techniques, the sensitivity needed and the complexity of
the biological matrix (1, 9). Therefore, generally a combination of a chromatography technique
with sensitive detection method is utilised.
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4.3

Gas Chromatography-Mass Spectrometry

4.3.1 Gas Chromatography
Various types of chromatography can be used in biomarker analysis (9, 16). The methodology
related to Gas Chromatography (GC) will be discussed in more detail. A GC system consists
of carrier gas, an injector, a column (with a stationary phase) and a detector (16) (Figure 4-3).

Figure 4-3 Gas Chromatography system diagram (17)

4.3.1.1 Sample preparation
Generally, an analyte may have to undergo derivatization to become more suitable for GC
analysis through making compounds more volatile or less polar, improving thermal stability
and introducing a marker on the compound that can be detected (18). The derivatization
reaction commonly occurs by alkylation, silylation, and acylation of polar functional groups.

4.3.1.2 Injection
The injection of a sample into the GC column involves rapid vaporisation of a liquid sample
(0.2 – 3µL) and subsequent mixing with a carrier gas, before injection via an inlet into the GC
column (17). The inlet is heated (to up to 400º Celsius) to ensure that the entire sample
evaporates quickly and mixes with the carrier gas. Carrier gases (mobile phase) are usually
very pure (<99.99%) sources of helium, hydrogen, nitrogen or argon, which carry the sample
through a GC column where it is separated into individual components.
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4.3.1.3 Column separation
The column (comprising tubing and a stationary phase) sits in a temperature controlled oven
that is able to separate compounds based on their solubility and boiling point. As the sample
reaches the column, it will cool and condense, moving in a tight band around the GC column
(20). The analytes that are lighter and have lower boiling points will move more quickly around
the column towards the detector. The oven temperature is pre-determined to rise in a tightly
controlled temperature program, which is established to manipulate the speed at which
compounds will be fed through the column, to enhance separation of the compounds of interest
(20).

4.3.1.4 Detection
After the separation of the analytes that are eluted from the column, they are individually
measured in a detector that converts a chemical or physical property into an electrical signal
(21). A PC based data system is used to process the signal from the GC to determine peak
areas: peak heights and widths and retention times. The chromatogram, which is the graphical
representation of the sample elution, is displayed. The height of the peak or the area under the
peak is used to determine the amount of the compound in the original mixture. Each peak is
displayed by the exact time it leaves the column and passes to the detector (retention time).The
retention time provides a qualitative measure of the compound, which can determine the
presence of a certain compound, by comparing the sample peak times with known reference
standard peaks times. Analysis of the peak area or peak height quantitates the amount of the
sample component. Standard amounts of the compounds can be used as a reference to make a
calibration curve to produce quantitative results for each calibration peak. Comparison of the
peaks produced by a sample to the calibration curve indicates the amount of the compound of
interest in the sample mix.

4.4

Mass spectrometry

Mass spectrometry (MS) is an analytical quantification technique designed to identify
molecules by measuring their mass-to-charge ratio (m/z). MS is highly regarded as a sensitive
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and quick analytical method, with a particular strength in application for biochemical
compound analysis (22). The principle of this technique is to ionize the molecules and create
smaller fragments, which can then be identified by molecular mass (21). The three essential
components of a mass spectrometer are the ion source, which converts the molecules into ions;
a mass analyser, which sorts the ions depending on their mass and charge and finally; a detector
that quantifies the amount of each ion (21) (Figure 4-4).

Figure 4-4 Schematic diagram of a Mass Spectrometer (23)

4.4.1.1 Triple Quadrupole Mass Spectrometer
In a triple quadrupole mass analyser is a tandem mass spectrometer consisting of two
quadrupole mass analysed with a collision chamber between them. Essentially, the triple
quadrupole mass spectrometers operate under the same pretence as the single quadrupole mass
analyser. However, a triple quadrupole mass analyser has the advantage of being more sensitive
and is able to detect smaller low energy low molecule reactions, which is useful when small
molecules are being analysed.

4.4.1.2 Ionisation
Ionisation is the first step in MS analysis, which acts to produce gas-phase ions of the
compound of interest. In the ionisation source, the sample molecule is bombarded with a highenergy electron beam to form a radical cation (also called a parent/precursor ion). The process
leaves the molecule with an excess of energy, leading to instability and fragmentation of the
molecule into various pieces (product ions). Fragmentation provides a unique 'fingerprint' for
that molecular structure, resulting in ion fragments with a certain mass and charge (m/z). Many
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impacts occur simultaneously, generating numerous different ions and fragments for each
compound.
4.4.1.3 Mass Filtration/Mass Analyser
The positive ions which are formed in the ioniser, are accelerated down a curved tube (deflected
by a magnet) into the mass analyser where they are separated in space, and are then identified
based on their mass/charge ratio (21). Lighter ions will be deflected to a greater extent than
heavier ions and a ‘mass spectrum’ is created by the different mass ions that are detected.

4.4.1.4 Detection
After the ions are separated they enter a detector and a ‘mass spectrum’ is produced. The xaxis represents the m/z ratios. The y-axis represents the signal intensity (abundance) for each
of the fragments detected during the scan. A computer database of mass spectra can be used to
match compounds in an unknown sample.

4.4.2 Benefits of combining GC with MS for measuring phenolic acids in biological samples
The combined GC-MS procedure is very useful when dealing with a sample that is a mixture
of two or more different compounds, as the various compounds are separated from one another
before being subjected individually to MS analysis. Combining GC and MS have great
advantages when analysing biological metabolites due to its high sensitivity and specificity.
High specificity (24) is desirable in an analytical method to accurately positively identify the
presence of a particular substance. A high sensitivity is necessary in assessments where the
biological concentrations are low, and only a small amount of biological is sample needed for
a reliable quantitative analysis (22). Additionally, there are extensive compound databases and
experimental protocol available to researchers developing this technique (22). Less favourable
attributes of GC-MS includes the need to derivatize samples to improve their volatility and
thermal stability before injection, which is labour-intensive and may produce derivatives that
will obstruct the quantification (9, 25).

While many analytical investigations into phenolic acids and flavonoids have been reported
(9), there is no gold standard method for their separation and quantification in biological
samples, leaving researchers to develop their own techniques.
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4.5

Aim

The aim of this work was to develop a sensitive method for analysing various phenolic acids
and flavonoids in biological samples using a standardised method with a GC-MS triple
quadrupole mass analyser.
The objectives of the study were to:
1. Develop a library of spectra (database) to provide a reference for the identification of
compounds in future analysis;
2. Optimise the programs for the GC and MS portions of the analysis for the separation
and detection of phenolic acids and flavonoids.

4.6

Methods

4.6.1 Materials
The instrument used was an Aligent 7000 GC/MS-Triple Quad, stationed at University of
Wollongong, Australia. The separation was carried out on 30 m long capillary column with a
diameter of 0.25 mm. The stationary phase was made up of a 0.25µM thick 5% phenyl
methylpolysiloxane film and 1 µl was injected through a splitless inlet. Helium was used as
carrier gas with a flow rate at 1.2 ml/min. Positive chemical ionisation (PCI) was used and the
reagent gas in the ionisation chamber was methane. Argon gas was used in the collision
chamber in the mass analyser.

4.6.2 Preparation of standards for database
To create an in-house library of spectra, injections of pure standards need to be processed for
reference. For an adequate database, all patterns of the retention times of compounds and the
mass spectrum of the pure standard need to be recorded.

Reference compounds of flavonoids and phenolic acids (full list in Table 4-5) were dissolved
in an appropriate medium (acetonitrile, methanol or isopropanol) and made up to a
concentration of 25mM. Seven internal standards were used for quantification (d5-benzoic
acid; phenyl-d7 acetic acid; 3-phenyl-d9 propionic acid; t-cinnamic acid (phenyl-d7); 2-OH,6144

MeO benzoic acid; 2,4,5-triMeO cinnamic acid and 6-methylflavone) and were prepared in the
same way. Internal standards are added in a constant amount to the samples, the blank and the
calibration standards and are used to account for the loss of analyte during processing.

Each compound was added to individual vials and dried off in a heater, before adding 10 µl of
acetonitrile and 30 µl of derivatizing agent N,O-bis-(trimethylsilyl)-trifluoroacetamide
(BSTFA). The samples were incubated for five hours before injecting to the GC-MS.
Assessment of retention times was conducted and the mass spectrum for each compound was
determined. As a compound's spectrum is very reliable and reproducible, the instrument can
search the database and identify each compound in the sample, based on similarities within the
database.
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4.7

Results

4.7.1 Assessment of retention times
The first step in this process is o optimise the separation of the compounds using GC. A mixture
of all compounds was made and analysed with various temperature programs designed to
improve the separation of compounds, so each compound elutes at a different time. Trial-anderror was used to optimise the separation. The initial temperature programs tested were based
on the method Jenner, Rafter and Halliwell (2005) (15), with some adjustments, resulting in
retention times (in minutes) as per Table 4-5. An example of the output for the elution from
the GC for Cinnamic Acid at 8.6minutes is shown in Figure 4-5.

Figure 4-5 Elution time for Cinnamic Acid (8.6m)
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Table 4-5 The 115 reference compounds, retention times and selected transitions comprising
the in-house database
Compound
4-ethyl phenol
benzoic acid - d5
benzoic acid
catechol (1,4-diOH benzene)
phenyl acetic acid - d7
phenyl acetic acid
1,3,5-triMeO benzene
3-phenylpropionic acid - d9
3-phenylpropionic acid
4 ethyl benzoic acid
2 MeO benzoic acid
3,4-diMeO phenol
1,2-diOH, 3-MeO benzene
1,4-diOH, 3-MeO benzene (3-MeO catechol)
3-MeO benzoic acid
2-MeO phenyl acetic acid
3,5-diMeO benzene
2-OH benzoic acid
4-MeO benzoic acid
2-MeO phenyl acetic acid
4-OH, 3-MeO benzaldehyde (vanillin)
t-cinnamic -d7
t-cinnamic acid
4-MeO phenyl acetic acid
pyrogallol (1,2,4 tri-OH benzene)
3-OH benzoic acid
2,3-diMeO benzoic acid
2-MeO phenylpropionic acid
2-OH phenylacetic acid
3-OH phenyl acetic acid
3,4-diOH benzaldehyde
4-OH benzoic acid - d4
4-OH benzoic acid
3-MeO phenylpropionic acid
2,6-diMeO benzoic acid
4-OH phenyl acetic acid
4-OH phenyl-2-propionic acid
1,3,5-triOH benzene (phloroglucinol)
4-MeO phenylpropionic acid
2,5-diMeO benzoic acid
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Retention Time
(m)
3.47
3.55
3.57
3.78
4.2
4.26
5.9
6.1
6.2
6.95
7.05
7.1
7.15
7.2
7.3
7.73
7.85
7.9
8
8.3
8.49
8.55
8.6
8.63
8.7
9.1
9.6
9.75
9.8
9.9
9.95
10.32
10.38
10.46
10.48
10.58
10.7
10.87
10.92
11.1

Transition
194.1 -> 179.1
184.1 -> 110.1
179.1 -> 105.1
254.2 -> 239.2
200.1 -> 172.1
193.1 -> 165.1
168.1 -> 139.1
231.2 -> 112.1
222.2 -> 104.1
207.1 -> 133.1
209.1 -> 135.0
226.1 -> 221.0
284.1 -> 269.0
284.1 -> 269.0
209.1 -> 135.0
238.1 -> 179.1
226.1 -> 211.0
209.1 -> 165.1
209.1 -> 165.1
238.1 -> 194.1
224.1 -> 209.1
212.1 -> 168.1
205.1 -> 161.1
238.1 -> 194.1
239.1 -> 211.1
267.1 -> 223.1
239.1 -> 224.1
252.1 -> 134.1
296.1 -> 252.1
296.1 -> 252.1
282.1 -> 267.1
271.1 -> 227.1
267.1 -> 223.1
252.1 -> 134.1
254.1 -> 239.1
296.1 -> 252.1
310.1 -> 193.1
342.1 -> 327.1
252.1 -> 134.1
254.1 -> 224.1

2-OH,6-MeO benzoic acid (IS1)
3,5-diMeO benzoic acid
2,OH,5-MeO benzoic acid
3,4-diMeO benzoic acid
3,4-diMeO phenylacetic acid
3-OH phenylpropionic acid
2,3-diOH benzoic acid
3,4,5-triMeO benzoic acid
1,3,5 triMeO benzoic acid
3-OH,4-MeO benzoic acid (isovanillic acid)
2,6-diOH benzoic acid
4-OH phenyl propionic acid
4-OH,3-MeO benzoic acid (vanillic acid)
2,3,4-triMeO benzoic acid
(H) homovanillic acid-d3
4-OH,3-MeO phenylacetic acid (homovanillic
acid)
2,5-diOH benzoic acid
2-OH cinnamic acid (o-coumaric acid)
3-MeO cinnamic acid
3,5-diOH benzoic acid
3,4-diOH benzoic acid
2,4-diOH benzoic acid
4-MeO cinnamic acid
3,4-diOH phenylacetic acid
4,5-O-diMe gallic acid
Shikimic acid
3,4,5-triMeO phenylacetic acid
3,4-O-diMe gallic acid
3-OH cinnamic acid
2,4,5-triMeO benzoic acid
4-OH,3-MeO phenylpropionic acid
4-O-Me gallic acid
3,5-O-diMe gallic acid (syringic acid)
2,3,4-triOH benzoic acid
4-OH cinnamic acid (p-coumaric acid)
3-O-methyl gallic acid
3,4-diOH phenyl propionic acid
3,4,5-triMeO cinnamic acid
3,4,5-triMeO phenylpropionic acid
3,4,5-triOH benzoic acid (gallic acid)
(H) 3,4-diMeO cinnamic acid-13C3
3,4-diMeO cinnamic acid
3,5-diMeO cinnamic acid
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11.75
11.85
11.9
12.1
12.2
12.35
12.8
13
13.1
13.15
13.17
13.2
13.3
13.31
13.32

297.1 -> 249.1
254.1 -> 239.1
297.1 -> 249.1
239.1 -> 195.1
268.1 -> 268.1
310.1 -> 192.1
355.1 -> 249.1
284.2 -> 269.1
284.2 -> 269.1
312.1 -> 297.1
355.1 -> 249.1
310.1 -> 192.1
282.1 -> 267.1
284.1 -> 269.1
270.1 -> 179.1

13.34

267.1 -> 179.1

13.45
13.98
14.05
14.25
14.32
14.35
14.36
14.45
14.5
14.6
14.7
14.9
15
15.08
15.16
15.2
15.4
15.65
15.76
15.84
15.85
15.9
15.95
16.03
16.4
16.45
16.5

355.1 -> 297.1
293.2 -> 147.1
235.1 -> 191.1
370.1 -> 355.1
370.1 -> 193.1
355.1 -> 281.1
235.1 -> 191.1
369.1 -> 179.1
312.1 -> 297.1
357.1 -> 147.1
298.1 -> 239.1
312.1 -> 297.1
308.2 -> 293.2
284.2 -> 269.1
310.1 -> 192.1
370.1 -> 355.1
312.1 -> 297.1
443.1 -> 281.1
293.1 -> 249.1
400.1 -> 223.1
412.1 -> 412.1
310.1 -> 295.1
312.1 -> 194.1
458.1 -> 281.1
283.1 -> 268.1
280.1 -> 265.1
280.1 -> 265.1

4-OH,3-MeO cinnamic acid (ferulic acid)
3-OH,4-MeO cinnamic acid (Isoferulic acid)
3,4-diOH cinnamic acid (caffeic acid)
2,4,5-triMeO cinnamic acid (IS2)
3,5-diMeO, 4-OH cinnamic acid
flavanone
diethyl stilbestrol
6-methylflavone
Resveratrol
Phloretin
Formononetin
Epicatechin
Naringenin
Catechin
Biochanin A
Genistein-d4
Hesperetin
Genistein
Daidzin
Taxifolin
Eriodictyol
Kaempferol
Chlorogenic acid
Apigenin
Quercitin
Isorhamnetin
Diosmetin
Myricetin
Luteolin
Diosmetin
Myricetin
Luteolin

16.85
16.95
17.26
17.5
17.7
18.4
18.5
19.1
20.1
20.2
20.6
20.9
20.95
21.05
21.06
21.38
21.4
21.41
21.55
21.57
21.59
22.25
22.3
22.7
23.08
23.15
23.5
23.5
23.75
23.5
23.5
23.75

308.1 -> 293.1
308.1 -> 293.1
396.1 -> 219.1
310.1 -> 279.1
368.1 -> 338.1
222.0 -> 194.0
412.2 -> 383.2
236.1 -> 208.1
444.2 -> 355.2
342.2 -> 327.2
340.2 -> 267.1
650.2 -> 355.2
560.2 -> 545.2
650.2 -> 355.2
413.2 -> 398.2
475.1 -> 403.1
575.1 -> 545.1
471.2 -> 399.1
398.1 -> 383.1
649.1 -> 368.1
560.2 -> 369.0
559.2 -> 487.2
345.1 -> 255.1
471.1 -> 399.1
647.2 -> 575.2
589.2 -> 559.2
501.2 -> 471.2
647.2 -> 575.2
559.1 -> 399.1
500.5 -> 471.0
734.5 -> 647.0
574.5 -> 559.0

The final temperature program is described in Table 4-6. The sample was injected at an initial
oven temperature of 100ºCelcius and held for 1.5 minutes. The ramp rate was then raised at
various increments until the oven reached 262ºCelcius, where it was held for 4minutes, and
then raised again to reach 290ºCelcius and held for 3 minutes to achieve adequate separation
of the compounds.
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Table 4-6 Final temperature program utilised to achieve adequate separation of compounds
Actual Run
Ramp rate

Next Temp

Hold

Time

(ºCelcius/min)

(ºCelcius)

(min)

(min)

100

1.5

1.5

10

140

0

5.5

15

150

0

6.17

2

160

0

11.17

15

215

0

14.84

20

262

4

21.19

10

290

3

26.99

4.7.2 Precursor ion identification
After separation by GC, the molecules are eluted into the MS. The MS first operates by
selecting precursor ions of a specific mass, to separate the ions from the chemical background.
To identify the most appropriate precursor ion of the compounds, the mass analyser was set in
an all-scan mode without any collision energy. For each of the compounds, the precursor ion
was identified in the spectrum. An example of this scan output is in Figure 4-6, for Cinnamic
Acid at 8.6m.

From the obtained spectrum for each compound, four ions were selected to be used in further
collision experiments to identify appropriate product ions for each precursor ion. The criteria
for selecting ions were to be abundant and of high mass. For example, the ions selected for
cinnamic acid were m/z 220, 205,161 and 145 (Figure 4-6).

150

Figure 4-6 Mass spectrum for Cinnamic Acid at 8.6m

4.7.3 Collision energy experiments
The precursor ions are then induced to further dissociate through collision energy experiments
(Figure 4-7), with all compounds and their four respective ions being analysed in separate
experiments with four different collision energies (2, 6, 15 or 30 eV). This experiment is used
to evaluate the best product ion generated from each identified precursor ion for each
compound. The most appropriate collision energy generates a fragment that is smaller than the
precursor ion, but still of reasonably high mass and abundance. This result is called a
‘transition’, which is written as precursor ion mass-> product ion mass, with each compound
providing a unique ion spectrum.
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Figure 4-7 Collision energy experiment output for Cinnamic acid; the ions in each collision
experiment are 220, 205, 161, 145 at CE 2, 6, 15 and 30 eV.
After the initial collision energy experiments, a multiple reaction monitoring (MRM)
experiment is conducted to assess the most suitable collision energy from nine different
collision energies (2.5, 5, 7.5, 10, 15, 20, 25, 30, 40 eV) for each selected transition. The
collision energy which produces the greatest signal detected is selected as the most appropriate.
An example of Cinnamic Acid is shown in Table 4-7.
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The most appropriate transition and corresponding collision energy to be utilised is selected
for each compound and is recorded for application in future analysis. The most appropriate
transition for each compound analysed was selected and is displayed in table 4-5.

Table 4-7 MRM experiment output for all Cinnamic Acid transitions
Transition
(precursor ion -> product ion)
205.0 -> 161.2

Collision Energy

Signal

4

1300000

205.0 -> 145.1

14

5200000

205.0 -> 131.1

14

13000000

205.0 -> 103.1

32

11000000

220.0 -> 205.1

4

3000000

220.0 -> 192.1

0

450000

220.0 -> 161.2

14

1300000

220.0 -> 135.2

4

1300000

220.0 -> 103.2

36

1100000

220.0 -> 75.2

24

380000

220.0 -> 73.2

24

90000

161.0 -> 145.1

4

7600000

161.0 -> 135.2

14

200000

161.0 -> 159.2

4

1300000

161.0 -> 105.1

32

710000

161.0 -> 59.2

16

3700000

145.1 -> 119.1

18

1400000

145.1 -> 129.1

36

340000

145.1 -> 105.1

24

720000

145.1 -> 93.1

32

700000

Finally, calibration curves were analysed using a blank matrix sample to determine whether
the compounds added to the analysis were present. Calibrations curves for all compounds were
obtained, with most producing good linearity, and some showing mixed linearity.
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4.8

Discussion

The chapter initially describes the potential of measuring flavonoids and phenolic acids in
biological samples as biomarkers of flavonoid intake, and the characteristics of GC-MS as a
method to measure flavonoid intake are explained and evaluated. Additionally, this chapter
describes the development of a GC/MS technique for the detection of 115 phenolic acids and
flavonoids in biological samples via the construction of an in-house database of spectra and
optimisation of the GC and MS methods. This method has been applied to measure some
specific phenolic acids in human plasma to confirm the consumption and uptake of potential
bioactive compounds in an anthocyanin-rich cherry juice, described in chapter 6 of this thesis,
and the details of its application are reported in chapter 6.

A GC-MS method for the determination of phenolic acids and flavonoids in biological samples
provides a sensitive and specific technique (24) and is a superior method for the separation of
compounds (24). A sensitive and specific tool for the measurement of phenolic acids and
flavonoids in biological samples is important, as the compounds are structurally similar and
are present at micromolar to sub-micromolar levels (24).

The ability of a GC-MS method to measure biomarkers to provide an accurate indication of
total dietary flavonoid exposure or quantify the intake of specific subclasses requires further
investigation. However, the potential of biomarkers to indicate dietary intake of specific foods,
such as tea (26), is more frequently studied, and more thoroughly understood.

Given the limitations that surround dietary measurement of flavonoids, it is important to
develop methods to investigate the impact of flavonoids on health through measurement of
intact flavonoids or related metabolites (to be used in conjunction or as stand-alone measures).
The development of dietary biomarkers as an objective measure of food intake or exposure to
bioactive molecules (4) is of significance for dietary studies, and in particular are useful when
little data exists surrounding bioactive molecules and their metabolism (4).

Traditionally, a single biomarker is selected to measure dietary exposure to a food component.
For example, vitamin C is often used as a measure of fruit consumption (4). However, early
metabolomics studies have indicated that the use of a combination of several biomarkers may
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improve the specificity of dietary exposure measurements (4), and could be applied when
investigating the intake of single compounds, foods or potentially even dietary patterns.

4.8.1 Conclusion
The limited knowledge regarding which biomarker(s) are indicative of total dietary flavonoid
intake, or which biomarkers should be measured to provide a relevant indication of the
bioactive components of a particular food, a comprehensive method that can quickly and
reliably measure multiple biomarkers of intake would be valuable in human trials. In this
instance, the developed method has the potential to measure up to 115 possible biomarkers,
which has a large applicability for exploratory ‘metabolomics’ related studies.
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CHAPTER 5: FOOD-BASED ANTHOCYANIN INTAKE AND COGNITION IN
HUMAN INTERVENTION TRIALS: A SYSTEMATIC REVIEW

Pre-clinical evidence suggests anthocyanins, a subclass of dietary flavonoids, that provide the
purple and red pigmentation in plant-based foods, may beneficially impact cognitive outcomes.
A systematic review was conducted to summarise and synthesise the published literature on
food-based anthocyanin consumption and cognitive outcomes in human intervention trials.
Four studies were included in this review, comprising acute trials (n=2) and longer-term (n=2)
interventions which assessed multiple cognitive outcomes in children, adults and older adults
with cognitive impairment. Three out of 4 studies reported improvements in either a single, or
multiple cognitive outcomes after anthocyanin-rich food consumption. Due to methodological
limitations and the large clinical and methodological diversity of the studies, pooling of data
was not feasible. The impact of food-based anthocyanin consumption on both acute and longterm cognition appears promising. However, adequately powered studies that include sensitive
cognitive tasks are needed to confirm these findings and allow translation of research into
dietary messages.

This manuscript has been updated and submitted for publication (Appendix G) :
Kent, K, Charlton, K, Netzel, M, Fanning K 2015. The impact of food-based
anthocyanin consumption on cognition in human intervention trials: a systematic
review. (Journal of human nutrition and dietetics)

KK designed and conducted the review, and prepared the manuscript. KC, MN and KF
provided critical revisions of the manuscript.
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5
5.1

Introduction

The rapidly aging population has led to a major projected increase in the prevalence of neurodegenerative diseases such as dementia (1), and resulted in intense research interest regarding
the role of diet in neuro-protection. Dietary approaches are highly regarded as safe and effective
methods for the prevention of cognitive disorders and the maintenance of cognitive function.
The consumption of dietary flavonoids has been shown to both enhance cognitive function (2)
and prevent age-related cognitive decline in older adults (3). The neuroprotective effects of
flavonoids have been well-documented (4-8), but most of the research has focused on animal
models, limiting translation to humans who utilise more complex cognitive domains, such as
executive functioning. Due to their strong antioxidant potential (9), it has been hypothesised
that flavonoids limit neurodegeneration by reducing neuroinflammation and protecting cellular
architecture in the brain (10). Flavonoids may also contribute to improved cognitive function
by increasing the number and strength of neuronal signals (11), through increased brain blood
flow (7) and an ability to initiate neurogenesis (5) in areas of the brain that are associated with
learning and memory. A large proportion of this research has specifically highlighted the
benefits of anthocyanin-rich foods (12-15).

Anthocyanins are a subclass of dietary flavonoids (different from proanthocyanidins, which
are polymers of flavanols), which provide the purple, red and blue pigmentation in plant based
foods (16). Typical food sources of anthocyanins are fruits such as apples, grapes, plums;
berries including strawberries, blueberries and blackberries; vegetables such as red cabbage,
red onion, eggplant, and beverages including red wine and grape juice (17). Approximately
640 individual anthocyanins have been identified to date(18), however anthocyanins naturally
occur most ubiquitously in six common agylcones (pelargonidin, cyanidin, delphinidin,
peonidin, petunidin, malvidin) in various glycosylated and acylated forms (18). Anthocyanins
are unique among flavonoids due to their ability to reversibly change their structures in
response to changing pH values, from the stable red to orange coloured flavylium cation at pH
<2 to the colourless and less stable carbinol and chalcone forms at higher or neutral pH (1820). This unique feature may impact their stability and binding ability (e.g. to enzymes)
throughout the gut which has a dramatically changing pH environment (“acid” stomach to
“neutral” intestine).
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The metabolism, absorption and bioavailability of anthocyanins is unique to other flavonoids
and has been well documented (21). Briefly, food based anthocyanins are consumed and are
either quickly absorbed as intact molecules via the stomach, or after extensive metabolism in
the small and large intestine or the colon, to enter the circulation as metabolites such as phenolic
acids (21). In previous animal and human studies, only very low amounts of intact (nonmetabolised) anthocyanin glycosides could be detected in plasma and urine after ingestion of
pure anthocyanin compounds and/or anthocyanin-rich food and beverages (15 animal and 17
human bioavailability studies were comprehensively reviewed by Pojer et al., 2013(19)).
However, recent human studies have clearly demonstrated that dietary anthocyanins undergo
intensive metabolism after consumption and that those metabolites are the main transport forms
in vivo (22-25). For example thirty-two anthocyanin-derived metabolites could be detected in
urine, serum and faeces of eight healthy volunteers after the consumption of 500 mg of 13Clabelled cyanidin-3-glucoside(23). In another study published by Ludwig et al. (22)17
metabolites were quantified in urine collected from nine volunteers after the consumption of
300 g blended raspberries(22). Previously, bioavailability of anthocyanins was considered to
be very low (urinary recoveries <2% of intake in most studies) but is now estimated as being
at least 15% if detectable in vivo metabolites are also taken into account(22).

The main biological activity of anthocyanins in vivo was thought to be their antioxidant
capacity and protection against lipid peroxidation (26). However, recent studies have identified
more complex molecular effects of anthocyanins on signalling pathways in cells that may play
a significant role in their protection against chronic diseases (19, 26, 27). Modulation of
neuronal functions by anthocyanin-rich food has been reported in several animal studies (cited
and reviewed by Pojer et al., 2013(19)). It is suggested that these neuroprotective effects (e.g.
improved memory, learning, cognitive and motor functions) by anthocyanins (and/or their in
vivo metabolites) are mediated by their ability to cross the blood-brain barrier and act to
inhibit/supress interleukin-1b (IL-1b), tumor necrosis factor-alpha (TNF-α), and nuclear factor
kappa B (NF-κB) (19). Furthermore, modulatory effects of anthocyanins on important
structural and synaptic plasticity markers have also been reported.

A body of evidence about the benefits of anthocyanin consumption in human health, including
protective effects against age-related neurodegeneration and cognitive decline, has been
accumulating over the past few years (16, 19). Animal studies have provided evidence that
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anthocyanin-rich food consumption can improve several cognitive functions, including longterm memory (28), spatial-working memory (29), object-recognition memory (30). In addition,
improvements in motor performance (i.e. balance and coordination) have been documented
after an anthocyanin-rich blueberry supplemented diet in an animal model (14). Intact (nonmetabolised) anthocyanins were been detected in the brains of rats as soon as ten minutes
after their consumption, and these concentrations were found to be correlated with
improvements in learning and memory tasks (13). Of particular interest is that supplementation
of the diet with anthocyanin-rich fruits, such as blueberries and strawberries, has been shown
to not only maintain, but also reverse, age-related cognitive decline in animal models (11, 31,
32).

A large epidemiological study of 16,010 older women enrolled in the Nurses Health Study
reported significant associations between anthocyanin-rich blueberry and strawberry
consumption and maintenance of cognitive function (a composite score of 6 cognitive tests,
including various measures of memory) over 4 years (33). It was reported that those who
consumed the highest amount of berries had delayed cognitive aging by up to 2.5 years,
compared to those who ate the least (33). Despite their known health benefits, anthocyanins
are often overlooked in human intervention trials that investigate the impact of overall
flavonoid intake on cognitive outcomes (34). In a 2009 systematic review of human
intervention trials assessing the impact of flavonoids on cognitive outcomes (34), no studies
related to anthocyanins were included.

There has been an increasing interest in other areas of anthocyanin research, with a 15-fold
rise in the number of published papers between 1990 and 2013 having the word “anthocyanin”
in their title and abstract (35) Important advances in an increased understanding of the
bioavailability and metabolism of anthocyanins (e.g. biotransformation by the gut microbiota),
coupled with a greater focus on the role of plant foods in brain health (e.g. neuroprotective
activities), warrant a targeted review to summarise the evidence to date of human trials on
anthocyanins and cognitive function.
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5.2

Objective

The aim of this systematic review is to summarise and synthesise the published literature on
food-based anthocyanin consumption and cognitive outcomes in human trials. The objectives
of the review are to:
a) Examine the effects of food-based anthocyanin consumption on cognition and;
b) Highlight the gaps in the literature and address the implications for future studies

5.3

Methods

A systematic review of the literature was performed using the following strategy.
5.3.1 Types of studies
Studies were considered for inclusion in this review if they:


had an experimental design (randomised or non-randomised controlled trials; crossover trials)



examined humans (any age, gender);



administered an anthocyanin-containing food or beverage (amount of anthocyanin
objectively measured);



measured change in cognitive function using a single, or multiple valid and reliable
tool/s;



included a control group;



had full text available.

Only studies written in the English language were considered due to a lack of translational
resources, but studies from any country were eligible if they met the rest of the inclusion
criteria.
5.3.2 Search terms
The following search terms were developed:


Anthocyan* and/or



Flavonoid* and



Cognit* and/or



Memory

The * indicates a truncation, to ensure all variations of the search terms were included.
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5.3.3 Databases
A three stage search was conducted. Firstly, a search of the following databases (abstract, title
and keywords) was performed using the search terms using the Boolean terms AND/OR as
appropriate (Table 5-1):


Scopus (1960 – Sept 2015)



Medline (1960 – Sept 2015)



CINAHL (1960 – Sept 2015)



Psychology and Behavioural Sciences Collection (1960 – Sept 2015)



PsychInfo (1860 – Sept 2015)



Web of Science (1965- Sept 2015)
Note: the differing search years relate to the database availability

The second stage consisted of a hand search of the reference list of identified studies. A third
search consisted of an internet search to identify any studies published outside the realms of
the

available

databases.

This

website

searched

was

google

scholar

(www

scholar.google.com.au) using the aforementioned key words (1960-Septermber 2015). The
records were managed in EndNote X4 software.

5.4

Results

The search (Table 5-1) returned 1,684 articles, and one other potential study was identified
through hand-sorting of reference lists. After duplicates were removed and the titles screened,
32 potential studies were identified. After screening abstracts a further 25 were excluded (Table
5-2) and after reading the full text articles of 7 studies, a further three were excluded (Table 52) according to the inclusion/exclusion criteria, leaving four final papers in the review (Figure
5-1).
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Figure 5-1 PRISMA flowchart for the search and study selection process of included and
excluded studies
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Table 5-1 Search strategy results
Terms

PsychInfo

Medline, CINAHL, Psychology and
Behavioral Sciences Collection

#
Results

1

anthocyan*.mp. [mp=title, abstract, heading word, table of contents, key concepts,
original title, tests & measures]

38

2

flavonoid*.mp. [mp=title, abstract, heading word, table of contents, key concepts,
original title, tests & measures]

285

3

memory.mp. [mp=title, abstract, heading word, table of contents, key concepts, original
title, tests & measures]

182671

4

cognit*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original
title, tests & measures]

445379

5

1 or 2

6

3 or 4

7

5 and 6

S3
S2

(memory OR cognit*) AND (S1 AND S2)
memory OR cognit*

S1

anthocyan* OR flavonoid*

3

#2 AND #1
Indexes=SCI-EXPANDED, SSCI Timespan=All years

315
556903
87
639
663,419
54,144
61

(TI=(cognit*) OR TI=(memory)) AND LANGUAGE: (English)

Web of science
2

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC
Timespan=All years
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20,397

(TI=(anthocyan*) OR TI=(flavonoid*)) AND LANGUAGE: (English)
1

Scopus

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, CCR-EXPANDED, IC
Timespan=All years
( ( TITLE-ABS-EY ( anthocyan* ) OR TITLE-ABS-KEY ( flavonoid* ) ) ) AND
( ( TITLE-ABS-KEY ( cognit* ) OR TITLE-ABS-KEY ( memory ) ) )
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298,592

897

Table 5-2 Excluded studies

Excluded

Study reference

Reason

(36)

No measure of cognition

2

(37)

No measure of anthocyanin in apples

3

(38)

Animal study

4

(39)

Not primary research

5

(40)

Not primary research

6

(41)

Animal study

7

(42)

Conference abstract

8

(43)

Animal study and non-food based

9

(44)

Conference abstract and study design

10

(45)

Review, not anthocyanin specific

11

(46)

Conference abstract

12

(47)

Editorial

13

(48)

Review of blueberries, not focussed on cognition

14

(49)

Full text cannot be found

15

(50)

Animal study

16

(51)

Pomegranate extract in pill form

17

(52)

Narrative review focussed on animal studies (small section

after 1

abstract reviewed

on Krikorian papers identified)
18

(53)

Animal study

19

(54)

Review of grape products, not focussed on cognition

20

(55)

Review of animal studies

21

(56)

Animal study

22

(57)

Intervention not flavonoid related

23

(58)

Review, cognitive outcomes not addresses

24

(59)

Review, not food vehicle

25

(60)

Animal study, black soy contains no anthocyanin

Excluded after full 26

(61)

No measure of anthocyanin in juice

text retrieved

27

(62)

No measure of anthocyanin in juice

28

(63)

No measure of anthocyanin in juice
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5.4.1 Description of studies
Four studies were deemed eligible for the review (64-67). For this review, statistical pooling
of the data was not possible due to the large clinical and methodological diversity (variability
in the participants, interventions, study design and outcomes studied) leading to a lack of
homogeneity of the studies, therefore the findings are presented in a narrative form. The
characteristics of each study are described in Table 5-3 and relevant information summarised
in Table 5-3. The publication dates ranged from 2010-2015. Of the four included studies, two
were randomised, double blind, placebo controlled studies (64, 65) that assessed chronic daily
consumption of anthocyanin-rich juices on cognitive outcomes, and one was a randomised (67)
and the other a non-randomised (66) placebo-controlled crossover trial that assessed the acute
impact of anthocyanin rich juices on cognitive outcomes. Two studies investigated older adults
with mild-cognitive impairment (MCI) (64, 65), one study was conducted in young, healthy
adults (67) while another was undertaken in children aged 8-10y (66). The studies were
undertaken in New Zealand (67), the USA (64, 65) and the UK (66).

5.4.2 Description of the interventions
In all four studies, the vehicle for anthocyanin administration was a beverage. Two studies
utilised a pre-formulated juice (64, 65) and placebo control, one study (67) utilised a juice
processed from fresh fruit (150g fruit yielded ~140ml juice) and a powdered fruit extract made
up with water, and one study (66) blended fresh fruit into a smoothie. Two studies based the
beverage serving size on the body weight of each participant (64, 65) providing between 6ml
– 9ml of juice/kg body weight of juice (providing between 428mg-598mg anthocyanin/day
divided over three servings). One study (67) altered the serving sizes of the juice to consistently
deliver 525±5 mg of polyphenols per 60 kg of bodyweight per participant. One study (68)
administered a standard serving size to each participant (143mg anthocyanin/serve), regardless
of body size.
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Table 5-3 Included studies
Author
Participants
Krikorian
Krikorian et
et al.,
al., 2012 (64)
2012 (64)

Design
21 older
adults, 68y+,
mild
cognitive
impairment
(clinical
dementia
rating scale)

Intervention
Randomised
double-blind
placebo controlled
trial

Dose
16 weeks, daily
consumption of
concord grape
juice (n=10) vs
placebo (n=11)
(colour, taste,
calorie & sugar
matched)

Cognitive tests
Anthocyanins: 425mg/L
(spectrophotometry).
Serving size calculated to
be between 6 & 9ml/kg
body weight over 3
servings/day

Results
Baseline & 16 weeks:
California Verbal
Learning Test II (verbal
learning & memory),
Geriatric depression scale
(mood), Sub-group (4 per
group) fMRI brain
imaging

Krikorian
et al.,
2010 (65)

Krikorian et
al., 2010 (65)

9 older adults
(5 men, mean
age 76.2±5.2)
mild
cognitive
impairment
(clinical
dementia
rating)

Randomised,
double blind,
placebo controlled
trial

12 weeks, daily
consumption of
blueberry juice
(n=9) vs placebo
(n=7) (not
matched, control
group from
another study
(62)).

Anthocyanins: 877mg
cyaninidin 3-glucoside
equiv/L (HPLC). Serving
size between 6 & 9ml/kg
body weight over 3
servings/day

Baseline & 12 weeks:
California Verbal
Learning Test (verbal
learning & memory),
Verbal paired associate
learning test (memory)

Watson et
al., 2015
(67)

36 young
adults (mean
age 24.8y ±
3.9)

Acute
randomised
double-blind
placebo
controlled
crossover
study

3 juices on
different
occasions:
placebo juice,
blackcurrant
extract or
blackcurrant juice

Placebo juice:
0mg/kg
anthocyanin;
Blackcurrant
extract: 7.7mg/kg
anthocyanin;
Blackcurrant fruit
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7 repetitions over 70m post
intervention: digital
vigilance (attention),
Stroop (attention,
inhibition), rapid visual
information processing
(RVIP, attention &

Sig. improvement in
RVIP accuracy after
supplementation with
anthocyanin-enriched
blackcurrant extract vs
control (p= 0.011). Sig.
improvement in reaction

Whyte et
al., 2015
(66)

16 children
(10 male,
mean age
9.17y ± 0.6)

Acute crossover placebo
controlled
trial

Intervention: 200g
fresh blueberries,
100mL milk & 8g
sucrose. Control
(sugar & vit C
matched): 0.02g
vit C powder,
8.22g sucrose,
9.76g glucose &
9.94g fructose &
100mL milk

juice: 8.0mg/kg
anthocyanin.
Serving size
10ml/kg body
weight

working memory), BondLader visual analogue
(mood)

Intervention: 143
mg anthocyanins
(method not
described)

Baseline and 2h post
intervention:
Go-No Go (response
inhibition), Stroop (verbal
reaction & interference),
RAVLT(verbal learning &
memory), Object Location
Task (spatial memory &
discrimination), & a Visual
N-back (visual attention &
short term memory)
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time on some repetitions
(1, 4, 7) on digit vigilance
task vs baseline for the
cold-pressed blackcurrant
fruit juice (overall effect
p=0.044). No sig. effect
on mood
Sig. improvement in
delayed recall of RAVLT
(word learning &
retention) for intervention
group (p=0.038). No sig.
improvement for other
tasks

5.4.3 Outcome assessment
Cognitive outcomes were measured using valid tools in all studies. Two studies measured acute
change in cognition (66, 67) while the other two studies measured longer term change in
cognition over 12 to 16 weeks (64, 65).

5.4.4 Longer term anthocyanin supplementation and cognition
The longer-term studies both evaluated verbal learning and memory in older adults with MCI
(64, 65) using the California Verbal Learning Test, one study measured change in explicit
episodic memory using Paired Associate Learning Test (65) and one study assessed change in
mood using the Geriatric Depression Scale (64). One study (64) measured cognition
objectively, using fMRI brain imaging, which indicates stimulation and activity in specific
regions of the brain.

Krikorian et al., (64) reported that after 16 weeks supplementation with concord grape juice,
there was no between-group difference for performance on the CVLT learning task, but there
was a reduction in interference on the CVLT memory task compared to baseline (p=0.04).
There was a NS effect on mood. Analysis of the fMRI brain analysis indicated that there was
greater activation in the anterior and posterior regions of the brain for the intervention group
only (64). In another study, the same research team of Krikorian et al., (65) reported significant
improvements on the verbal paired associate learning task (p=0.009) after 12 weeks of
supplementation with blueberry juice. However, both of these studies had small sample sizes
of only n = 10 in the Concord grape juice intervention arm (64) and n = 9 in the blueberry
juice intervention arm (65).

5.4.5 Acute anthocyanin supplementation and cognition
The two acute feeding studies evaluated change in acute cognition using the Digital Vigilance
test (a measure of attention) (67), the rapid visual information processing test (attention and
working memory) (67), the Go-NoGo test (response inhibition) (66), Rey Auditory Verbal
Learning Task (RAVLT) (verbal learning, memory) (66), an objective location task (spatial
memory) (66) and a visual-n back test (attention and short term memory) (66). Both studies
used the Stroop test to measure attention and inhibition (66, 67).
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Watson et al., (67) compared three conditions (placebo vs powdered blackcurrant extract with
7.7mg anthocyanins/kg vs blackcurrant juice with 8mg/kg, based on body weight) on acute
cognition in 36 young adults by administering tasks seven consecutive times during a period
of 65 minutes after consumption of the beverages. The authors reported significant
improvements in accuracy as measured by the Rapid Visual Information Processing test
(p=0.011) when participants consumed the blackcurrant extract vs placebo, and improvements
in reaction time for some repetitions (1, 4 and 7) on the digital vigilance task compared to
baseline tests (p=0.044) for blackcurrant juice or extract vs placebo. No change in mood or
other tasks was recorded.

Whyte et al., (66) assessed acute change in cognition after consumption of 200g fresh
blueberries (143 mg anthocyanins) provided in a milk-based smoothie in 16 children. There
was a significant improvement in the delayed recall portion of the RAVLT task after
consumption of the blueberry smoothie (p=0.038), but no improvements seen for any other
task.

5.5

Discussion

The aim of this systematic review was to assess the effects of anthocyanins consumed from
food, not supplements, on domains of cognitive function, as well as highlight gaps in the
literature and address the applicability of the available evidence for development of future
study designs. Despite over a decade of pre-clinical evidence supporting the association of
anthocyanin intake on cognitive outcomes (69), there remains a lack of experimental studies
conducted in humans. The four studies included in the review reported positive benefits of
anthocyanin consumption on some aspects of cognition; however the interpretation of the
studies is limited by small sample sizes and inconsistent methodologies.

There remains a lack of consensus regarding which cognitive domain is impacted by flavonoid
(including anthocyanin) intake. This limits choice of best instruments and methods to employ
in studies that investigate potential change in cognitive function (34). The four identified
studies used a wide range of tools to address multiple cognitive domains. This inconsistency
limits comparability between studies and prevents the study findings from being synthesized.
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This limitation has been recognised, as pointed out in a recent methodological review paper
(70). The review concluded that future research should be guided by positive findings from
previous similar research and that it may be best to continue to include a battery of sensitive
and specific tools that address multiple cognitive domains, until there is better understanding
of specific brain functions that are influenced by these bioactive components in foods.

The length of the intervention needed to demonstrate outcomes in both acute and chronic trials
is also poorly understood. The results of the studies by Krikorian and colleagues (64, 65)
indicate that an intervention of 12 weeks is long enough for cognitive improvements to be
observed, and that extending study to 16 weeks may not improve the strength of the association.
The timing related to the acute impact of food-based anthocyanins on cognition is hampered
by the limited knowledge related to their metabolism and the exact intrinsic effects of
anthocyanin-rich foods. Understanding to date of anthocyanin metabolism (71) suggests that a
small proportion of anthocyanins are absorbed within 1-2h of consumption and that the
remainder pass through to the colon (at 5-6h post consumption), where they are extensively
metabolised by colonic microflora into metabolites with many potential bioactivities. It is not
yet clear whether the intact anthocyanins or their metabolites, or both, are responsible for the
beneficial effects of an anthocyanin-rich diet (72). The two acute studies reviewed in this paper
did not extend their trial times to encompass the secondary uptake of anthocyanin-related
metabolites in the colon, and thus may have missed an important later interaction that these
compounds have on cognition.

Another outcome from our systematic literature review is that biomarker data for anthocyanin
uptake is largely unavailable. Only one study (67) conducted an objective analysis of biological
specimens to determine the uptake and metabolism of the anthocyanin present in the
intervention foods. This fundamental data needed to confirm the bioavailability of
anthocyanins from different foods and to determine which of the bioactive components are
specifically associated with the observed health benefits. Current information suggests that the
level of absorption of flavonoids, and especially anthocyanins, is very low (73) which makes
them difficult to detect in plasma and urine samples. Identification of the full complement of
phenolic acid metabolites produced from the breakdown of anthocyanins has not yet been
made.
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Different age groups may respond differently to anthocyanin intake. The studies included in
this review investigated groups ranging in age from children (8-10y) to older adults (>68y)
with mild-cognitive impairment. Disease states that affect brain function, including vascular
and non-vascular dementia, as well as Alzheimer’s disease may also result in different
measureable outcomes in these groups (74), as shown by the limited impact of antioxidant
clinical trials in this group(74). Therefore, it is important to clearly define patient groups and
the differences in the effect between children, and young and older adult’s needs to be
investigated.

The provision of anthocyanins through a juice/beverage vehicle was not well explained in all
of the studies. It can be speculated that the provision of a pre-formulated juice is an ideal way
to control the variation of anthocyanins in the fresh-fruit equivalent, which can be heavily
influenced by growth conditions and can differ between seasons. Provision of a juice also
reduces the impact of fruit seasonality on intervention timing. However, the impact of food
processing can substantially alter the anthocyanin content of foods, especially with regard to
heating or cooking. For example heating of dark anthocyanin-rich blood plums during jam
making resulted in losses of up to 70% of their total anthocyanin content (75). Additionally,
some studies administered relatively large doses of anthocyanin-rich beverages (up to over
600ml), presumably to maximise the potential of the bioactive anthocyanins. The division of
the anthocyanin-rich food over 3 servings per day in the longer-term trials (64, 65) may have
diminished their bioactivity. The provision of smaller doses may not have provided a sufficient
concentration of anthocyanin to exert a physiological effect, compared to an increased
bioactivity if a larger serve is consumed at once. However the dose-response mechanisms for
the impact of anthocyanin-rich food on cognition have not been well investigated. There is a
trade-off in clinical trial methodology between reflecting usual intake of anthocyanin-rich
foods, as spread throughout the day, and ensuring a sufficiently high dose is provided (in a
single serving) to observe outcomes. Future trials are needed to further elucidate the dosedependent responses associated with consumption of anthocyanin-rich foods.

Background diet was considered by only one of the intervention studies(76), whereby
recommendations were provided on which foods to avoid the evening prior to testing day. Diet
was controlled on the day of the intervention in the longer acute trials (76, 77), but was not
controlled in the longer-term trials. Controlling the background diet, or at least monitoring it,
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is an important consideration in flavonoid trials (78) in order to isolate the effect of the
intervention. Provision of low flavonoid and/or washout diets before and during trials may be
an effective way to reduce the impact of habitual diet on intervention outcomes, although
monitoring habitual diet throughout the period of longer term interventions may also be useful
to identify potential dietary confounders (78). However, the ideal protocol for standardising
with the background diet, including the length of run-in periods in flavonoid trials has not been
investigated and identified, although a minimum of 3 days has been suggested (78).

Berries, particularly blueberries and blackberries, have received the most interest in studies
investigating the health impacts of anthocyanin-rich foods. Many other anthocyanin-rich
sources have been overlooked, including vegetables such as red onions and cabbage. The
potential for these foods to influence cognition needs to be confirmed, as the large dependence
in research on berries limits the translation of the outcomes to nutritional advice for the
population. The consumption of large amounts of berries is not always feasible, as berries are
often expensive, seasonal (not available year-round) and can spoil quickly. The use of freezedried fruits to overcome these barriers may be a possibility, providing that the anthocyanin
content of the fresh fruit equivalent is not spoiled. Freeze-dried fruit may be a nutritionally
more preferable way in which to consume anthocyanins, compared to encapsulated
anthocyanins or anthocyanins added to other processed foods. This is because anthocyanin
pigments present within natural foods are unlikely to be working independently, as plants
typically contain a complex mixture of phytochemicals that have synergistic bioactivities (79).
Some studies have found that anthocyanin bioactivity may be increased when they are
consumed within a mixture of polyphenols, for example as they would naturally occur within
a complex food matrix (80). This emphasises the importance of investigating whole food
sources of anthocyanins, rather than isolated and encapsulated anthocyanins when studying
health related outcomes.

The implication of study design (ie a cross-over design versus parallel groups) is important
when considering flavonoid trials. Due to the high intra-individual variability in the metabolism
of flavonoids (81), a cross-over design whereby each individual serves as their own control, is
arguably more appropriate, especially in trials with small sample sizes.
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The studies identified in this systematic review that were conducted by Krikorian et al.,(64, 65)
have been criticised for using the placebo control results from one study, as the placebo control
in the other(82). It may have been preferable to analyse this data three-arm study. Lamport et
al., (82) has suggested that this method may reduce the significance of the results (loss of power
from increased number of comparisons). Another limitation of these studies is the differences
in mean age between the placebo and the control groups (5 years), which may be associated
with the difference in cognitive performance.

Three studies were excluded on the basis of not having a measure of anthocyanin in the
intervention juice (61-63). Hendrickson et al., 2008 (63) measured total phenolic content, but
did not report anthocyanin content specifically. Despite previous research showing that both
cranberry (83) and grape juice (64) contain anthocyanins, without an objective measure of their
anthocyanin content the extent to which their bioactivities relate to the anthocyanin content
cannot be speculated. These studies showed that in older adults (n=5), daily concord grape
juice consumed (4-6ml/kg body weight divided over 3 servings per day) over 12 weeks was
associated with significant improvements (p=0.04) in verbal learning and memory on the
California Verbal Learning Test. In young adults (n=35), grape juice (10ml/kg body weight)
had no impact on acute cognition (implicit memory as measured by a word fragment
completion task) and cranberry juice consumption (~470ml consumed twice per day) had no
significant impact on cognitive outcomes.

5.5.1 Conclusion
The impact of food-based anthocyanin consumption on both acute and long-term cognition
appears promising. However, adequately powered studies that include sensitive cognitive tasks
are needed to confirm these findings and allow translation of research into dietary messages.
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CHAPTER 6: FLAVONOID RICH CHERRY JUICE ACUTELY REDUCES
BLOOD PRESSURE, BUT NOT COGNITION IN YOUNG ADULTS, OLDER
ADULTS AND DEMENTIA PATIENTS: A PILOT CROSSOVER STUDY

This chapter describes a pilot cross-over study that was conducted to assess the acute effects
on cognitive function, blood pressure and plasma biomarkers associated with consumption of
a 300 ml flavonoid-rich fruit juice, provided either as a single quantity or as 3x100ml doses
administered over 2h. Young adults (n=6), older adults (n=5), and older adults with dementia
(n=5) received in random order either a single 300ml dose or 3x100ml doses of high-flavonoid
cherry juice at 0, 1 and 2h. Blood pressure and plasma levels of phenolic metabolites were
measured at 0, 2 and 6h. A battery of cognitive tests was administered at baseline and 6h.
Regardless of dose, cherry juice did not impact acute cognitive function. The single 300ml dose
of juice significantly reduced heart-rate (p=0.024) and diastolic blood pressure (p=0.016), with
a trend for reduced systolic blood pressure (p=0.066) after two hours. The 3x100ml doses did
not result in blood pressure reductions and no group effect was evident in either dose. Plasma
phenolic metabolites increased at 2 and 6 hours, however changes were higher after the single
300ml dose. The methodology used in this acute pilot study contributes to study design for
food-based trials of cognition. Flavonoids delivered in cherry juice did not acutely improve
cognition; however a single 300ml quantity of juice reduced blood pressure in all groups
similarly. The data suggests that dose-interval administration may be an important factor when
administering the intervention, as a minimum threshold of uptake may need to be reached in
order to induce acute bioactive effects.

This chapter has been published in two separate manuscripts, but will be presented here as a
cohesive chapter.
Appendix A
Caldwell* K, Charlton KE, Roodenrys S, Jenner A. 2015. Anthocyanin-rich cherry
juice does not improve acute cognitive performance on RAVLT. Nutritional
Neuroscience. DOI: 10.1179/1476830515Y.0000000005
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6
6.1

Introduction

A growing body of evidence suggests that consumption of flavonoids, a group of polyphenols
synthesised by plants is associated with enhanced cognitive function (1) and protection against
neurodegenerative diseases (2). Dementia is a common mental and behavioural disorder in
Australia and limited successful treatment options highlights the need for alternative practices
to improve cognitive outcomes. Reviews of pre-clinical evidence have shown that flavonoids
act to suppress neuroinflammation, improve cerebrovascular blood flow inducing angiogenesis
and neurogenesis, as well as improve synaptic plasticity and scavenging neurotoxins and proinflammatory species in the brain (3, 4). Intense interest relates to class of flavonoids known
as anthocyanins, that are concentrated in purple and red fruits (5). Anthocyanins have been
shown to improve cognitive function (6-10), with various anthocyanin derivatives providing
among the greatest antioxidant and free radical scavenging activity of all flavonoids (11).
Sweet cherries are a rich source of anthocyanins and to a lesser degree contain flavan-3-ols,
flavonols (12, 13) and phenolic acids (14) but have been overlooked in investigations of the
cognitive effects of flavonoid and anthocyanin-rich foods.

6.1.1 Anthocyanins and acute cognition
While large scale epidemiological research has provided evidence that anthocyanin
consumption is associated with improved cognition (15, 16) and slower cognitive decline (15)
the ability of these bioactive compounds found in fruit and other foods to modulate acute
cognition has yet to be fully examined. In the context of large-scale trials investigating the
long-term cognitive benefits of flavonoid rich foods, focussed acute trials are also necessary to
determine differences in acute and chronic effects.

Few well designed human trials have investigated the acute impact of flavonoid-rich food on
cognition, and the development of appropriate study protocols is required. Notable gaps in
existing knowledge relate to potential age differences associated with consumption of
anthocyanins, variations in health outcomes related to dosage and timing of consumption, as
well as identification of which cognitive domains are affected and the metabolic fate of
flavonoid-rich foods.
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Flavonoid consumption has been linked with cardiovascular benefits (17) and experimental
studies indicate that the underlying biological mechanisms by which flavonoids regulate blood
pressure include effects on vascular blood flow and vascular reactivity (18, 19). Regulation of
blood pressure is an important clinical consideration for maintenance of cognition (20).
Hypertension has been associated with poorer cognition in older adults (21, 22), which may
relate to mechanisms that link flavonoid consumption to cognitive functioning. There is some
evidence that suggests a weaker association between anthocyanin intake and cardiovascular
outcomes in older adults (18) and additionally, the differences in acute responses between
younger and older adults have not been adequately addressed.

There is no consensus regarding the quantity of flavonoids needed to induce bioactive effects
and studies rarely consider a dose-timing analysis, with a few exceptions (23). The dosedependent association on blood pressure reduction has not been supported (23) and is largely
unexplored at the acute level. Studies often administer unrealistically large doses of flavonoidcontaining foods in order to ensure a physiological result (8-10, 23), which limits translation
into practical nutritional advice or generalisability to usual diets.

6.1.2 Measurement of flavonoid biomarkers in acute trials
Regarding biomarkers, only a few methods have been developed to measure the intake of
flavonoids in biological samples, with little consistency in the literature. Flavonoids are quickly
and extensively metabolised by the gut into phenolic acid metabolites (24), which may have
different bioactivity to intact flavonoids. Plasma phenolic acids have been promoted as valid
biomarkers of flavonoid intake (25, 26). Phenolic acids may reflect the absorption and
metabolism of flavonoid rich foods and may be useful in understanding the metabolic fate of
specific flavonoid rich foods (27).

The aim of this study was to develop and evaluate methodology to examine the acute impact
of flavonoids from cherries on cognition and blood pressure; compare acute dose-timing effects
of flavonoids from cherry juice on cognition and blood pressure in young people, older adults
and older adults with mild to moderate dementia; and examine dose-timing effects relating to
the absorption and metabolism of flavonoids from a feasible serving of cherries, over time and
between groups, using Gas Chromatography/Mass Spectrometry.
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6.2

Methods

Ethics approval was awarded by the University of Wollongong Human Research Ethics
Committee. Participants were recruited through advertisements pursuing young healthy adults
(18-35y) (n=6), older adults aged (55+y) (n=5) and older adults with dementia (n=5).
Participants were screened for exclusion criteria of uncontrolled hypertension and dysphagia.
Dementia diagnosis from a geriatric physician was required for inclusion in the dementia subgroup. Written informed consent was obtained and consent was provided by a carer when
appropriate. Consenting participants were randomised to a treatment allocation and cognitive
assessment order by computer-aided block randomisation by an independent statistician.
Participants attended the study clinic on two occasions with a one-week washout period
between visits.

On both occasions, participants fasted for 12 hours and were provided with a standardised
breakfast with negligible flavonoids (wheat biscuits and milk). Cherry juice was administered
either as a single 300ml at 0hrs or 3x100ml servings at 0, 1 and 2hrs. Cherry juice was produced
from a single seasonal batch, underwent novel processing to minimally damage anthocyanin
content and was frozen at ≤-0.20oC. Oxygen Radial Absorbance Capacity of the cherry juice
was 58.99 µmol Trolox Equivalent/g and the Anthocyanin content was determined to be
69mg/100ml using a validated HPLC (28) method. A standardised snack with negligible
flavonoids (ham and cheese on white bread) was provided at 4 hrs.

6.2.1 Anthropometrics
Height and weight were measured and BMI calculated. Nutritional status was assessed using
an interviewer-administered Mini Nutritional Assessment (MNA) (29). Resting blood pressure
and heart rate were measured using an Omron HEM7200 Deluxe Automatic Blood pressure
Monitor, while seated, in triplicate and averaged at baseline, 2 and 6 hours post-intervention.

6.2.2 Blood collection
Blood samples were collected in EDTA tubes at baseline, 2 and 6 hours post-intervention and
centrifuged within 1 hour, with plasma extracted and stored at -0.80oC until batch analysis.
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Phenolic acid analysis was performed according to Loke et al, (25) on an Aligent-7000 Gas
Chromatography/Mass Spectrometer-Triple Quad. Briefly, the collected blood was treated
with 18 µl of indomethacin (5 mM). The sample was centrifuged at 3000 rpm for 10 min at 4
°C. Plasma (250µl) was then pipetted to microfuge tubes preloaded with 10 µl of 2mM
butylated hydroxytoluene (BHT) and frozen at -20 until analysis. Internal standards were added
to a vial and dried off before 100µl plasma was added. The samples were acidified with 3M
acetate buffer pH 4.8 (50 µl/ml). To hydrolyse the conjugated compounds in the sample, H.
Promatia extract with β-glucuronidase and sulfatase activity, was used (25 µl/ml). After
overnight incubation at 37°C, concetrated HCl (2% v:v) was added and the sample was
centrifuged for 10 min at 8000 rpm. The supernatant was added to a solid phase column filled
with diatomaceous earth (100 mg/100 µl), which retains the water-soluble compounds. The
phenolic acids were eluted with ethyl acetate. The eluate was dried and derivatized by adding
10 µl of acetonitrile and 30 µl of derivatizing agent N,O-bis-(trimethylsilyl)-trifluoroacetamide
(BSTFA). Eight anthocyanin-related phenolic acid metabolites were targeted for
quantification: ferulic, isoferulic, caffeic, p-coumaric, syringic, vanillic, 4-OH benzoic and tcinnamic acids.

6.2.3 Cognitive tasks
Four sensitive and specific cognitive tasks were administered at baseline and at 6 hours to
reflect acute change. The interview administered tasks were conducted individually by a trained
research assistant. These tasks were selected on the basis of previous research findings (30, 31)
which critiqued the application of various cognitive tasks in previous flavonoid interventions
and provided recommendations for future studies. Specifically, measures of executive
functioning were recommended, however, the specific cognitive domains affected and the tools
which are able to measure this change have not yet been elucidated. Consequently the following
tasks were selected on the basis of previous research and the fact that they were quick to
administer, and challenging but not cognitive draining. A task switching test measured higher
executive function by asking participants to alternate between two simple tasks at once (32).
The Rey Auditory Verbal Learning test (RAVLT) (33) assessed verbal learning and memory
by asking participants to recall a list of words over 5 trials. Pattern and letter comparison tasks
(34) assessed speed of processing, asking participants to compare strings of patterns or letters
as quickly as possible.
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6.2.4 Statistical analysis
Statistical analysis was conducted using SPSS statistical program (V17.0: 2006, SPSS, Inc.,
Chicago, II, USA). Descriptive analysis was performed for cognition, blood pressure and
biomarker variables (mean, SD, range).

Cognitive data were assessed for normality using the Shapiro–Wilk test and found to be
normally distributed. Mixed ANOVA with repeated measures determined if differences
between age groups or dosage existed for each of the four cognitive tests. Post hoc analyses
(Bonferroni correction, p=0.05) were conducted to assess whether outcomes differed between
time points for either dose.

Blood pressure data were assessed for normality using the Shapiro–Wilk test and found to be
normally distributed. Mixed ANOVA with repeated measures determined if differences
between age groups or dosage existed for blood pressure variables (Systolic blood pressure
SBP, Diastolic Blood Pressure DBP, Heart Rate HR). Post hoc analyses (Bonferroni
correction, p=0.05) were conducted to assess whether outcomes differed between time points.

A large inter-individual variation in baseline levels of biomarkers between individuals
(regardless of group) was accounted for by calculating the percentage change (from baseline)
at 2 and 6 h post-intervention for each biomarker. These variables were assessed for
normality using the Shapiro–Wilk test, showing that all variables were not normally
distributed. Variables were transformed using a Log transformation. The percentage change
at 2 and 6 h post intervention was compared over time for each dose using repeated measures
ANOVA and Bonferroni post hoc analyses.

6.3

Results

Sixteen participants were recruited including 6 young healthy participants, 5 older healthy
adults and 5 older adults with dementia (Table 6-1). Three healthy older adults withdrew before
the second session. No difference between the three groups at baseline was found for BMI.
MNA score differed significantly between groups, but mean values fell within the wellnourished category (MNA>24) for all groups (Table 6-1).
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Table 6-1 Subject sample characteristics according to group at baseline
p-value †

Characteristic

Young group

Older group

Dementia group

Average (SD)

n=6

n=5

n=5

Age in years

21.8 (0.97)

74.1 (7.9)

79.8 (3.6)

<0.001

BMI (kg/m2)

26.3 (4.6)

27.6 (4.6)

29.6 (3.2)

0.189

MNA Score

30 (0)

27.79 (1.0)

25.3 (2.2)

<0.001

† ANOVA for differences between groups
BMI: Body Mass Index, MNA: Mini Nutritional Assessment.

6.3.1 Cognitive tasks
One way ANOVA showed significant differences between all groups for all cognitive tasks at
baseline, except the task switching test, where the older and dementia groups performed
similarly. No significant differences were found in cognitive performance for the RAVLT, task
switching test and pattern or letter comparison tasks, with the exception of the task-switching
test in older adults after the single 300ml dose, which was statistically significantly different
6h post cherry juice consumption (p=0.021) (Table 6-2).

6.3.2 Blood pressure
No group effect was observed for change in blood pressure and heart rate over time following
administration of either dose so groups were analysed together. A single 300ml dose of cherry
juice resulted in a significant reduction at 2h in heart rate (p=0.024) and diastolic blood pressure
(p=0.016), and approached significance for systolic blood pressure (p=0.066). A significant
quadratic trend was evident. Post Hoc analysis using the Bonferroni correction showed no
significant differences between baseline and 6 hours for any of the blood pressure measures.
However, a significant difference between baseline and 2h was found for diastolic blood
pressure (p=0.02) and heart rate (p=0.032), and between 2h and 6h for systolic (p=0.017) and
diastolic (p=0.046) blood pressure, and heart rate (p=0.013) (Figure 6-1). The 3x100ml dose
of juice showed a similar but weaker trend and lacked significance.

Table 6-2 Change in performance on cognitive assessments over 6 hours according to group.
3x100ml serving over 3h
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1x300ml serving

Assessment

Baseline

Mean

Baseline

Mean

Average (SD)

difference at Average (SD)

difference at

6h

6h

Young group

n=6

n=6

RAVLT (total)

63.7 (6.7)

+2.0

62.5 (5.6)

+1.5

RAVLT (20m delay)

12.0 (2.5)

+0.5

12.0 (3.2)

+1.3

Task Switching

91.2 (29.9)

-143

78.8 (10.2)

-3.5

Pattern Comparison

21.5 (2.1)

+1.2

21.2 (3.9)

+2.0

Letter Comparison

13.0 (1.9)

+0.67

13.8 (3.3)

-0.33

Older groupa

n=2

RAVLT (total)

35.0 (2.8)

+2.0

44.6 (5.7)

-4.8

RAVLT (20m delay)

5.0 (1.4)

-0.5

5.8 (2.7)

-0.4

Task Switching

84.6 (3.4)

+0.36

126.6 (28.7)

-21.6 *

Pattern Comparison

14.0 (1.1)

-0.5

12.0 (1.3)

+1.2

Letter Comparison

9.5 (2.1)

-1.0

8.6 (1.5)

+0.8

Dementia group

n=5

RAVLT (total)

25.8 (11.6)

+1.8

25.0 (11.4)

+1.8

RAVLT (20m delay)

0.00 (0)

0

0.00 (0)

0.00 (0)

Task Switching

178.1 (130.1)

+13.4

132.1 (109.7)

-3.5

Pattern Comparison

9.2 (5.6)

-0.6

8.2 (4.8)

-0.8

Letter Comparison

4.0 (2.7)

+1.2

4.6 (3.2)

+0.6

n=5

n=5

RAVLT (total) and (20m delay) = number of words recalled
Task switching = seconds taken to complete task
Pattern and letter comparison = number of correct answers in 1 minute
* p=<0.05
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Figure 6-1. Acute change in blood pressure and heart rate over 6 hours after either a single
300ml dose of cherry juice (a, b, c) or 3 x 100 ml doses over 3 hours (d, e, f)

6.3.3 Phenolic acid biomarkers
Eight phenolic acids were detected in all plasma samples, with the exception of vanillic and tcinnamic acid for older adults at the 3x100ml dose visit (n=2). On both occasions, baseline
concentrations of plasma phenolic acids were highly variable and differed between groups,
except for syringic and vanillic acid (Table 6-3). A single 300ml serving of cherry juice resulted
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in large changes in all plasma phenolic acids at 2 and 6h post intervention (Figure 6-2),
particularly caffeic acid. The 3x100ml dose of the juice administered over 3 hours resulted in
smaller plasma phenolic acid fluctuations, and in some individuals, plasma concentrations
declined from baseline. No significant difference between the absolute plasma phenolic
concentrations over time was evident for either serving or between groups. Percentage change
in plasma phenolic acid concentration at 2h and 6h was calculated for each individual, relative
to the baseline concentration, to mediate individual inter-variability. The mean percentage
change was calculated for each group at 2h and 6h from baseline (Figure 6-2).

Table 6-3 Mean baseline concentrations of plasma phenolic acids according to group (average
of two baseline measures)
Group
Mean

Feruli
+ c
Acid*

Isoferulic
Acid *

Caffeic

p-

Acid *

coumaric
Acid *

Syringic

Vanillic

Acid

Acid

4-OH-

t-

Benzoic

cinnamic

Acid*

Acid *

Young

0.20

0.21

0.084

0.019

0.041

1.047

4.19

0.31

Older

0.13

0.51

0.0054

0.04

0.027

0.94

8.37

0.059

Dementia

0.23

0.61

0.027

0.032

0.018

0.70

7.13

0.081

+ nm/ml, *p<0.001 One way ANOVA
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Figure 6-2. Percentage change in plasma phenolic and aromatic acid concentration at 2 and 6h
post intervention; a) young b) old c) dementia for 1x300ml dose and d) young e) old f) dementia
3x100ml dose over 3h
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6.4

Discussion

This exploratory study developed methodology to examine the acute dose dependent impact of
flavonoids from cherries on cognition and blood pressure, in young people, older adults and
older adults with mild to moderate dementia. Evaluating the intervention highlights several
positive and negative characteristics of its design. The intervention was well tolerated, with no
adverse reactions to the juice. The attrition of three participants in this small cohort was related
to study burden and length of testing. The cross-over design appears to appropriately account
for the high intra-individual variations in the metabolism and absorption of flavonoids.
However, there are limitations associated with this study, including the small number of
participants, which restricts our interpretation of the comparison between the groups. Also, the
lack of a control group in this pilot study hinders the inferential interpretation of these results.
However, it was the aim of this study to describe the differences between two dose-timing
administrations. The results should be interpreted with caution.

6.4.1 Cognitive outcomes
Data from this pilot study indicates that a feasible serving of cherry juice, regardless of dosetiming, does not appear to influence acute cognition. The significant difference over 6h for the
older group between doses for the task-switching test may be attributed to the attrition of
subjects in that group. While the cognitive assessment tasks included in this study have
previously been shown to be sensitive measures for nutrition interventions (30, 35) this pilot
study is underpowered to detect changes in cognition. However, the cognitive assessment
battery may be useful for application in a larger study as they were easily applied, interpreted
and analysed in all patient groups in this study. The single 300ml dose of cherry juice provided
in our study, and consequent dose of anthocyanins (≈55mg) is lower than doses of flavonoids
provided through a variety of foods in other studies (36) may also explain the lack of effect.
Other limitations relate to the lengthy testing sessions, leading to fatigue or lack of motivation,
which may implicate performance in the cognitive tasks (37). Different versions of each task
were administered at each time-point; however, trends for improvements in cognition may be
attributed to a learned practice effect (38). Additionally, the influence of study timing should
be further considered, whereby blood pressure may be influenced (potentially increased) by the
timing of cognitive tasks. Therefore, future research should be informed by recent reviews of
sensitive and specific cognitive tests for nutrition interventions (31, 35). Additionally, it is
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important to link the hypothesised physiological effects more closely with application of
cognitive tasks. A cognitive task administered 2h post intervention would reflect the immediate
absorption of intact flavonoids in the small intestine as well as avoiding testing fatigue;
however the sensitivity of cognitive tests needs to be improved.

6.4.2 Blood pressure
A reduction in acute blood pressure and heart rate measurements were seen after a single 300ml
dose of cherry juice after 2 hours in all three groups similarly, before returning to baseline
levels at 6h (Figure 6-1). The reduction of blood pressure and heart rate measurements at 2
hours is supported by data from other acute anthocyanin feeding studies (39), whereby
anthocyanins reportedly reach the circulatory system within 0.25–2hrs and are excreted by 4hrs
post-prandially. However the same amount provided in three smaller doses over a 3 hour period
did not provide the same effect. This highlights potential dose-dependency and suggests that a
minimum threshold of ingestion or uptake may need to be reached in order to induce bioactive
effects. However, replication of these results in a larger sample is required. Ambulatory
BLOOD PRESSURE monitoring may be more precise to accurately explore blood pressure
fluctuations over 6 hours and could be utilised to measure the extended effects of flavonoid
rich foods. Our exploratory study did not investigate possible mechanisms for blood pressure
lowering effects and as fluctuations in plasma phenolic acids generally peaked at 6h post
intervention, reflecting their uptake in the colon, they are unlikely to have influenced blood
pressure changes. Given the large body of existing research demonstrating reductions of
inflammatory and oxidative stress markers and increases to endothelial function associated
with anthocyanin consumption, these mechanisms should be primary considerations in future
studies (23).

6.4.3 Plasma biomarkers
After correcting for baseline plasma concentrations to account for individual inter-variation in
flavonoid metabolism and absorption (40), the percentage change in plasma phenolic acids
increases at 2h and 6h post intervention for both the single 300ml and 3x100ml doses of juice.
However, the relative increase for the single 300ml serving of juice was greater than the single
300ml serving, indicating a larger uptake of cherry related phenolic acids after the single 300ml
serving. Older adults and dementia patients showed a lessened response to the 3x100ml serving
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over 3 hours when compared to younger adults, which may indicate a reduced ability to absorb
and metabolise flavonoids in this group. This hypothesis requires further investigation on a
larger and more controlled scale alongside studies of dose-timing relationships for flavonoid
consumption.

The increase in plasma phenolic acids at 2h post intervention are likely to reflect the absorption
of flavonoids and phenolic acids from cherry juice in the small intestine, as well as smaller
absorption from the stomach (41). The increases shown at 6h post intervention are more likely
to reflect absorption of flavonoid metabolites from the colon (41). The eight phenolic acids
measured in the study are related with anthocyanin metabolism and should reflect the
metabolism and uptake of anthocyanins in cherry juice. However, due to the wide spanning
nature of phenolic acids in foods and diet, and endogenous phenolic acids generated by human
metabolism that the phenolic acids may have come from other sources, such as the metabolism
of the standardised breakfast. There was no statistically significant difference in plasma
phenolic acid concentration between groups or over time for either serving, which is largely
reflective of their extreme variability in this small cohort. Due to the high intra-individual
variation of flavonoid metabolism and bioavailability, the fact that phenolic acids are
influenced by factors other than intake, such as bioavailability and genetic factors, the
combined use of plasma biomarkers and dietary intake estimates may be the best choice in
future studies (42).

The methodology piloted in this study provides an indication of both positive and negative
aspects of its design. An important aspect of the research design is the feasibility of the
intervention in terms of translation into practice. Small changes to the study protocol will likely
improve the accuracy of larger trials. This pilot study indicates that acute intake of flavonoids
in a feasible serving of cherry juice does not change cognitive performance, but may reduce
blood pressure. A lack of effect for the three small servings of juice over 3 hours suggests doseinterval administration may influence the bioactive effect of flavonoids, which require further
investigation.
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6.4.4 Conclusion
The findings from this pilot study suggest that further study of cherry juice and dose response
variations from consumption on vascular and cognitive outcomes is warranted in light of the
evaluated methodology. Further application of the phenolic acid biomarkers in a larger sample
should be conducted to assess their ability to reflect flavonoid intake, and confirm the
absorption and metabolism of cherry-related flavonoids.
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CHAPTER 7: CONSUMPTION OF ANTHOCYANIN-RICH CHERRY JUICE
FOR 12 WEEKS IMPROVES MEMORY AND COGNITION IN OLDER
ADULTS WITH MILD TO MODERATE DEMENTIA

The chapter describes a 12-week randomised controlled trial that aimed to assess whether daily
consumption of anthocyanin-rich cherry juice changed cognitive function in older adults with
dementia. Blood pressure and anti-inflammatory effects were examined as secondary
outcomes. Older adults (+70y) with mild to moderate dementia (n=49) consumed 200ml/day
of either a cherry juice or a control juice with negligible anthocyanin content. Blood pressure
and inflammatory markers (CRP, IL-6) were measured at 6 and 12 weeks. Improvements in
verbal fluency (P=0.014), short term memory (P=0.014) and long term memory (P=<0.001)
were found in the cherry juice group. A significant reduction in systolic (P=0.038) blood
pressure and a trend for diastolic (P=0.160) blood pressure reduction was evident in the
intervention group relative to the control. Markers of inflammation (CRP and IL-6) were not
altered. Inclusion of an anthocyanin-rich beverage may be a practical and feasible way to
improve total anthocyanin consumption in older adults with mild to moderate dementia, with
potential to improve specific cognitive outcomes.

This chapter has been published in the European Journal of Nutrition:
Appendix B
Kent, K, Charlton K, Roodenrys S, Batterham M, Potter J, Traynor V, Gilbert H,
Morgan O, Richards R, 2015. Consumption of anthocyanin-rich cherry juice for 12
weeks improves memory and cognition in older adults with mild to moderate
dementia. European Journal of Nutrition DOI: 10.1007/s00394-015-1083-y

Analysis of the baseline dietary and cognitive data has published in the Journal of Aging:
Research and Clinical Practice:
Appendix D
Kent, K, Roodenry, S, Charlton, KE, 2016. Dietary flavonoid intake and cognitive
performance in older adults with Alzheimer’s type dementia. Journal of Aging:
Research and Clinical Practice, vol. 5.
This data was also presented at several National conferences:
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Caldwell*, K., Charlton, K., Roodenrys, S., Batterham, M., Potter, J., Richards, R.,
Gilbert, H. & Morgan, O. 2014. The impact of fruit flavonoids from cherries on
memory and cognition in older adults with mild to moderate dementia. Abstracts of
HSA 2014 Annual Scientific Meeting (pp. 1-1). Australia: HSA. Abstract of a
presentation that was present at the NSA 2014 Annual Scientific Meeting, 26-28
November, Hobart, Australia.

Caldwell*, K. & Charlton, K. 2013. Dietary intake and major sources of flavonoids in
older Australians with Alzheimer's type dementia. Enabling Active Ageing
Conference Proceedings: The 12th National Conference of Emerging Researchers in
Ageing (pp. 44-44). 25 and 26 of November 2013, Sydney, Australia. Australia:
Emerging Researchers in Ageing Australia.

Caldwell*, K., Charlton, K. E. & Roodenrys, S. J. 2013. Estimation of dietary flavonoid
intake and cognitive performance in older adults with Alzheimer's type dementia.
Australasian Medical Journal, 6 (11), 612. Abstract presented at The Nutrition Society
of Australia and Nutrition Society of New Zealand 2013 Joint Annual Scientific
Meeting, 4-6 December 2013, Brisbane, Australia

KK was responsible for organisation and leading of the study, data collection and analysis
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7
7.1

Introduction

Plant-based foods form an integral component of the human diet and their consumption is
consistently linked to the maintenance of health and the prevention of a vast array of diseases
(1). A growing body of evidence has shown that phytochemicals, non-nutritive bioactive
compounds, contribute to the antioxidant activity of individual fruits and vegetables and are
consequently credited with the observed health benefits (2). Flavonoids are a class of
polyphenols that have been studied intensively and are categorised into six major classes:
anthocyanins, flavanols, flavanones, flavones, flavonols, and isoflavones (3). Flavonoids are
found in particularly high concentrations in fruits and vegetables, wine, tea and cocoa (4). The
consumption of flavonoids has been associated with a reduction in risk for cardiovascular
diseases and some cancers (5, 6) and more recently there has been attention directed to their
potential to protect against neurodegenerative diseases and improve cognitive performance in
older adults (7).

The sub-groups of flavanols, anthocyanins and flavanones have been shown to be the most
beneficial of the flavonoid family in terms of neuro-protection (8). Specifically, literature
investigating the impact of fruit flavonoids on cognitive and physical outcomes is
predominately pre-clinical (9) and while promising, remains inconclusive. Much of the foodbased research has focused on flavonoid-rich blueberries and strawberries (9). The biological
actions of flavonoids on cognitive function have been attributed to a number of hypothesized
mechanisms. Their antioxidant actions assist to scavenge free radicals in the brain (8), while
their neuro-protective effects include protection of vulnerable neurons against inflammation,
enhancement of existing neuronal function, increased blood flow to the brain and neurogenesis
initiation in areas of the brain that are associated with cognition (10).

Preliminary dietary supplementation studies have shown that blueberries (11) and concord
grapes (12, 13) improve aspects of memory in older adults over a 12 and 16 week intervention.
Cherries, both the sweet and tart varieties, are a rich source of anthocyanins and to a lesser
extent also contain flavan-3-ols and flavonols (14). Cherries have been found to lower
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inflammation and scavenge nitrous oxide radicals within the body (15). However the potential
of cherry flavonoids to influence cognitive function has not been investigated, despite them
being a commonly consumed fruit in Australia (4) and other countries.

Research to date has investigated the cognitive enhancing effects of flavonoid-rich foods in
participants with both normal cognitive function (16) and people with mild cognitive
impairment (11-13) but effects in dementia patients remains under researched (17). In light of
projections indicating rapid increases in the prevalence of the dementia (18) and in the absence
of successful treatments, alternative measures to slow the development and progression of
dementia are imperative.

A randomised clinical trial was conducted to assess changes in cognitive function in older
adults with mild to moderate dementia after daily consumption of a feasible serving of
anthocyanin-rich cherry juice over 12 weeks. Secondary outcomes included anti-inflammatory
effects, changes in functional and physical ability and mood.

7.2

Methods

7.2.1 Participants
Participants were recruited from a geriatric outpatient dementia clinic and residential aged care
facilities in the Illawarra region of New South Wales, Australia. Participants were aged 70
years or older and had been diagnosed as having mild to moderate dementia Alzheimer’s type,
as confirmed by the consultant geriatrician responsible for their clinical management (JP).
Exclusion criteria include non-English speaking, uncontrolled hypertension, uncontrolled
diabetes, any other unstable physical or mental health condition or dysphagia. Written informed
consent was obtained. For participants with cognitive impairment deemed by their geriatrician
to be too severe to provide informed consent, consent was provided by family carers or
guardians. Consenting participants (Table 7-1) were randomised to a treatment group and
randomised by computer-aided block randomisation, conducted by a statistician that was
independent to the research interface (MB) (Figure 7-1). All other researchers were blinded to
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the grouping. This study was approved by the University of Wollongong Human Research
Ethics Committee and the Illawarra Shoalhaven Local Health Districts ethics committee
(HE11/175). This study was registered as a clinical trial through the Australian New Zealand
Clinical Trials Registry (ANZCTR) and was allocated the ACTRN: ACTRN12614001298606.

7.2.2 Study Procedure
Over 12 weeks participants received 200ml/day of cherry juice (intervention arm) or 200ml/day
of commercially prepared apple juice (control arm). Juice was delivered weekly, by a research
assistant not involved in data collection, to the homes of participants, chilled in 1L plastic
bottles. Instructions were provided to participants and carers for the juice to be consumed daily,
at any time in one sitting, using a cup provided that indicated 200ml with a fill line. A weekly
calendar was provided with the juice, with daily check boxes ticked when the juice was
consumed. The sweet, Bing cherry juice was produced using a novel method that aims to retain
the phenolic bioactives, developed by a research company (Agritechnology) based in Orange,
NSW, Australia. The high antioxidant activity and anthocyanin content of cherries is well
retained in the juice which had a high Oxygen Radical Absorbance Capacity (3200 µmol
Trolox Equivalents/g) and contained 69 mg red pigments (anthocyanins) per 100g of juice as
determined by HPLC (19) (Table 7-2). The apple juice was provided by Appledale, based in
Orange, NSW, Australia (Table 7-2). Nutritional content of the intervention and control juices
are shown in Table 7-2. A serving size of 200ml per day was determined as being a feasible
quantity that could be consumed by an older adult with mild-moderate dementia, and was
chosen in the absence of empirical research that highlights a dose requirement for anthocyanin
intake and cognitive outcomes. The serving size provided a more feasible serving of juice than
has been used in previous similar studies, where the quantity of anthocyanin-rich beverages
provided may exceed the amount that can be feasibly achieved over the long term, especially
by older adults living with a neurodegenerative disease (11, 13). No change to regular diet was
advised.
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Table 7-1 Baseline characteristics of participants in the study according to group
Characteristic
Control group Intervention
group
n=25, mean ± n=24, mean ± SD
SD

Age (years)

80.6 ± 6.6

78.9 ± 5.2

BMI (kg/m2)

26.6 ± 3.5

25.7 ± 3.4

Current smokers (count)

1 (4%)

0 (0%)

Previous smokers (count)

10 (40%)

7 (29%)

Hand grip strength (kg)

52.1 ± 16.4

62.5 ± 16.1*

Mid arm circumference (cm)

26.9 ± 4.5

27.2 ± 4.1

Calf circumference

33.4 ± 3.7

34.9 ± 3.4

Education (years)

17.5 ± 3.2

18.2 ± 2.4

Mini Nutritional Assessment

23.4 ± 3.5

25.6 ± 2.8*

Instrumental Activities of Daily Living 5.7 ± 2.4

7.5 ± 0.8*

Total flavonoid intake (mg/day)

429.8 ± 384.2

599.0 ± 352.2

Flavonol intake (mg/day)

20.0 ± 13.2

32.9 ± 26.5

Flavone intake (mg/day)

0.3 ± 0.3

1.2 ± 1.7

Flavanone intake (mg/day)*

8.8 ± 16.4

11.7 ± 17.9*

Flavon-3-ol intake (mg/day)*

382.9 ± 379.6

518.9 ± 338.9*

Anthocyanin intake (mg/day)

13.1 ± 29.7

34.2 ± 55.6*

*P<0.05, for differences between groups.
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Assessed for eligibility
Enrolment

(n=56)
Excluded (n=7)




Randomized (n=49)

Not meeting
inclusion criteria
(cognition) (n=5)
Declined to
participate (n=1)
Other reasons
(n=1)

Allocation
Allocated to intervention (n= 24)


Allocated to control (n= 25)


Received allocated
intervention (n= 24)

Received allocated
control (n= 25)

Follow-Up
Lost to follow-up (n= 0)
Discontinued intervention (n=
4)
 Died (n=1)

Lost to follow-up (n= 0)
Discontinued intervention (n= 3)



Indefinitely Hospitalized
(n=1)
Study Burden (n=2)



Moved (n=1)



Study Burden (n=3)

Analysis
Analysed at baseline (n= 21)


Analysed at baseline (n= 21)


Excluded from analysis
at 6 and 12wk (n= 0)

Excluded from
analysis
at 6 and 12wk (n= 0)

Figure 7-1 CONSORT flow diagram of enrolment, allocation, follow up and analysis.
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Table 7-2 Nutritional properties of intervention and control juice
Cherry Juice (100ml)

Apple Juice (100ml)

Energy

395kJ

180kJ

Protein

1.5g

0.1g

Fat Total

<0.2g

0.1g

Saturated

<0.2g

0.1g

Carbohydrate Total

21.0g

10.5g

Sugars

16.0g

9.3g

Dietary fibre

0.7g

0.0g

Sodium

<1mg

1.0mg

3200 µmol TE a/ g

15.55 µmol TEa/ g

69 mg b

0.02mg c

Oxygen

Radial

Absorbance

Capacity
Red Pigment (Anthocyanin) content
a

Trolox Equivalent

b

Iland Method (19).

c

USDA database for the flavonoid content of selected foods (release 3.1) (14).

7.2.3 Measurements
Outcome variables were measured at three time points: baseline, 6 weeks and 12 weeks with
all interviews conducted at the same time of the day (am). At baseline and 12 weeks participants
arrived fasting and a blood sample was collected by a trained phlebotomist. A standardised
breakfast was offered to participants (cereal, milk, banana, tea and/or coffee) and they were
instructed to consume the meal ad-libitum, before the remainder of the interview was
conducted. At 6 weeks, participants arrived at the clinic after having consumed their usual
breakfast at home.

At each interview, a questionnaire was administered by a single researcher, with the assistance
of a guardian or carer, where appropriate, reporting selected demographic characteristics,
tobacco use, and consumption of alcohol, supplements and medications. Nutritional status was
assessed using an interviewer-administered Mini Nutritional Assessment (MNA) (20) and
dietary intake, including flavonoid intake, was assessed using a 24hr dietary recall method,
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with the assistance of a carer or guardian. Dietary records were entered into the FoodWorks
dietary assessment programme to assess nutritional parameters (Xyris Software, Highgate Hill,
QLD, Australia, Version 5, 2007). To estimate usual flavonoid intake, dietary records were
cross-referenced with the 2013 USDA database for the flavonoid content of selected foods
release 3.1 (14). Resting BP and heart rate were measured using an Omron HEM7200 Deluxe
Automatic BP Monitor, while seated, in triplicate and averaged. To monitor physical outcomes
over 12 weeks, anthropometric measurements included height, weight, and mid arm and midcalf circumference. Lawton’s Instrumental Activities of Daily Living Scale (IADL) (21)
determined functional impairment and hand grip strength was assessed using a digital Jamar
handgrip dynamometer (Lafayette Instruments, Indiana, USA). The blood sample assessed
changes in markers of inflammation (C-reactive protein (CRP) and Interleukin-6 (IL-6) and
plasma vitamin C levels. Blood samples were prepared and stored at -80oC for batch analysis
by an independent laboratory where IL6 was measured by High Sensitivity cytokine panel
(millipore), CRP was measured by hsCRP (Kamiya), and Vitamin C by an in-house method.

7.2.4 Outcome assessment
Cognitive function was assessed using a battery of seven cognitive tests, including the Rey
Auditory Verbal Learning Test (RAVLT) (22, 23) , the self-ordered pointing task (SOPT)(24),
the Boston naming test (25), the trail making test (TMT) (26), digit span backwards task (27)
and category and letter verbal fluency (28). The RAVLT measured verbal learning and memory
by the participant learning a list of words over presentation-test and delayed-test trials. The
SOPT is a test of working memory, and the Boston naming test assessed confrontational
naming, related to semantic memory. The TMT A and B evaluated executive function and the
relative difference between B and A was used as the measure. Digit span backwards task
examined short-term memory storage and executive control processes by requiring participants
to repeat a series of numbers in the reverse order they were given. Category and letter verbal
fluency measured executive function, requiring participants to recite as many words as possible
that belonged to the category “animals” or began with the letter “F” and “A”. The geriatric
depression scale (GDS) (29) assessed mood state. The battery of cognitive assessments was
selected on the basis of previous research findings (30) and the suitability of each assessment
as applied in the dementia cohort. Each task had been previously validated and shown to be a
sensitive and specific task at measuring the appropriate cognitive domain.
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7.2.5 Statistical Analysis
Statistical analysis was conducted using SPSS statistical program (V17.0: 2006, SPSS, Inc.,
Chicago, II, USA). Analysis was completed using the full cohort that completed each of the
time points. Continuous data are described as the mean and standard deviation (SD) as
appropriate. Non-normally distributed variables were transformed and treated as normally
distributed. Baseline differences between the intervention and control group’s characteristics
and nutrition information were analysed by unpaired t-tests for continuous variables. A 2-way
repeated measures ANOVA analysed the effect of time, treatment, and time*treatment
interactions for blood pressure measurements at 6 and 12 weeks. Analysis of covariance
(ANCOVA) using the baseline data as a covariate was used to analyse the group effect at 6 and
12 weeks for all cognitive tasks, to isolate the effect of the intervention while controlling for
group differences at baseline. Repeated measures ANOVA assessed differences in markers of
inflammation and vitamin C at baseline and 12 weeks. A p value less than or equal to 0.05 was
considered to indicate statistical significance. Eta-squared (η2) values were calculated to
indicate the strength of the main effect. The Cohen’s f effect size estimates were characterised
as small (0·10), medium (0·25) and large (0·40) (31).

7.3

Results

Forty-nine participants (24 female, 25 male) were recruited and seven participants withdrew
from the study (2 indefinitely hospitalised, 4 due to study burden and 1 moved away).
Participants were randomised into the control group (n=25) and intervention group (n=24)
(Figure 7-1).

7.3.1 Baseline:
No differences between groups were found for age, BMI and anthropometrics, years of
education or total flavonoid intake at baseline. Significant differences at baseline were found
between groups for measures of malnutrition, activities of daily living, and hand grip strength.

Differences in habitual intake of several flavonoid subclasses was found between the groups,
according to a 24h recall administered at baseline (Table 7-1), with the intervention group
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consuming more flavonoids than control subjects. Mean total flavonoid intake was estimated
as 510mg/day. Black tea (80%) was the most significant dietary source of total flavonoids
followed by green tea (7.5%), red wine (4.5%), apples (1.7%) and oranges (1.6%) with their
respective fruit juices. Flavonols contributed 5.15% of total flavonoid intake. Dominant
sources included black and green tea, onion, broccoli and apples. Flavones contributed the
smallest percentage (0.15%) with the major source being parsley. Total flavanone intake
provided 2% with major sources including oranges and orange juice, and lemons. Flavon-3-ols
contributed 88.1% of total intake, with black tea as the major source and wine and apples
contributing somewhat. Anthocyanins (4.6%) were provided by red wine, red grapes and
bananas.

At baseline, the only significant difference between the groups for nutrient intake was for
carbohydrates (p=0.023) and caffeine intake (p=0.03), with the intervention group with a
higher intake than the control.

7.3.2 Post-intervention:
A trend for improvement in most of the cognitive tasks is evident as shown by the mean
difference between baseline and 12 weeks for the intervention group only (Table 7-3). Analysis
of covariance showed significant improvement in cognitive performance in the intervention
group relative to the control (Figure 7-2), at 6 and 12 weeks for the Category Verbal Fluency
task (p=0.014) , RAVLT total (p=0.014) , RAVLT delayed recall (p=0.005) and RAVLT 20
minute delayed recall (p=<0.001) tasks. The effect sizes for Category Fluency (η 2 = 0·711),
RAVLT total (η2 = 0.713), RAVLT delayed recall (η2 = 0.433) were large and the effect size
for RAVLT 20 minute delayed recall (η2 = 0.242) was moderate. No significant improvements
from baseline were found for cognitive performance tasks in the control group.
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Table 7-3 Mean scores for cognitive performance and mood by group a
Control group
Intervention group

Letter Verbal Fluency
(executive function)
Category Verbal Fluency
(executive function)
RAVLT total (I-V)
(learning and memory)
RAVLT

delayed

recall

(memory)
RAVLT 20m delayed recall
(memory)
Trail

b

task

(executive functioning)
Self-ordered pointing task
(working memory)
Digit span backwards task
(short-term memory)
naming

task

(semantic memory)
Geriatric Depression Scale b
(mood)

12 weeks

Mean

Baselin

12 weeks

n=25

n=21

Differenc

e

n=21

e

n=24

13.1 ±

13.1 ±

0.015 ±

18.9 ±

19.0 ±

7.5

7.9

0.4

11.0

10.3

8.4 ± 4.5

8.3 ± 4.7

-0.1 ±

11.9 ±

13.4 ±

0.19

4.5

5.1

19.3 ±

17.5 ±

-1.8 ±

25.5 ±

29.1 ±

9.2

13.1

3.85

10.6

11.5

1.2 ± 1.9

1.4 ± 2.2

0.2 ± 0.4

0.7 ± 1.2

0 ± 0.07

0.72 ±
1.2

making

Boston

Baseline

2.3 ±
2.6
0.6 ±
1.0

1.6 ± 1.4

81.1

85.0

1.3 ± 1.3

1.6 ± 1.8

0.3 ± 0.5

2.3 ± 1.1

2.8 ± 1.1

0.5 ± 0

33.1 ±

31.9 ±

-1.2 ± -

40.6 ±

40.0 ±

15.5

13.6

1.8

13.1

13.6

7.3 ± 4.7

6.9 ± 3.5

-0.4 ± -

6.9 ±

1.2

4.5

a

101.9 ±

65.0

67.3

3.0 ±
1.0

3.9 ± 0.88

2.3 ± 2.6

125.1 ±

1.0

1.9 ± 0.17

1.6 ± 0.4

128.6 ±

0.6 ±

0.13 ± 0.7

3.8 ± 2.9

129.8 ±

-1.2 ± 4.0

Mean Difference

-23.2 ± 2.32

0.6 ± 0.8

0.0 ± -0.2

3.4 ± 1.2

0.4 ± 0.2

6.3 ± 4.3

-0.5 ± 0.5

-0.6 ± -0.2

Data are given as mean ± SD. Baseline refers to measures obtained at the pre-intervention
assessment. Final refers to measures obtained during the final week of the intervention.
Difference
=
final
score
(mean)
less
baseline
score
(mean).
b
A negative score is indicative of improved outcomes. Otherwise, a positive difference in score
indicates improved outcomes.
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**

Figure 7-2 Significant changes in category fluency (A), RAVLT total (B), RAVLT delayed recall (C) and RAVLT – 20minute delayed recall (D)
at 6 and 12 weeks post intervention
*p=<0.05**p=<0.001
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Table 7-4 Blood pressure and heart rate measurements according to group at baseline, 6 and 12 weeks a
Control group
Intervention group
Baseline

6 weeks

12 weeks

Baseline

6 weeks

12 weeks

n=25

n=21

n=21

n=24

n=21

n=21

Systolic BP*

140 ± 19.7

138.5 ± 12.3

137.0 ± 10.1

138.2 ± 16.4

133.7 ± 9.9

130.5 ± 12.2

Diastolic BP

80.6 ± 9.8

81.0 ± 8.0

81.3 ± 11.6

78.6 ± 11.7

77.0 ± 9.9

77.0 ± 12.6

Heart Rate

70.2 ± 10.2

70.2 ± 11.1

74.2 ± 11.8

67.9 ± 10.7

66.0 ± 7.2

67.5 ± 7.9

*p=<0.05
Data are given as mean (mmHg) ± SD.
a

Baseline refers to measures obtained at the pre-intervention assessment. 6 weeks and 12 weeks refers to measures obtained at these time points

during the intervention.
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Repeated measures ANOVA, with the baseline as a covariate, showed a significant
difference in systolic blood pressure (p=0.038) at 6 and 12 weeks post baseline, with
a similar trend evident for diastolic blood pressure (p=0.160) in the intervention group
relative to the control (Table 7-4). No significant differences in blood pressure are
evident for the control group.

At follow up, there were no significant between-group differences in nutrient intake
or for change in nutrient intake from baseline.

Repeated Measures ANOVA showed no significant difference between the
intervention and control groups for serum vitamin C, IL-6 or CRP at baseline or 12
weeks (Table 7-5). There were no improvements in serum vitamin C levels after 12
weeks in either group. Mean levels of plasma CRP and IL-6 were not significantly
different after the intervention.

Table 7-5 Serum vitamin C and inflammatory markers at baseline and 12 weeks
Control group n=25
Intervention group n=24
Baseline

Baseline

12 weeks

IL6 (pg/mL)a

4.3±2.9

6.3±5.8

3.7±1.8

3.8±3.5

hsCRP (mg/L)b

2.0±2.5

2.0±2.3

1.6±1.5

1.7±1.8

19.3±13.1

13.6±8.2

18.2±10.6

13.3±11.0

Vitamin C (uM)
a

12 weeks

IL-6 Interleukin-6; bhsCRP C-Reactive Protein

Data are given as mean ± SD

7.4

Discussion

This study found that daily consumption of a feasible serving of anthocyanin-rich
cherry juice for 12 weeks improved cognitive performance across almost all tasks in
older adults with mild to moderate dementia. To our knowledge, this is the first
controlled human trial examining cognitive and physical responses to a dietary
intervention involving sweet cherries as a source of flavonoids and anthocyanins.
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Our study suggests that provision of anthocyanins through an achievable and
acceptable daily quantity of sweet cherry juice over 12 weeks has benefit for cognitive
function in older adults with Alzheimer’s type dementia. Trends are evident, showing
improvements in cognitive performance across all tasks with regular cherry juice
consumption. Statistically significant improvements are seen for category verbal
fluency and tasks relating to verbal learning and memory (Figure 7-2). The moderate
and large effect sizes seen for the cognitive tasks highlight the clinical relevance of
these cognitive improvements. These findings are consistent with those of recent
human and animal studies showing improvement in cognitive performance in these
domains with dietary supplementation with other anthocyanin-rich food sources (1113, 32-34). Although, we have previously shown that intake of cherry juice does not
impact acute cognition over 6h (35). The ability of flavonoids to modulate Alzheimer’s
disease progression is still poorly understood (17). As explored by the hypothesis in
the current study, flavonoids may be more likely to hinder both normal and diseaserelated losses in cognitive performance through their actions on the brain's cellular and
molecular architecture of memory, rather than halt disease progression.

Some nutritional differences existed between the intervention and control juices
(Table 7-2). As intended, the ORAC measure of oxidative capacity (3200 vs 15.55
µmol TE/g) and the red pigment (anthocyanin) content (690mg/L vs 0.2mg/L) is much
higher in the experimental cherry juice compared to the control apple juice. Apple
juice was chosen as a control juice as it represents a commonly consumed beverage in
older adults, but that has negligible anthocyanin. Despite literature indicating
beneficial effects of apples and apple flavonoids for health outcomes, the juice utilised
in the experiment was processed in a way that likely degraded the flavonoid content.
This important aspect of the research design is relevant to translation of the findings
into dietary messages. However, it is important for future work to investigate whether
dose-response effects are evident in such nutrition interventions.

Despite randomisation, differences in several anthropometric and nutritional factors
existed between the intervention and control group at baseline (Table 7-1). We
attempted to mediate this factor statistically, by applying baseline as a covariate in the
analyses. However, these differences in general health and baseline cognition may
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have influenced the outcomes seen for the intervention group. The estimation of total
flavonoid intake and intake of specific flavonoid subclasses at baseline revealed large
variability between subjects. This can be principally attributed to variations in tea
(confirmed by significant differences in caffeine intake between groups), wine and
other fruit juice consumption, which were the main sources of flavonoids in this
sample. Total intake and major sources of flavonoids of participants at baseline was
similar to that reported for Australians aged 65+ years (510 vs 575 vs 683mg/day
respectively) (4, 36, 37). The higher anthocyanin intake in our sample, compared to
national estimates, may be explained by a relatively high consumption of red wine in
the study group. The addition of cherry juice to the diet of the intervention group
provided them with an additional 138mg anthocyanin/day, which increased their total
anthocyanin intake to 46 times greater than the national estimate for the daily intake
of adults aged 65+y (3.02mg/day). In the absence of a Nutrient Reference Value
(NRV) for flavonoids (38), this magnitude of increase in consumption can be
considered to be a significant increase above habitual intake levels for this age group.

Secondary outcome measures included anti-inflammatory effects, changes in
functional and physical ability and depressive symptomatology. There was a
significant reduction in systolic blood pressure and a trend for diastolic blood pressure
in the intervention group relative to the control; however the study was not adequately
powered to detect blood pressure changes. Previous intervention trials have
hypothesised that the mechanisms relating to the improvements seen in cognitive
performance after anthocyanin-rich food supplementation are due to a reduction in
inflammatory markers, resulting in a blood pressure-lowering effect (13). Our study
showed that markers of inflammation were not significantly altered after cherry juice
supplementation (Table 7-5) and remained within the clinically normal ranges (CRP
<5mg/mL; IL-6 <10pg/mL). This finding suggests that the bioactive components
provided by the cherry juice may provide other benefits, such as stimulating an upregulation of signalling cascades in areas of the brain relating to memory (8).
Additionally, as Alzheimer’s disease is associated with progressive and chronic
inflammation (39), the disease pathology may mask any potential anti-inflammatory
effects provided by the cherry juice.
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Surprisingly, serum vitamin C levels decreased in both groups at 12 weeks of follow
up (Table 7-5). This difference cannot be explained through changes in dietary patterns
over the study duration as vitamin C intake did not differ according to 24h diet recall
data. Additionally, self-reported fruit and vegetable intake was not significantly
different at baseline and follow up. A possible explanation may be the study juices
may have replaced consumption of commercial fruit juices that could have been
fortified with high levels of ascorbic acid. The reported reduction in serum vitamin C
parameters is not clinically significant as mean levels remained in the clinically normal
range (11-114 micromoles/L). Although under-researched in humans, some preclinical evidence indicates that high-doses of flavonoids may inhibit ascorbate
absorption (40), which may explain the reduction in serum vitamin C. Alternatively,
the reagents that were utilized to prepare the serum prior to Vitamin C analysis may
have degraded over the study period.

The study limitations include a relatively small sample size and short intervention
length (12 weeks). However, preclinical studies indicate that flavonoids from berry
fruits may require only several weeks to accumulate in brain regions associated with
cognition (41). Despite this, a short time frame limits our ability for observations
regarding changes in dementia progression. Given the moderate to large effect sizes
found in this study, a longer duration of follow up with larger numbers would be the
next progression in research. Another limitation of the study relates to the generally
better cognitive and physical ability of the intervention group, which is evident despite
randomisation. Interestingly, the measure of effect for improvements on cognitive
tasks in the intervention group relative to the control was the same, regardless of the
cognitive ability of participants. At the baseline and 12 week visits, a standardised
breakfast meal was provided, however at the 6 week visit participants arrived at the
clinic facility in a non-fasted state, after having consumed their usual breakfast at
home (as a fasting blood sample was not collected). If there was a large difference in
the nutritional composition of their usual breakfast to the standardised breakfast (e.g.
a significantly greater intake of caffeine), this may have either positively or negatively
influenced cognitive performance at this time point. However, this effect was
minimised by the participants consuming their breakfast at 6 and 12 weeks ad-libitum,
and as the improvements in cognitive performance seen at 6 and 12 weeks are not
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significantly different, a difference in breakfast is unlikely to be of great importance.
Lastly, while it is likely the bioactivity of the cherry juice relates to its high
anthocyanin content, the potential bioactive effects of other polyphenols cannot be
excluded.

Regardless of their exact mechanisms, the potential of flavonoids to improve cognitive
outcomes for older adults with Alzheimer’s type dementia cannot be underestimated
and a notable strength of this study is the very low possibility of any harm to this
vulnerable group. Further research is required to improve the knowledge base to
inform dietary recommendations for this patient group, as an adjunct to traditional
dementia treatment. For older adults living with reduced cognitive capacity, the
inclusion of an anthocyanin-rich beverage, in addition to or in replacement of another
processed fruit juice, may be a practical way to improve their total flavonoid
consumption, which has been shown to provide positive outcomes for prevention of
cognitive decline.

7.4.1

Conclusion

The findings of this study suggest that regular anthocyanin-rich cherry juice
consumption over 12 weeks can improve cognition in older adults with dementia and
provides a basis for more comprehensive human trials to study the potential of cherry
flavonoids to influence neuro-cognitive health.
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8
8.1

Overview of core findings

The research presented in this thesis utilised various methodologies to address the
central research questions surrounding the measurement of dietary flavonoid intake
(chapters 2, 3, 4) and the impact of dietary flavonoid supplementation on cognitive
and physical outcomes (chapter 5, 6, 7).

In order to associate the impact of dietary flavonoids on health outcomes, accurate
measures of dietary flavonoid intake are fundamental. The gaps in knowledge
surrounding how dietary flavonoid intake is measured, presented in the introduction
(chapter 1) to this thesis, indicated the need for improved methods for measuring
dietary flavonoid consumption. A systematic evaluation of the various methods
employed by current literature to measure flavonoid intake, and their associated
limitations were highlighted in a literature review (chapter 2). The review emphasised
the reliance on studies that utilise flawed or limited dietary assessment methods to
measure dietary flavonoid intake. Additionally, the review established that despite
several studies outlining the development and validation of biomarkers of flavonoid
intake, few studies actually utilised biomarkers as an objective measure of dietary
flavonoid intake.

In response to the limitations to the current methods of measuring dietary flavonoid
intake, novel methods of measuring flavonoid intake were developed. Chapter 3 of
this thesis identified that the measurement of dietary flavonoids in older Australians
was inadequate and consequently performed secondary data analysis of detailed
dietary information to describe flavonoid intake in this population (chapter 3.1).
Consequently, a tool for the estimation of dietary flavonoid intake in this cohort was
developed based on these findings (chapter 3.2). The tool was adequately validated
against food records and assessed for reliability in a group of older Australians, and
proved to be a relatively useful tool for application to measure flavonoid intake in
future research in older Australians. However, the tool needs to be refined further to
reduce participant burden (perhaps to shorten in length) and to assess for its usefulness
beyond that of currently applied dietary assessment tools.
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A sensitive and specific GC-MS method was developed (chapter 4) with the potential
to measure around 115 flavonoid-related biomarkers in biological samples. The
potential application of this method in future research is vast, especially for
exploratory metabolomics-related studies, in which this GC/MS method could be
applied to determine the most suitable biomarker related to flavonoid intake depending
on the research objectives. However, the usefulness of this biomarker assessment
method for determining total dietary flavonoid intake needs to be addressed. It is
unlikely that a metabolite profiling approach for the measurement of dietary flavonoid
intake is a straightforward technique, and therefore its application relative to dietary
assessment methods must be investigated.

Overall, the dietary flavonoid intake measurement strategies developed by this thesis
improved upon current methods (1, 2) of measuring flavonoid intake, and contributed
novel tools with potential for application in future research studies.

In order to inform the development of interventions to assess the impact of dietary
flavonoid intake on cognitive and physical outcomes, a literature review of relevant
current findings was required. A literature review (chapter 5) identified a paucity of
research regarding food-based anthocyanin consumption and cognitive outcomes.
However, the preliminary findings indicated positive cognitive outcomes associated
with anthocyanin-rich food consumption. Various methodological limitations were
highlighted from the acute and longer-term trials included in the review, including
issues surrounding dosages and cognitive tools employed. The findings of the review
were utilised to develop acute (chapter 6) and longer-term (chapter 7) intervention
studies which assessed the impact of a flavonoid and anthocyanin-rich cherry juice on
cognitive and physical outcomes.

A pilot cross-over study assessed the acute effects on cognitive function, blood
pressure and plasma biomarkers associated with consumption of a 300ml cherry juice,
provided either as a single quantity or as 3x100ml doses administered over 2h. The
methodology used in this acute pilot study contributed to an improved study design
for flavonoid-based trials of cognition, with the results indicating that the acute impact
of anthocyanin-rich cherry juice consumption on cognition was not supported.
229

However, a potential dose-timing administration effect may influence acute blood
pressure outcomes. The application of the GC/MS method developed in chapter 4,
measured eight related biomarkers of anthocyanin-intake, confirming the metabolism
and uptake of cherry-related anthocyanins in this study.

The final study of this thesis comprised a longer-term intervention, which was
conducted to assess whether daily consumption of anthocyanin-rich cherry juice
changed cognitive function in older adults with dementia, with blood pressure and
anti-inflammatory effects examined as secondary outcomes. The results of this study
indicated that anthocyanin-rich cherry juice consumption improved cognitive
performance and significantly reduced blood pressure, but did not impact markers of
inflammation in this group. This study contributed significant findings to the limited
human clinical trial literature regarding flavonoid supplementation and cognitive
outcomes, in a group of individuals who may be most likely to benefit from
improvements to cognitive performance. This study provided the first evidence that
regular consumption of a feasible serving of flavonoid-rich food may have beneficial
consequences in older adults with Alzheimer’s type dementia, and these findings
warrant further investigation.

Overall, the findings of these studies support the hypothesis that dietary flavonoids,
and especially anthocyanin-rich food, is beneficial for cognitive and physical
outcomes (3).

8.2

Strengths and limitations

Each study comprising this thesis had its own set of methodological strengths and
limitations, which have been addressed in the preceding chapters. Consequently, some
general strengths and limitations are considered here.

This thesis has highlighted that there are considerable limitations relating to the
accurate measurement of dietary flavonoid intake, which hinders the ability for
convincing associations between flavonoid intake and health outcomes to be drawn
(2). Study 1, 2 and 3 of this thesis addressed significant gaps in knowledge surrounding
230

the estimation of dietary flavonoid intake, and the tools developed within these studies
can be usefully applied in future research. However, the dietary assessment method
(FFQ) developed and validated to measure dietary flavonoid intake is specific for the
older Australian population, and thus may have limited generalisability outside of this
setting. Additionally, the validity of this tool could be further strengthened by
evaluating its association with flavonoid-related biomarkers through the application
of the method of triads (4, 5). This work is planned by our research team, in
conjunction with collaborators at the QLD Government's Department of Agriculture
and Fisheries and the University of Queensland, Australia, but is outside the scope of
this thesis.

Our laboratory work has shown that the GC/MS method is able to determine
flavonoid-related biomarkers, which is suitable in exploratory studies to confirm the
metabolism and uptake of flavonoids. However, its ability to measure biomarkers as a
measure of total dietary flavonoid intake required further validation. While similar
methods have shown to be useful indicators of flavonoid intake associated with pure
flavonoid supplementation (6), the application of the GC/MS method to measure
dietary flavonoid intake in population-based research needs further investigation.

This thesis has additionally emphasised the considerable limitations in research that
investigates the cognitive and physical benefits of flavonoid consumption, and
specifically foods that are rich in anthocyanins. Study 4, 5 and 6 of this thesis
addressed significant gaps in knowledge relating to the cognitive and physical benefits
of anthocyanin-rich food supplementation. Theses studies contribute to evidence for
the dose-timing administration of flavonoid-rich food supplementation in acute trials,
the cognitive benefits associated with anthocyanins in a little researched fruit variety
(cherries) and the first investigations of the neuro-cognitive benefits of anthocyaninrich food supplementation in older adults with dementia. While the contributions
provided by this thesis are promising, the relatively small sample sizes of the
intervention studies limit the interpretation of the results. The positive results indicated
in both the acute and longer-term supplementation trials indicate that further research
on a larger scale is required to confirm the findings.
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8.3

Future directions

While this thesis has contributed novel investigations to the literature regarding the
measurement of dietary flavonoid intake and the impact of flavonoid intake on
cognitive and physical functioning, it also highlights the need for further research.
Based on the findings of this thesis, the following recommendations are made for
future research.

Complete food composition databases for flavonoids and appropriate dietary
assessment methods are essential for any flavonoid-related research. Future
investigations attempting to measure dietary flavonoid intake should apply validated
flavonoid specific dietary assessment methods to ensure greater precision when
measuring total flavonoid intake and the intake of specific subclasses. Ideally, future
estimates of flavonoid intake will consider the growth, processing and preparation
conditions on the flavonoid content of foods. While investigators are responsible for
selecting appropriate methods for their studies, this step also heavily involves the
improvement of flavonoid food composition databases. Analytical studies are needed
to fill existing gaps on commonly eaten flavonoid rich foods, and to ensure that all
appropriate foods, including values for their cooked and processed alternatives, are
included in flavonoid databases. The differences between flavonoid intake estimates
associated with applying different flavonoid food composition databases should also
be assessed.

Identification of suitable biomarkers of flavonoid intake is imperative for an objective
measurement of total flavonoid intake, and/or in the intake of flavonoid subclasses.
The lack of validated biomarkers of total flavonoid intake has been highlighted as a
significant problem, and has been attributed to inter-individual variation in the
metabolism of flavonoids (2). Validating estimates of flavonoid intake with a relevant
biomarker where possible should be considered a priority for future research.
However, the limitations of biomarker assessment methods should be considered, and
a burden/benefit analysis of choosing this method over others (e.g. dietary assessment
methods) should be a priority for studies if crucial advances are not made in the near
future.
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The potential therapeutic utility of flavonoid-rich food supplementation in dementia
has been highlighted (7). However, further elucidation of the practicality of
anthocyanin-rich food supplementation in the ‘free-living’ environment is needed,
especially for older adults with dementia for whom nutritional changes may be
difficult to sustain. Previous research has speculated that the effects of specific fruit
and vegetable consumption on cognitive outcomes in a general population are likely
to be subtle (8). The clinical relevance of improvements in cognitive function, or the
potential for flavonoids to mediate dementia disease progression, in older adults after
anthocyanin-rich food supplementation needs to be further investigated. The
differences in outcomes for supplement and food based interventions needs to be
elucidated. While the use of pure supplements are useful when considering flavonoid
bioavailability and mechanisms of action, future research needs to consider feasible
dietary interventions in order to generalise results and inform dietary messages.

As our knowledge of flavonoid–disease relationships becomes clearer, it may soon be
possible to specify recommended intake levels. Interestingly, recommendations
associated with phytochemicals are beginning to be included in widely disseminated
dietary guidelines (9), in addition to guidelines surrounding fruit and vegetable
consumption. However, much additional work is needed before evidence-based
recommendations will be possible and public health policy developers must be
cautious when using information regarding flavonoid consumption specifically.

8.4

Summary

In conclusion, this thesis has highlighted the current limitations associated with
estimating dietary flavonoid intake and developed new tools for measuring flavonoid
intake. Additionally, this research has investigated the current research surrounding
the cognitive and physical benefits associated with flavonoid intake and assessed the
impact of anthocyanin-rich food supplementation on acute and longer-term health
outcomes.

The research constituting this thesis has extended current knowledge regarding the
assessment of dietary flavonoid intake and the impact of flavonoid supplementation
233

on cognitive and physical outcomes. The culmination of the six studies constituting
this thesis contributes to the fields of nutrition, psychology, public health and basic
science, with each study contributing a novel and innovative investigation. Together,
these studies advance scientific knowledge regarding the most significant gaps
surrounding dietary flavonoids. In a broader context, these studies ultimately
contribute to a larger wealth of knowledge regarding how diet and dietary components
can influence health outcomes in humans.
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